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!! i!
Summary 
Numerous studies have demonstrated that the gastrointestinal tract (GIT) microbiota plays 
important roles for the human host. Since the GIT microbiota interfaces with the immune 
system and represents a first line of defense against infectious agents, interest has grown 
in whether the GIT microbiota may influence the outcome of different anticancer 
treatments. In this study, the GIT of pediatric patients with different cancer types as well 
as adult patients with hematologic malignancies undergoing an allogeneic hematopoietic 
stem cell transplantation were sampled throughout their treatment. In order to deeply 
profile not only the composition of the community, but also the functional capacity and 
expression, recently developed wet- and dry-lab methodologies for integrated multi-omic 
analyses were applied. The trajectories of the prokaryotic and microeukaryotic GIT 
communities of the patients were described in detail using 16S, 18S rRNA gene amplicon 
sequencing, as well as metagenomic and metatranscriptomic shotgun sequencing. 
Indeed, changes in the GIT microbiome in response to treatment were detected. Some 
changes that are generally thought to be detrimental for human health were detected 
during treatment, such as a decrease in alpha-diversity, a decrease in relative abundance 
of bacteria associated with health-promoting properties (such as Blautia spp., Roseburia 
spp. and Faecalibacterium spp.), as well as an increase in the relative abundance of 
antibiotic resistance genes. These changes were more pronounced in the adult 
hematology patients than in the pediatric patients, which is likely due to the more intensive 
treatment. Some observations need further investigation in order to explain their 
implication in human health. For example, in the pediatric patients, lower relative 
abundance of Akkermansia muciniphila was associated with mucositis and functional 
gene categories that are linked to bacteriophages or the bacterial defense mechanism 
against bacteriophages were associated with the overall status of the patient and 
mucositis development. Importantly, in both cohorts, high inter-individual but also high 
intra-individual variation in the prokaryotic communities were detected while the 
microeukaryotic community did not exhibit drastic changes. In conclusion, the employed 
integrated multi-omics analysis allowed detailed profiling of the GIT community including 
archaea, bacteria, eukaryotes and viruses as well as the functional potential including 
antibiotic resistance genes. In the future, analysis of the individual-specific processes 
within the GIT microbial community of patients throughout treatment might allow to adjust 
therapy regimens accordingly and improve the overall outcome of the therapy. 
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1 Introduction  
1.1 The human microbiome 
The human body is colonized by a multitude of different microorganisms, commonly 
referred to as the 'microbiota', with their associated genomes being referred to as the 
'microbiome' (Ursell, Metcalf, Parfrey, & Knight, 2013). Various sites such as the skin, the 
oral cavity and the gastrointestinal tract (GIT) are highly colonized by these organisms. 
This ecosystem is assumed to be composed of about 100 trillion microorganisms, 
including 500 – 1500 different species of bacteria, archaea, fungi, unicellular eukaryotes 
and viruses (Hooper & Gordon, 2001; Kinross, von Roon, Holmes, Darzi, & Nicholson, 
2008; Schwiertz, 2016; Sekirov, Russell, Antunes, & Finlay, 2010). The human 
microbiome, especially the GIT microbiome has recently gained much research interest 
worldwide (Figure 1.1.1). For a long time, it was believed that the number of human cells 
that makes up the human body is outnumbered by the number of microorganisms living in 
and on it, by at least a factor of ten (Luckey, 1972). However, this was based on a rough 
estimate and has recently been revised and rectified. According to more recent studies, 
the number of microorganisms associated with the human body is approximately equal to 
the number of human cells (Sender, Fuchs, & Milo, 2016). Recent studies focussing on 
the microbiome of different body sites have highlighted that the community structure of a 
specific body site remains relatively constant within one person and that the inter-
individual variation of the community structure is in general higher than the variation over 
time within one person (The Human Microbiome Project Consortium, 2012; Zhou et al., 
2013).  
 
Figure 1.1.1: Number of published articles including the words 'human microbiome' per year. The plot 
indicates the number of published articles in PuBMed (Medline) including the words 'human microbiome' per 
year (Corlan, 2004). 
0
2000
4000
6000
2000 2005 2010 2015
Year
Hi
ts
1. Introduction 
!2 
1.1.1 The technology-driven revolution of human microbiome research 
It is known that only a small part of the microorganisms present in the GIT are culturable 
in isolation under laboratory conditions. Therefore, for a long time, culture-dependent 
analyses have allowed to only characterize and inspect a part of the microbiome. Novel 
culture-independent methods have allowed a much deeper characterization of the human 
microbiome. Targeted amplification and sequencing of specific phylogenetic marker genes 
such as 16S (for prokaryotes) and 18S (for eukaryotes) ribosomal ribonucleic acid (rRNA) 
gene or internal transcribed spacer (ITS, mostly used for fungi) has led to a revolution in 
microbiome research. 16S and 18S rRNAs are part of the small ribosomal subunits, 
meaning that they are present in each prokaryotic and eukaryotic organism, respectively. 
Furthermore, they contain conserved regions, allowing the construction of universal 
primers used for polymerase chain reaction (PCR) amplification, as well as hypervariable 
regions (Figure 1.1.2), which can be utilized to identify different species. These traits 
make the 16S rRNA gene the 'gold standard' genetic marker for bacterial phylogeny 
(Case et al., 2007).  
 
Figure 1.1.2: Secondary structure of the 16S ribosomal RNA. Double lines represent variable or 
hypervariable regions, single lines represent highly conserved regions. V1 to V9 represent hypervariable 
regions (Tortoli, 2003). 
Organisms are classified into a hierarchical system, the taxonomic classification. Different 
levels or ranks have been defined. Ideally, taxonomy reflects evolutionary relationships 
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among organisms. In the past, bacteria were classified based on their morphologic and 
phenotypic characteristics (e.g. shape, Gram stain, motility) while more recently, gene 
sequences (including the 16S rRNA gene) are used to identify relationships. Table 1.1.1 
includes the taxonomic classification of Escherichia coli as an example.  
Table 1.1.1: Example of the taxonomic classification of Escherichia coli. 
Taxonomic rank Taxon 
Domain Bacteria 
Phylum Proteobacteria 
Class Gammaproteobacteria 
Order Enterobacteriales 
Family Enterobacteriaceae 
Genus Escherichia 
Species Escherichia coli 
 
On one hand, amplicon sequencing has allowed to characterize the composition of the 
microbiome much more in detail than cultivation. Around 80 % of the sequenced taxa had 
not been cultivated before (Eckburg et al., 2005). On the other hand, this method allows to 
solely identify different taxa, whereas culturing of isolates is necessary to describe the 
biological and genetic nature of the organisms. However, the creation of isolate cultures is 
difficult and often even impossible. Reasons for this 'unculturability' include the need for 
specific growth conditions such as nutrients, pH, incubation temperatures, or dependence 
on the presence of other community members (Vartoukian, Palmer, & Wade, 2010).  
The third approach, metagenomics, refers to culture-independent genomic analysis of an 
assemblage of microorganisms. The emergence of high-throughput random shotgun 
sequencing and the continuous decrease in sequencing costs (Figure 1.1.3) have made it 
possible to explore complex communities using metagenomic (MG) sequencing without a 
priori knowledge, without reference database. 
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Figure 1.1.3: Development of DNA sequencing costs over time. The sequencing cost is represented in 
US Dollar per megabase. Data taken from https://www.genome.gov/sequencingcostsdata (Wetterstrand, 
2016). 
The collective genomes of a community within a sample is called the metagenome 
(Handelsman, Rondon, Brady, Clardy, & Goodman, 1998), while the associated RNA is 
called metatranscriptome. Metatranscriptomic (MT) sequencing allows community-wide 
gene expression to be resolved. At a sufficient sequencing depth, de novo MG 
assemblers are now able to assemble genomes of a complex community, such as a fecal 
microbiome (Segata et al., 2013). Large-scale international MG studies (Human 
Microbiome Project, MetaHIT) are concentrating on characterizing the human microbiome 
and the complex interplay between this microbial community and its human host 
(Peterson et al., 2009; The Human Microbiome Project Consortium, 2012). A reference 
gene catalogue of the GIT microbiome has been assembled, including 9.9 Mio non-
redundant genes (Li et al., 2014). The functional potential of the microbiome is estimated 
to be two orders of magnitude greater than that encoded by the human genome 
(Bäckhed, Ley, Sonneburg, Peterson, & Gordon, 2005). Meta-omic studies, combining 
metagenomics and metatranscriptomics are currently arising and will change microbiome 
studies, allowing an even more precise characterization of the community, its functional 
potential and gene expression and thus, its relationship and importance for the human 
host.  
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1.1.2 Characteristics of the human gastrointestinal microbiome 
While every body site has its own unique microbial community, the composition of each 
community varies between individuals and over time, due to external influences such as 
changes in diet, antibiotic administration and important lifestyle changes (Lozupone, 
Stomabaugh, Gordon, Jansson, & Knight, 2012).  
The majority of the microorganisms associated with the human body live in the GIT. This 
organ system includes the most stable and diverse microbiome, the colon being the most 
densely colonized compartment, with densities of around 108 cells per ml in the cecum to 
up to 1012 cells per ml in stool (Dethlefsen, Eckburg, Bik, & Relman, 2006). Although this 
microbiome is considered to be quite stable in healthy individuals, it is difficult to 
determine features of a 'healthy' microbiome, as it might be different for people according 
to their age, geographical location and genetics (Greenhalgh, Meyer, Aagaard, & Wilmes, 
2016). Upon birth, neonates are exposed to a high number of microorganisms which 
influence colonization if the neonate GIT. Gestational age and the mode of delivery affect 
the initial colonization and following succession of the infant GIT (Arboleya et al., 2015; 
Jakobsson et al., 2013). After birth, the first food (breast milk versus formula milk) as well 
as the subsequent diet (including solid food) influences the GIT microbiome (Thompson, 
Monteagudo-Mera, Cadenas, Lampl, & Azcarate-Peril, 2015). Increasingly improved 
hygiene and antibiotic usage in early childhood are believed to negatively affect the GIT 
microbiome (Shen & Wong, 2016). In addition, throughout lifetime, external environmental 
factors such as the living area (urban versus rural environment) (Nakayama et al., 2015), 
siblings (Penders et al., 2006), pets (Azad et al., 2013) and the general familial 
environment further influence the GIT microbiome (Figure 1.1.4). 
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Figure 1.1.4: Generic and age-specific factors which influence the GIT microbiome (Greenhalgh et al., 
2016). 
1.1.3 The gastrointestinal microbiome in human health and disease 
On the one hand, colonization by microorganisms can negatively affect humans, 
infectious diseases being one example. On the other hand, microorganisms perform 
essential functionalities such as carbohydrate metabolism, modulation of epithelial barrier 
function and nutrient absorption (Hollister, Gao, & Versalovic, 2014). In the GIT, they also 
play important roles for the host as for example in shaping the immune system 
(Mazmanian, Cui, Tzianabos, & Kasper, 2005), synthesis of vitamins (Qin et al., 2010), 
providing the host with short-chain fatty acids (SCFAs) (Qin et al., 2010), prevention of 
colonization by pathogens (Ivanov et al., 2009; Stecher & Hardt, 2011) and the 
metabolism of xenobiotics (Maurice, Haiser, & Turnbaugh, 2013) (Figure 1.1.5).  
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Figure 1.1.5: Roles of the GIT microbiome. The GIT microbiome exerts many protective, structural and 
metabolic functions within the host. IgA = Immunoglobulin A; IEC = intestinal epithelial cell (O’Hara & 
Shanahan, 2006). 
Recent MG analysis has shown that the GIT microbial community is mainly comprised of 
bacteria, with 97.6 % of the reads belonging to this domain, while 2.2 % of the reads 
belonged to the archaea and less than 0.01 % to eukaryotes. An additional 0.2 % of the 
reads could be associated with viruses (Zhernakova et al., 2016). The intestinal 
microbiota is primarily composed of four different bacterial phyla, Firmicutes, 
Bacteroidetes, Actinobacteria and Proteobacteria, with Firmicutes and Bacteroidetes 
accounting for more than 90 % of the total bacterial community (Ley, Peterson, & Gordon, 
2006). Proportions between these phyla can vary between individuals and also within one 
individual over time.  
In a healthy person, the GIT microbiota usually includes a balanced composition of 
different organisms, which is essential for human health. These include different 
commensals, symbionts and pathobionts. Commensals are residents that do not provide 
any benefit nor harm to the host. Symbionts are organisms that benefit the host. 
Pathobionts are organisms that do not normally elicit an inflammatory response, but have 
the potential to cause inflammation and lead to disease (Round & Mazmanian, 2009). 
Several factors might lead to a shift and significant alterations in the composition of the 
microbiota with either a decrease in symbionts and commensals and/or an increase in 
pathobionts (Figure 1.1.6). This disruption of the balanced state between the intestinal 
microbes is called dysbiosis. The term 'dysbiosis' was already used in 1890 by Dr. E. E. 
Furney where he related to plant, animal and human resiliency (Furney, 1890). This state 
refers to an altered composition with associated functional changes. In this scenario, 
reviews
©2006 EUROPEAN MOLECULAR BIOLOGY ORGANIZATION EMBO reports VOL 7 | NO 7 | 2006
The forgotten organ
A.M. O’Hara & F. Shanahan
689
production ands serum immunoglobulin levels, smaller Peyer’s
patches and fewer intraepithelial lymphocytes, but increased entero-
chromaffin cell area (Shanahan, 2002). However, reconstitution of
germ-free mice with an intestinal microflora is sufficient to restore
the mucosal immune system (Umesaki et al, 1995). Indeed, colo-
nization of germ-free mice with a single species, Bacteroides
thetaiotaomicron, affects the expression of various host genes that
influence nutrient uptake, metabolism, angiogenesis, mucosal barrier
function and the development of the enteric nervous system (Xu &
Gordon, 2003). Moreover, ligands from commensal bacteria and
commensal-derived symbiosis factors influence the normal devel-
opment and function of the mucosal immune system (Mazmanian 
et al, 2005; Rakoff-Nahoum et al, 2004). Commensal bacteria pro-
foundly influence the development of humoral components of the
gut mucosal immune system (Weinstein & Cebra, 1991) and also
modulate the fine-tuning of T-cell repertoires and T-helper (Th)-cell
type 1 or type 2 cytokine profiles (Cebra, 1999; Shanahan, 2002). Thus,
it is possible that the composition of the colonizing flora influences
individual variations in immunity.
The intestinal microbiome has a etabolic activity that is both
adaptable and renewable (Bocci, 1992). Through the production of
short-chain fatty acids, resident bacteria positively influence
intestinal epithelial cell differentiation and proliferation, and
mediate other metabolic effects (Fig 1B; Shanahan, 2002).
Together, this complex metabolic activity recovers valuable energy
and absorbable substrates for the host, and provides energy and
nutrients for bacterial growth and proliferation. Colonization
increases the uptake of glucose in the intestine and, compared
with colonized mice, germ-free mice require a greater caloric
intake to sustain a normal body w ight (Backh d et al, 2004). This
implicates gut bacteria as modulators of fat deposition in the host.
Host–flora communication at the mucosal surface
Host defence requires an accurate interpretation of the micro-
environment to distinguish commensal organisms from episodic
pathogens and a precise regulation of subsequent responses. The
epithelium provides the first sensory line of defence and active sam-
pling of resident bacteria, pathogens and other antigens is mediated
by three main types of immunosensory cell (Fig 2). First, surface
enterocytes serve as afferent sensors of danger within the luminal
microenvironment by secreting chemokines and cytokines that
alert and direct innate and adaptive immune responses to the
infected site (Shanahan, 2005). Second, M cells that overlie lym-
phoid follicles sample the environment and transport luminal 
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Fig 1 | Functions of the intestinal flora. (A) Bacteria density increases in the jejunum/ileum from the stomach and duodenum, and in the large intestine, colon-
residing bacteria achieve the highest cell densities recorded for any ecosystem. The most common anaerobic and aerobic genera are listed. (B) Commensal bacteria
exert a miscellany of protective, structural and metabolic effects on the intestinal mucosa.
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pathobionts can become pathogenic and cause non-specific inflammation and possibly 
diseases (Cerf-Bensussan & Gaboriau-Routhiau, 2010; Round & Mazmanian, 2009).  
Dysbiosis has recently been linked to different diseases or conditions such as 
inflammatory bowel disease, obesity, colorectal cancer, cardiovascular diseases, 
diabetes, allergies, infection and multiple sclerosis (Bollyky et al., 2009; Hill et al., 2012; 
Kamada, Seo, Chen, & Núñez, 2013; Ley, Turnbaugh, Klein, & Gordon, 2006; Manichanh 
et al., 2006; Moore & Moore, 1995; Qin et al., 2012; Z. Wang et al., 2011). Most of these 
conditions involve inflammation, which is a result of an altered immune response, in this 
case as consequence of an altered intestinal microbiome. Thus, immune dysregulation 
and GIT dysbiosis often concur, one as a result of the other.  
 
 
Figure 1.1.6: Factors influencing the GIT microbiome composition and subsequent effects on host 
health (F. Sommer & Bäckhed, 2013). 
As mentioned before (section 1.1.2 and Figure 1.1.4), many factors such as diet, lifestyle, 
hygiene, antibiotics and other medication, shape and influence the GIT microbiome. The 
altered composition of the GIT microbiome can lead to modulation of production of pro-
inflammatory mediators (such as (interleukin) IL-6, IL-12 and tumor necrosis factor (TNF)) 
or anti-inflammatory mediators (such as IL-10), while nucleotide-binding oligomerization 
domain-containing protein 2 (NOD2) polymorphisms have been linked to Crohn's disease 
and GvHD (Penack, Holler, & van den Brink, 2010). This regulation of the immune system 
can in turn influence the GIT microbiome and lead to dysbiosis (Figure 1.1.6). 
Perturbations of the GIT microbiota may allow 'blooms' of harmful bacteria that are usually 
only lowly abundant, contributing to development of a disease. Especially blooms of 
Enterobacteriaceae (such as E. coli, Proteus spp. or Klebsiella spp.) are often observed in 
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a dysbiosis. Additionally, this may result in a vicious cycle of pathobiont blooms induced 
by inflammation and further inflammation induced by pathobionts. 
In individuals with colorectal cancer, the abundance of Fusobacterium nucleatum is 
frequently increased in the fecal microbiome (Castellarin et al., 2011). In both Crohn's 
disease and ulcerative colitis, the two main forms of inflammatory bowel disease, a lower 
diversity in the GIT microbiome as well as changes in the microbiome composition (i.e. an 
increased abundance of mucosal-associated aerotolerant bacteria compared to healthy 
individuals) have been observed (Gevers et al., 2014; Wlodarska, Kostic, & Xavier, 2015).  
Although specific patterns or shifts in the GIT microbial communities could be linked to 
diseases and disorders, often it is still unknown what is cause and consequence. 
Considering the multitude of different microbial populations living in and on the human 
body and the important roles they are playing in health but also in disease, it is clear that a 
precise characterization of the microbial community composition, its functional potential 
and actual expression of genes, but also specifically of changes in the community 
composition throughout time is needed, in order to be able to link these changes to the 
development of a disease or disorder.  
1.1.4 Relationship between the gastrointestinal microbiome and the immune 
system  
The GIT is densely populated with an important variety of microorganisms and they are in 
close contact with the host intestinal mucosa and its innate and adaptive immune 
systems. Here, the immune system helps in maintaining a balanced community of 
commensals, which in turn plays a part in protecting from pathogen invasion, for example 
by occupation of specific niches and by nutrient competition. 
Physical barriers such as the mucus layer (produced by goblet cells), tight junctions and 
secretion of certain anti-microbial peptides (by Paneth cells) regulate the relationship 
between the microbiota and the host (Hooper, Littman, & Macpherson, 2012). Peyer's 
patches are collections of lymphoid follicles in the intestinal mucosa, which harbor 
antigen-presenting cells (such as macrophages and dendritic cells). Together with 
mesenteric lymph nodes and lamina propria lymphocytes, they are part of the gut-
associated lymphoid tissue (GALT) (Cerf-Bensussan & Gaboriau-Routhiau, 2010; Schuijt, 
van der Poll, de Vos, & Wiersinga, 2013). Epithelial cells, dendritic host cells and 
macrophages express pattern recognition receptors (PRRs) such as Toll-like receptors 
(TLRs) and nucleotide-binding oligomerization domain-like receptors (NLRs) which 
recognize microbe-associated molecular patterns (MAMPs), evolutionary conserved 
molecular structures produced by various microorganisms (Clemente, Ursell, Parfrey, & 
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Knight, 2012). Activation of these receptors can induce a spectrum of signalling events 
from a pro-inflammatory cytokine response up to the presentation of antigens to regulatory 
T cells (Tregs). Activation of these Tregs conveys tolerance towards commensal bacteria 
from the initial colonization of the GIT during early life (Fukata, Vamadevan, & Abreu, 
2009). Some GIT bacteria produce SCFAs such as butyrate, propionate and acetate. 
Butyrate is one of the most important energy sources for enterocytes and has important 
anti-inflammatory properties by inhibiting nuclear factor kappa-light-chain-enhancer of 
activated B cells (NF-κB) signaling (Vinolo, Rodrigues, Nachbar, & Curi, 2011). It was also 
shown to upregulate expression of tight junction proteins, thereby strengthening the 
physical epithelial barrier (Peng, Li, Green, Holzman, & Lin, 2009). 
While most bacteria occupy the GIT lumen, segmented filamentous bacteria (SFB) seem 
to be able to penetrate the mucus layer and interact closely with the epithelial cells, 
inducing signaling events that lead to differentiation of T helper (TH) 17 cells (Ivanov et al., 
2009). These are cytokine (mainly IL-17A, IL-17F, IL-21 and IL-22) producing CD4+ 
effector T cells which are specialized in responses to extracellular bacteria and fungi 
(Ouyang, Kolls, & Zheng, 2012). On the other hand, polysaccharide A (PSA) produced by 
Bacteroides fragilis prevents expansion of TH17 cells. It has anti-inflammatory or 
regulatory characteristics, which include induction of IL-producing Tregs cells, which in turn 
suppresses the production of pro-inflammatory cytokines (Troy & Kasper, 2010).  
Additionally, epithelial innate antimicrobial effector molecules, called antimicrobial 
peptides (AMPs) are important effectors of innate immunity and can shape and regulate 
the composition of the GIT community. The peptide RegIIIγ depends on microbiome 
induced TLR signalling. Besides killing Gram-positive bacteria, it also prevents 
overstimulation of the immune system by limiting penetration of bacteria to the epithelial 
surface (Ubeda, Djukovic, & Isaac, 2017). Probiotics such as Bifidobacterium breve 
induce RegIII expression (Natividad et al., 2013). α-defensins are antibacterial peptides 
which are secreted by Paneth cells in response to bacteria or their antigens (Ayabe, 
Ashida, Kohgo, & Kono, 2004). Secretory immunoglobulin A (sIgA) is the most abundant 
class of antibodies in the intestinal lumen. Besides protecting the intestinal epithelium 
from pathogenic bacteria, viruses and toxins, it is also capable of downregulating pro-
inflammatory responses (Mantis, Rol, & Corthésy, 2011).  
Table 1.1.2 includes some of the most common representatives of the GIT microbiome 
along with the generally associated immune response or role in the GIT. However, it 
should be kept in mind that this is only the generally assumed consensus within a healthy 
adult person. Additionally, also commensals can become pathogenic under specific 
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circumstances and specific strains of otherwise nonpathogenic bacteria can harbor 
virulence factors, turning them into pathogens. 
Table 1.1.2: Common bacterial members of the GIT microbiome and the general response in the GIT 
Taxon Response in the GIT 
Roseburia anti-inflammatory (butyrate producer) 
Blautia anti-inflammatory (SCFA producer) 
Faecalibacterium anti-inflammatory (butyrate producer) 
SFB formation of TH17 cells 
Clostridium cluster IV and XIVa induction of Treg cells 
Escherichia pro-inflammatory, TLR4 mediated NF-κB 
activation (response to lipopolysaccharide) 
Bifidobacterium induction of RegIII expression 
Bacteroides induction of Treg cells 
Akkermansia muciniphila mucin degrading, anti-inflammatory 
 
Studies with germ-free (GF) mice show that microbial colonization has consequences on 
the development of the immune system, especially of lymphoid structures (Macpherson & 
Harris, 2004). GF mice develop smaller Peyer's patches than mice grown under specific-
pathogen-free (SPF) conditions and are deficient in secretory immunoglobulin A (IgA) 
(Round & Mazmanian, 2009). A mixture of 17 SCFA-producing bacterial strains from the 
order Clostridiales has been shown to be important for induction of colonic Tregs (Atarashi 
et al., 2013). This indicates how diet, microbes, their products and the immune system are 
interconnected and complexly regulated. 
In short, one role of the immune system is not to extinguish all microorganisms living in 
the GIT but to confer tolerance, establish homeostasis, which includes commensals, 
which exert essential functions on the host as for example in digestion. This homeostasis 
is maintained by an intricate balance of pro-inflammatory cells (like TH1 cells and TH17 
cells) and anti-inflammatory Tregs (Hooper et al., 2012). This highly sensitively regulated 
relationship between the microbiota and the host can be disturbed by many factors (such 
as antibiotic intake, drastic dietary changes or the invasion by pathogens) and this can 
lead to dysbiosis, an imbalance in the intestinal microbial community. Resulting 
inflammation can lead to epithelial damage and a resulting decreased intestinal barrier 
function. In immunocompromised patients, for example in cancer patients during intensive 
treatment, this 'leaky gut' allows translocation of microorganisms and microbial products 
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from the GIT lumen to neighboring tissues and/or bloodstream (Yu et al., 2014), putting 
the host at risk for local and systemic infections and sepsis (Khosravi & Mazmanian, 2013; 
Stecher, Maier, & Hardt, 2013). 
 
1.2 Cancer and anticancer treatment 
1.2.1  Cancer 
Cancer is one of the leading causes of mortality with 8.2 million deaths worldwide in 2012 
(Stewart & Wild, 2014). In adults, 80 % of the cancer types affect the respiratory, 
gastrointestinal and reproductive organs, while in children, less than 5 % of the 
malignancies affect these organs (Imbach, Kühne, & Arceci, 2004). More than 100 types 
of cancer have been categorized, with around 85 % of cancers affecting epithelial cells 
(carcinomas). Cancers derived from mesodermal cells (e.g. bone, muscle cells) are called 
sarcomas and cancers arising of glandular tissue (e.g. breast) are called 
adenocarcinomas (Pecorino, 2012). Every year, around 1 out of 500 children under the 
age of 16 years are diagnosed with childhood cancer, with acute lymphoblastic leukemia 
and brain tumors being the most frequent kinds of childhood cancer, accounting for 47 % 
of all pediatric neoplasia (Imbach et al., 2004). Within the past 30 years, chances for 
longterm survival have significantly increased to over 70 % in pediatric oncology (Imbach 
et al., 2004). Overall, in the United States the 5-year survival rate has increased by 23 % 
within the last 30 years, to now 69 % (Siegel, Miller, & Jemal, 2016). Globally, the cancer 
mortality rate decreases by approximately 1 % per year (Hashim et al., 2016). 
All cancers arise due to changes in the DNA sequence of the cancer cell genomes. 
Tumorigenesis is thought to be a multistep process which is often compared to Darwin's 
theory of evolution, where cells with mutations are selected to survive, due to increased 
replicative and survival abilities (Stratton, Campbell, & Futreal, 2009). In 2000, Hanahan 
and Weinberg defined six key 'hallmarks of cancer', which include: sustained proliferative 
signalling, evasion of growth suppressors, resistance against apoptosis, immortality, 
induction of angiogenesis and inflammation as well as activation of invasion and 
metastasis (Hanahan & Weinberg, 2000). In 2011, emerging hallmarks and enabling 
characteristics were added to this list, including inflammation as tumor-promoting 
characteristic (Hanahan & Weinberg, 2011). 
Mutations leading to this abnormal behaviour can be acquired or inherited. Acquired 
mutations are the most common cause of cancer in adults and can be caused due to 
factors like chemicals in tobacco smoke, ultraviolet radiation and viruses (Hyndman, 
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2016). These mutations often affect tumor suppressor genes, proto-oncogenes or DNA 
repair genes. Tumors of different origins show a high complexity and heterogeneity in their 
patterns of mutations (Luo, Solimini, & Elledge, 2009).  
The lifetime risk of cancer for people has increased over time. In Great Britain, 1 in 2 
people born after 1960 will be diagnosed with some type of cancer during their lifetime 
(Ahmad, Ormiston-Smith, & Sasieni, 2015). Considering this, it is clear that there is an 
urgent need for effective anticancer treatments. However, the high number of different 
types of cancer and their heterogeneity make this very difficult. 
1.2.2  Anticancer therapies 
The main treatment options for malignancies are radiotherapy, chemotherapy and 
surgery. After discovery of X-rays in 1895 by Wilhelm Conrad Röntgen, they were used 
diagnostically and first successful treatments of different skin tissue malignancies were 
reported in 1899 (Tomlinson & Kline, 2005). The most common forms of ionizing radiation 
used for the treatment of cancer are high-energy photons, gamma-rays or X-rays 
(Stockham, Balagamwala, Macklis, Wilkinson, & Singh, 2014). Other types of radiation 
include proton therapy and electron beams (Stockham et al., 2014). While passing 
through cells, energy of the ionizing radiation can directly result in DNA damage or 
indirectly in production of free radicals which provokes DNA damage, and thereby, lead to 
cell death (Baskar, Ann-Lee, Yeo, & Yeoh, 2012). Radiation treatment alone can be 
curative for some kinds of cancer (for example cervix carcinomas, head and neck 
carcinomas) but for others such as for example pediatric tumors and breast carcinomas, it 
is used together with other treatments (Baskar et al., 2012). Often, it is used before 
surgery to shrink the tumor, or after surgery to destroy cancer cells that could not be 
removed surgically.  
Single drugs or combinations of chemotherapy drugs are used for treatment of many 
kinds of cancer, often together with surgery and/or radiotherapy. Chemotherapeutic 
agents either arrest cell growth (cytostatic) or kill rapidly dividing cells (cytotoxic). The 
principle of most cytotoxic drugs is that they attack actively dividing cells, therefore cancer 
cells, which divide more rapidly, are more affected than normal cells (Newman, 2010). 
However, due to the lack of selectivity for cancerous cells, non-malignant cells, especially 
those that undergo rapid division (e.g. hematopoietic, mucosal and gastrointestinal cells), 
are also affected, culminating in some of the side effects like bone marrow suppression 
and mucositis (Tomlinson & Kline, 2005).  
Chemotherapy agents can be classified into cell cycle phase-specific agents 
(antimetabolites and plant derivatives) and cell cycle phase non-specific agents (alkylating 
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agents, antitumor antibiotics, corticosteroids and others) (Tomlinson & Kline, 2005). In 
general, these agents interfere with DNA synthesis, culminating in cell death. There are 
however differences in their modes of action. Antimetabolites are folic acid, pyrimidine or 
purine analogues and interfere with DNA production by inhibiting enzymes needed for 
nucleic acid production. Alkylating agents such as busulfan and cyclophosphamide act by 
attaching an alkyl group to DNA. Angiogenesis inhibitors interfere with the binding of 
angiogenesis-signalling molecules to receptors on endothelial cells (Shewach & Kuchta, 
2009). 
Which drugs and combinations of treatments are used depends on the underlying 
disease, the stage and the status of the patient. In pediatric oncology, dosage is based on 
body size, usually considering surface area or body weight (Ratain, 1998). Trials have 
shown, which combination of drugs (called combination chemotherapy) is most effective 
against a specific malignancy. As an example, in the following I will briefly explain the 
mode of action of different therapeutic agents, which were frequently used in this project 
for treatment of the pediatric patients. One combination often used for treatment of 
Hodgkin's lymphoma in children is 'OEPA', composed of vincristine (oncovin), etoposide, 
prednisone and doxorubicin (adriamycin) (Imbach et al., 2004). Vincristine is a vinca 
alkaloid, which works by binding to the tubulin protein, preventing the polymerization of 
tubulins, stopping the cell from separating chromosomes during metaphase, thereby 
leading to apoptosis. In addition to this, vincristine can also damage DNA and interfere 
with DNA, RNA and protein synthesis (Mohammadgholi, Rabbani-Chadegani, & Fallah, 
2013). Etoposide derives from a toxin found in the American mayapple (also known as 
mandrake) and was first approved for cancer therapy in 1983 (Montecucco, Zanetta, & 
Biamonti, 2015). This cytotoxic cancer drug belongs to the topoisomerase inhibitor drug 
class. Topoisomerases are involved in essential cellular functions such as DNA 
replication, repair and transcription. Etoposide interferes with the topoisomerase II and 
DNA complex (called cleavable complex) and prevents religation of the DNA strands, 
causing DNA strand breaks and thus, apoptosis (Montecucco et al., 2015). Prednisone is 
a glucocorticoid that reduces inflammation and has been shown to cause regression of 
lymphoid tumors (Walsh & Avashia, 1992). Doxorubicin is an anthracycline antitumor 
antibiotic that was first extracted from Streptomyces peucetius var. caesius in the 1970’s. 
Two mechanisms of action are proposed: it can inhibit topoisomerase II-mediated DNA 
repair by intercalation into DNA and it can damage membranes, DNA and proteins via 
production of free radicals (Thorn, Caroline; Oshiro, Connie; Marsh, Sharon; Hernandez-
Boussard, Tina; McLeod, Howard; Klein, Teri; Altman, 2012). 
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Another approach is the activation of the immune system in order to fight cancer cells, in 
the so-called immunotherapy. It can be subdivided into active immunotherapy and 
adoptive immunotherapy. Common targets in this area are immune checkpoint inhibitors 
(ICI), monoclonal antibodies, cancer vaccines and cytokines. Some proteins (like CTLA-4 
and PD-1) on the surface of T cells act like checkpoints or brakes, preventing the cells 
from attacking cancer cells. Checkpoint inhibitors block these checkpoints, allowing the T 
cells to fight cancer (Ott, Hodi, & Robert, 2013). Monoclonal antibodies (a form of targeted 
therapy) identify abnormalities on cancer cell surfaces, bind to them and mark them for 
the immune system, while cancer vaccines help to recognize cancer cells and stimulate 
the immune system. Cytokines including interleukins, interferons and colony-stimulating 
factors all increase the immune system's reaction to cancer cells (S. Lee & Margolin, 
2011).  
1.2.3 Allogeneic stem cell transplantation 
For many relapsed hematologic malignancies, allogeneic hematopoietic stem cell 
transplantation (allo-HSCT) is the only potentially curative treatment (Figure 1.2.1). It 
consists of a preparative conditioning treatment, which often comprises high-dose 
chemotherapy, sometimes combined with total body irradiation. This conditioning has 
three aims: It is used to eradicate the malignancy, to make space to allow engraftment of 
the donor stem cells and to prevent host-versus-graft reactions via immunosuppression 
(Vriesendorp, 2003). These conditioning treatments damage and kill the patient's immune 
cells and often lead to immunodeficiency and myeloablation. The conditioning treatment is 
followed by the stem cell transplantation whereby hematopoietic stem cells (harvested 
from the bone marrow, peripheral blood or umbilical cord blood) from a healthy donor are 
given to the patient intravenously. The stem cells travel to the bone marrow and restore 
hematopoiesis, differentiating into the different types of blood cells. Engraftment is usually 
defined as the first of three consecutive days with an absolute neutrophil count  
> 0.5 * 109/L. The time of engraftment depends on different factors such as the source of 
the graft. It usually occurs around three to four weeks after transplantation. However, 
complete restoration of the immune system can take up to two years.  
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Figure 1.2.1: Allogeneic hematopoietic stem cell transplantation. Donor stem cells are collected after 
treatment with granulocyte colony-stimulating factor (G-CSF). Recipients receive a treatment, which has 
different goals (prevent graft rejection, reduce the number of tumor cells and create a niche for engraftment). 
The patient receives the peripheral-blood stem cells (PBSCs) and engraftment takes place. DC: dendritic cell; 
HSC: hematopoietic stem cell; NK: natural killer (Shlomchik, 2007). 
While the patient's immune cells have failed at recognizing and fighting the cancer cells, 
immune cells from the donor might succeed at eradicating residual cancer cells, an effect 
called graft-versus-cancer (GVC) or graft-versus-tumor (GVT) (Blazar, Murphy, & Abedi, 
2012). However, donor T cells can also respond to proteins on the surface of host cells, 
especially to human leukocyte antigens (HLA) which are encoded by the major 
histocompatibility complex (MHC), resulting in an immunological disorder typically referred 
to as graft-versus-host disease (GvHD) (Ferrara, Levine, Reddy, & Holler, 2009). Class I 
HLA (A, B and C) proteins are expressed on nearly all nucleated cells. Consequently, 
donor selection is mainly based on their HLA profile with preferentially choosing an 
identical donor, although allo-HSCT is also feasible with near-identical donors. However, 
these HLAs are highly polymorphic and in addition to GvHD development, HLA disparity is 
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challenge is initiated. There is no specific pathogen and 
therefore no specific subset of antigen-presenting cells 
(APCs) that present immunogenic antigens. Instead, 
every APC can present self peptides. Also, maturation 
and migration of APCs to secondary lymphoid organs is 
not linked with a target pathogen. Rather, APCs stimu-
lated to mature by any mechanism could be licensed to 
prime allo reactive T cells, and how and which APCs 
are matured could instructively influence the nature of 
GVHD. Unlike responses to infection in which antigen 
can be eliminated, in GVHD self antigen is limitless, and 
in this regard GVHD resembles a chronic viral infection. 
Target antigens are also likely to be almost ubiquitously 
expressed, which is distinct from the tissue tropisms 
associated with most pathogens. In GVHD, there is no 
specific pathogen-induced tissue inflammation that 
might dictate where effector T cells will traffic, although 
tissue damage from conditioning regimens may in part 
have this role5,6. Therefore, activated alloreactive T cells 
might encounter cognate antigens when entering tissues 
that are already inflamed for any reason7.
Because alloantigens are ubiquitous, alloimmune 
responses should be able to engage most, if not all, of 
the repertoire of adaptive immune mechanisms avail-
able to fight infection. This may in part explain why 
(despite the stereotypical manifestations of GVHD) the 
severity, the mixture of organs involved and the histo-
pathology are varied in this disease, both in animal 
models and in clinical transplantation. In particular, 
chronic GVHD in humans has protean manifestations, 
including lacrimal and salivary gland involvement, 
eosinophilic fasciitis, serositis and skin involvement 
similar to that seen in systemic sclerosis8. In turn, this 
may in part explain why the manipulation of nearly 
all immune mediators, for example cytokines, cytolytic 
molecules or co-stimulatory molecules, can alter the 
phenotype of GVHD in mouse models.
Target antigens
Perhaps the most fundamental way in which GVHD 
differs from pathogen-specific immunity is in the 
identity of the target antigens (FIG. 2). The nature of allo-
reactive antigen–T-cell recognition differs depending 
on whether the presenting MHC molecule is matched 
or mismatched with the donor. The precursor fre-
quency of T cells that can recognize a mismatched 
MHC molecule is very high and the molecular expla-
nation for this remains the subject of debate9–11. In one 
extreme, there is some evidence indicating that T-cell 
receptors (TCRs) recognize primarily intact epitopes 
on MHC molecules. In the other extreme, recognition 
can be peptide-dependent, although for individual 
alloreactive T-cell clones there may be peptide promis-
cuity. In either case, in MHC-mismatched transplants 
all MHC-class-I-positive tissues are likely to express 
peptide–MHC class I complexes that are recognized 
by allogeneic donor T cells.
In situations in which the MHC molecules of donors 
and recipients are matched, donor T cells can only 
recognize MHC-bound peptides derived from the 
protein products of polymorphic genes that are present 
in the recipient but not in the donor (known as minor 
histocompatibility antigens (miHAs); some of these miHAs 
were identified in REFS 12–26). The genes encoding 
miHA allelic pairs can be very polymorphic, as is the case 
with the Y chromosome gene SMCY, which differs from 
the X chromosome homologue SMCX by more than 200 
residues, and can generate male-specific H-Y antigens 
restricted to multiple MHC class I molecules in both 
mice and humans13,27. By contrast, the human HA-1 and 
HA-2 miHA allelic pairs differ by single amino acids12,28. 
Genes that are not expressed in the donor but that are 
expressed in the recipient can also generate miHAs24,29, 
as can amino-acid polymorphisms that interfere with 
the processing or post-translational modification of a 
peptide15,20.
Figure 1 | Allogeneic peripheral-blood stem-cell transplantation. Donors receive 
granulocyte colony-stimulating factor (G-CSF) to mobilize haematopoietic stem cells 
(HSCs), which are collected by leukapheresis. Patients (recipients) receive chemotherapy 
(and radiotherapy), which is designed to prevent immunological graft rejection, reduce 
the number of tumour cells (when the allogeneic stem-cell transplantation (SCT) is used 
to treat cancer) and to create niches for HSC engraftment. The leukapheresis product 
(peripheral-blood stem cells (PBSCs)) is then infused intravenously into the recipient. 
Engraftment of donor neutrophils and platelets typically occurs between 10 and 20 days 
post-transplantation, but engrafment of other cell lineages, such as T cells, B cells, 
macrophages, dendritic cells (DCs), Langerhans cells and erythroid cells, may take longer. 
When conditioning regimens are of lower intensity (for example low-dose irradiation), 
patients can remain as mixed donor–recipient chimaeras for months, and donor 
leukocyte infusions may be required to convert this mixed chimerism to a full donor 
chimerism. NK, natural killer.
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also associated with graft failure, delayed immune reconstitution and mortality (Park & 
Seo, 2012). Even with a matched donor, many allo-HSCT receivers develop GvHD, which 
is caused by differences in the minor histocompatibility antigens. As GvHD prophylaxis, T-
cell depletion, monoclonal antibodies and immunosuppression by mycophenolate mofetil, 
cyclosporine and/or tacrolimus is often applied (Ferrara et al., 2009). As the patients are 
immunocompromised due to the treatment, they are prone to severe infections, which is 
the most common cause of mortality after allo-HSCT (Sahin, Toprak, Atilla, Atilla, & 
Demirer, 2016). Therefore, additional supportive treatment includes antibiotic and 
antifungal prophylaxis.  
1.2.4  Side effects 
1.2.4.1   Mucositis 
Mucositis is probably the most common complication of anticancer treatment. Each year, 
it affects over two million people worldwide and occurs in approximately 40 % of patients 
receiving standard chemotherapy and nearly all the patients undergoing high-dose 
chemotherapy and allo-HSCT or radiation for head and neck cancers (Elting et al., 2003; 
Elting, Cooksley, Chambers, & Garden, 2007; Legert, Remberger, Ringdén, Heimdahl, & 
Dahllöf, 2014). It is the painful inflammation and ulceration (disintegration of tissue) of the 
mucosal lining of the GIT. Symptoms evolve gradually, from atrophic lesions to deeper 
ulceration, causing severe pain and diarrhea (Van Sebille et al., 2015; Sonis, 2004). In 
particular, the lesions in the oral cavity can be very painful, requiring parenteral nutrition 
and treatment with narcotics and antibiotics, which may lead to a longer hospital stay. This 
condition often implies reducing the dosages of chemotherapeutics or postponing 
treatment. Ultimately, this can decrease the chance for remission or cure and compromise 
survival outcome in cancer patients. 
In 2004, Sonis introduced a model which divides mucositis pathogenesis into five phases 
(Figure 1.2.2): initiation with formation of reactive oxygen species (ROS), primary damage 
response including induction of messenger molecules, signal amplification, disruption of 
the epithelial barrier with ulceration and finally healing lead by cell proliferation (Sonis, 
2004).  
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Figure 1.2.2: The five stages in the pathobiology of mucositis. (Sonis, 2004) 
More precisely, cytotoxic agents and radiation lead to damage and apoptosis of quickly 
dividing cells, such as cells of the oral and GIT mucosa. Additionally, ROS are formed, 
damaging cells and tissues, while also stimulating macrophages and inflammatory 
pathways. Altogether, different control mechanisms including the transcription factor  
NF-κB are activated, which mediates gene expression and synthesis of different 
inflammatory molecules including pro-inflammatory cytokines (such as TNF-α, IL-6 and IL-
1β) and tissue injury begins. These cytokines further activate NF-κB in other cells, 
marking the signal amplification phase followed by ulceration, the formation of painful 
lesions. At this stage, the loss of mucosal integrity increases the risk for infection, 
especially in neutropenic patients. In most cases, ulcers heal spontaneously once the 
cancer treatment has been halted (Al-Dasooqi et al., 2013; Sonis, 2004).  
1.2.4.2   Graft-versus-host disease 
Graft-versus-host disease is an immunological disorder that mostly affects the skin, GIT 
and liver and is the main complication after allo-HSCT (Ferrara et al., 2009). The severity 
of acute GvHD (aGvHD) is scaled according to the involvement of the three mainly 
affected organs with overall grades ranging from I (mild) to IV (very severe). In 1966, 
Billingham defined three requirements for development of GvHD: (1) the graft must 
contain immunologically competent cells; (2) the recipient must express antigens that are 
not present in the donor; and (3) the recipient must be incapable of immunologically 
eliminating the transplanted cells (Billingham, 1966). 
In general, aGvHD is defined as GvHD occurring within 100 days after allo-HSCT while 
GvHD arising later is defined as chronic GvHD. Symptoms of aGvHD include skin rash, 
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Mucositis
tiate a series of dynamic interactions that push the
process along and, in some cases, amplify activity
within the tissue.
For the sake of convenience, the biological de-
velopment of mucositis can be divided into five
phases: (1) initiation, (2) messag  generati n, (3)
signaling and amplification, (4) ulceration, and (5)
healing (Figure 3).
Initiation. Both DNA and non-DNA damage are
noted almost immediately after exposure to
radiation or chemotherapy. DNA strand breaks are
noted in the epithelium as well as in the cells of
the submucosa, causing a relatively small propor-
tion of cells to die quickly. For the majority of oth-
ers, however, the initial insult starts a cascade of
biological events. Many of these events are medi-
ated by the generation of reactive oxygen species,
which occurs shortly after radiation and chemo-
therapy. Reactive oxygen species have a far-ranging
and broad biological downstream impact.
Message generation. Besides their ability to cause
cellular injury directly, radiation, chemotherapy,
and reactiv  oxygen species effectively activate a
number of central biological control mechanisms,
Figure 3 Pathobiology of Mucositis: A Five-Stage Process
The biological sequence of mucositis can be arbitrarily divided into five stages or phases: initiation, upregulation and message
generation, amplification and signaling, ulceration, and healing. Initiation is characterized by direct irreversible and reversible
damage to DNA, generation of, and the coincident activation of other pathways that are independent of reactive oxygen spe-
cies. During the upregulation and message generation phase, transcription factors, such as NF-κB, are activated to upregulate a
number of genes in the endothelium, fibroblasts, macrophages, and epithelium, resulting in the production of messaging and
effector proteins, such as pro-inflammatory cytokines and enzymes. Apoptosis and tissue injury ensue, as do a series of biolog-
ically mediated feedback events that result in amplification of injury (amplification and signaling). All of this activity culminates
in ulceration, the stage in which epithelial integrity is destroyed. Not only is this stage the most symptomatic, but bacteria
colonizing the ulcer’s surface potentiate the injury through shed cell-wall products and, in the presence of granulocytopenia,
may cause bacteremias and sepsis. Ultimately, spontaneous healing occurs. This phase also is biologically dynamic, its success
being dependent on effective communication between the mesenchyme and the epithelium.
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including a select group of transcription factors.
Among them, perhaps one of the most important
is NF-κB [33]. Until activated, NF-κB lies d rmant
in the cytoplasm. Once activated, it moves to the
nucleus, where it is capable of upregulating up to
200 genes, including genes that code for pro-in-
flammatory cytokines and adhesion molecules. As
these genes are upregulated, effector proteins are
produced and tissue injury begins. Other transcrip-
tion factors are also activated, and each is associ-
ated with the expression of genes and their associ-
ated biologically active proteins. Simultaneously,
sphinogmyelinases (neutral and acidic) and cera-
mide synthase are activated by radiation, chemo-
therapy, and reactive oxygen species. Ceramide-
mediated apoptosis results in the death of
submucosal endothelial cells [22] and fibroblasts.
Fibroblast destruction is associated with the gen-
eration of fibronectin, the production of metallo-
proteinases, and additional apoptosis. All of these
changes occur rapidly and in tissue that clinically
appears normal.
Signaling and amplification. The production of
proteins has two effects, one directly aimed at caus-
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nausea, watery or bloody diarrhea, vomiting and severe abdominal pain. Chronic GvHD 
comprises different symptoms as for example skin dispigmentation, nail dystrophy, vaginal 
sclerosis, weight loss and pericarditis (Ferrara et al., 2009).  
Different factors influence the risk of developing GvHD, such as the source of the graft 
(Bensinger, 2013), recipient age (Hahn et al., 2008), sex disparity between donor and 
recipient (Flowers et al., 2011; Jagasia et al., 2012), related or unrelated donor (Flowers 
et al., 2011) and number and kind of HLA-mismatches (Flowers et al., 2011). GvHD 
occurs in 50-80 % of patients where there is an HLA mismatch, but even with HLA 
identity, 40 % of recipients develop aGvHD, due to differences in the minor 
histocompatibility antigens (Ferrara et al., 2009; Tabbara, Zimmerman, Morgan, & Nahleh, 
2002).  
 
Figure 1.2.3: The pathophysiology of aGvHD. APC: antigen presenting cell; TNFα: tumor necrosis factor α; 
IL 1=interleukin 1; IFN γ=interferon γ; LPS=lipopolysaccharide; Treg=regulatory T cell; Th1=T helper 1 cell; 
CTL=cytotoxic T lymphocyte; Mϕ=macrophage (Ferrara et al., 2009). 
GvHD occurs when donor T cells respond to proteins on the host cells such as the HLAs, 
which are highly polymorphic and individual-specific. Pathophysiology of aGvHD can be 
divided into three phases (Figure 1.2.3). Conditioning damages patient cells and causes 
Seminar
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The third eﬀ ector phase of the graft-versus-host process 
(fi gure 3) is a complex cascade of cellular mediators (such 
as cytotoxic T lymphocytes and natural killer cells) and 
soluble infl ammatory agents (eg, TNFα, interferon γ, 
interleukin 1, and nitric oxide).2,29 These molecules work 
synergetically to amplify ocal tissue injury and further 
promote infl ammation and target tissue destruction.
The cellular eﬀ ectors of acute GVHD are mainly 
cytotoxic T lymphocytes and natural killer cells.49 Cytotoxic 
T lymphocytes that prefer to use the Fas and FasL pathway 
of target lysis seem to predominate in GVHD liver 
damage (hepatocytes express large amounts of Fas) 
whereas cells that use the perforin and granzyme 
pathways are more important in the gastrointestinal tract 
and skin.2,74 Chemokines direct migration of donor T cells 
from lymphoid tissues to the target organs in which they 
cause damage. Macrophage infl ammatory protein 1α and 
other chemokines (such as CCL2–CCL5, CXCL2, CXCL9, 
CXCL10, CXCL11, CCL17, and CCL27) are overexpressed 
and enhance homing of cellular eﬀ ectors to target organs 
during experimental GVHD.75 Expression of integrins, 
such as α4β7 and its ligand MADCAM1, is also important 
for homing of donor T cells to Peyer’s patches during 
intestinal GVHD.52,76,77
Microbial products such as lipopolysaccharide, which 
leak through damaged intestinal mucosa or skin, can 
stimulate secretion of infl ammatory cytokines through 
Toll-like receptors.49,78 The gastr intestinal tract is 
especially susceptible to damage from TNFα, and the 
gastrointestinal tract has a major role in amplifi cation 
and propagation of the cytokine storm characteristic of 
acute GVHD.49 TNFα can be produced by both donor and 
host cells and it acts in three diﬀ erent ways: (1) it activates 
APCs and enhances alloantigen presentation; (2) it 
recruits eﬀ ector cells to target organs via induction of 
infl ammatory chemokines; and (3) it directly causes 
tissue necrosis (as its name suggests).79–81
Prevention of GVHD
On the basis of evidence from animal models for the 
central role of T cells in initiation of GVHD, many clinical 
studies of T-cell depletion as prophylaxis for the disease 
were undertaken in the 1980s and 1990s. Three main 
depletion strategies were studied: (1) negative selection 
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Figure 3: Pathophysiology of acute GVHD
IL 1=interleukin 1. IFN γ=interferon γ. LPS=lipopolysaccharide. Treg=regulatory T cell. Th1=T-helper 1 cell. CTL=cytotoxic T lymphocyte. 
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release of inflammatory cytokines (such as TNF-α, IL-1 and IL-6), which leads to 
activation of antigen-presenting cells (APCs, such as dendritic cells, macrophages, 
Langerhans cells and B cells) (Ferrara et al., 2009; Harris, Ferrara, & Levine, 2013). In the 
second step, host APCs activate mature donor cells, producing T helper cell type 1 (TH1) 
cytokines (like interferon γ, IL-2 and TNF-α). In the third phase, TH1 cells activate 
proliferation of activated cytotoxic T lymphocytes and natural killer cells. Local tissue injury 
is amplified by the interplay of these cellular mediators and inflammatory agents.  
1.2.5 Influence of the microbiome on anticancer treatment side effects and on 
treatment outcome  
A relatively new area of investigation is whether the GIT microbiome influences the 
occurrence of side effects during anticancer treatment and the outcome of therapy. 
Especially interesting in this context are development of mucositis and GvHD. The main 
affected organs in both cases are body parts, which are highly colonized by bacteria, such 
as the oral cavity and the GIT, which points towards a possible involvement of bacteria in 
development of those side effects. 
According to the generally accepted model introduced by Sonis, the GIT microbiome plays 
no role in the development and pathophysiology of mucositis (Sonis, 2004). A review by 
van Vliet and co-authors however, suggests an important role of the commensal GIT 
microbiome in the development of inflammatory digestive tract diseases, including 
mucositis (van Vliet et al., 2010). Their review suggests different pathways in which the 
intestinal microbiome can influence development of mucositis, which are listed hereafter. 
Some bacteria or bacterial parts decrease NF-κB activation, herewith they decrease 
production of inflammatory cytokines and influence the inflammatory process. Commensal 
bacteria increase tight junction strength, influence the composition of the mucus layer and 
contribute to epithelial repair. Therefore, they improve the epithelial barrier function in 
different ways. Moreover, the resident microbiota in a healthy intestine regulate the 
expression of immune effector molecules such as IgA (van Vliet et al., 2010). On the other 
hand, anticancer treatment can damage the GIT epithelium, reduce intestinal integrity and 
lead to a loss of barrier function. Tissue damage and translocation of microbes and 
microbial products can elicit an inflammatory response, aggravating mucositis. 
A systematic review by Touchefeu et al. indicates that cytotoxic and radiation therapy 
leads to important changes in the composition of the GIT microbiota, generally with a 
decrease in Bifidobacterium, Clostridium cluster XIVa, Faecalibacterium prausnitzii and an 
increase in Enterobacteriaceae and Bacteroides (Touchefeu et al., 2014). It is suggested 
that these changes might be linked to development of mucositis, diarrhea and bacteremia. 
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As mentioned above, studies have established that NF-κB is implicated in regulation of 
mucositis and is being upregulated in the signal amplification phase (Logan et al., 2008; 
Stringer et al., 2013). Different bacterial molecules such as lipopolysaccharides (LPS) and 
flagellin activate TLRs, which, in turn upregulate the NF-κB pathway. Changes in the 
composition of the GIT microbiome and following activation of TLRs and NF-κB which is 
usually down-regulated by commensals, might link the microbiota to development of 
mucositis. Prophylactic fluconazole mouthwash has been shown to decrease the rate of 
severe mucositis (Rao et al., 2013), indicating that also fungi can amplify mucositis. 
According to the generally accepted pathophysiology of GvHD, the microbiome could also 
be involved in its development or amplification. Both in the first and in the third phase (as 
described in the previous section), pathogen-associated molecular patterns (PAMPs) such 
as LPS could lead to further activation of immune cells and secretion of pro-inflammatory 
cytokines (Ferrara et al., 2009). Additionally, the damaged intestinal mucosa could allow 
translocation of PAMPs and thereby trigger additional inflammatory cytokine production 
causing apoptosis. 
Intensive cancer treatment results in damage to the GIT and decreases its epithelial 
barrier function, which allows microorganisms or bacterial products to enter the blood 
circulation (Fuji, Kapp, & Einsele, 2014; van der Velden et al., 2013). Immune response in 
form of inflammatory cytokine production, followed by sepsis or systemic infections is a 
consequence. Therefore, it used to be a quite common approach to apply total or 
selective gut decontamination on patients receiving allo-HSCT for prevention of GvHD 
development and infection. This is based on fundamental murine studies by van Bekkum 
and colleagues in which they treated mice with irradiation and allogeneic bone marrow 
transplantation. Less severe GvHD respectively no GvHD development was observed in 
mice treated with bacterial decontamination respectively when working with germ-free 
(GF) mice (Van Bekkum & Knaan, 1977; Van Bekkum, Roodenburg, Heidt, & Van der 
Waaij, 1974). However, in clinical practice, incomplete rather than complete 
decontamination is often achieved (Holler et al., 2014). In addition, newer studies have 
shown that a diverse microbiome correlates with a lower occurrence of GvHD and a 
higher survival rate (Jenq et al., 2015; Y Taur et al., 2014).  
Several recent studies, which have focused on the analysis of the microbiota composition 
before and after allo-HSCT observed a drastic loss in microbial diversity in the patient 
after receiving the treatment. This shift was more pronounced in patients who developed 
GIT GvHD (Holler et al., 2014; Jenq et al., 2012). Lower diversity has been linked to 
higher mortality, especially to death due to transplant related causes like infection and 
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GvHD (Y Taur et al., 2014) whereas higher diversity, likewise, has been associated with 
reduced GvHD-related mortality (Jenq et al., 2015). A retrospective study indicated that 
treatment of neutropenic fever with different antibiotics (imipenem-cilastatin and 
piperacillin-tazobactam) was linked to increased GvHD-related mortality at 5 years (Shono 
et al., 2016). Similarly, a recent retrospective study linked early use of antibiotics to higher 
transplant-related mortality (Weber et al., 2017). Although it is not exactly clear how 
diversity relates to the lower mortality, one aspect might be that the normal commensals 
present in a diverse community enhance resistance against infection by GIT pathogens by 
colonization resistance, filling specific ecological niches within the GIT. Likewise, a diverse 
microbial community might contain SCFA producers, which contribute to induction of 
colonic Tregs.  
The onset of GvHD was often accompanied by an increase in the abundance of members 
of the genus Enterococcus (Biagi et al., 2015; Holler et al., 2014) as well as by a reduction 
in abundance of Clostridiales or specific members of this order, including 
Faecalibacterium  spp. and Ruminococcus spp. (Biagi et al., 2015; Jenq et al., 2012; 
Simms-Waldrip et al., 2017). A higher abundance of another Clostridiales member, the 
genus Blautia has been linked to reduced GvHD-related mortality (Jenq et al., 2015). 
Many members of the order Clostridiales (including the genera mentioned beforehand 
Faecalibacterium spp. and Ruminococcus spp.) are known butyrate-producers (Morrison 
& Preston, 2016). Butyrate is known to reinforce the epithelial barrier and inhibit 
inflammatory response (Canani et al., 2011). In this way, depletion of these health-
promoting bacteria might result in higher inflammation rate and thus, onset of GvHD. In a 
recent murine study, butyrate was the main component found to be linked to mitigation of 
GvHD, overall survival and improved intestinal epithelial cell junction integrity (Mathewson 
et al., 2016). The same effect could be observed when administering the mice 17 
rationally selected strains of Clostridia that have been shown to increase amounts of 
butyrate and induction of Treg cells (Atarashi et al., 2013; Mathewson et al., 2016).  
Severe GIT GvHD has been seen to correlate with a loss in Paneth cells in biopsies 
(Levine et al., 2013). α-defensins, the principal AMPs secreted by Paneth cells, play an 
important part in keeping a balanced microbiome by having bactericidal activity against 
noncommensals. Eriguchi et al. observed that Paneth cells in mice were affected by GIT 
GvHD (Eriguchi et al., 2012). Therefore, GIT GvHD itself could lead to a loss in Paneth 
cells, which would in turn promote a dysbiotic state, allowing the overgrowth of pathogens 
and thus, result in an overall decrease in diversity.  
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Although the attention to commensal intestinal bacteria in human health and disease is 
growing, the link between the intestinal microbiome and anticancer treatment-induced 
mucositis and GvHD is still obscure. Understanding the clinical relevance of imbalance in 
the GIT microbiome and further the possibility to restore homeostasis could improve the 
treatment of cancer patients and therefore decrease the overall mortality from cancer.  
1.2.6 Influence of the gastrointestinal microbiome on the efficacy of anticancer 
treatments 
Recently, the GIT microbiome has been shown to influence efficacy of anticancer 
components (Iida et al., 2013; Sivan et al., 2015; Vétizou et al., 2015; Viaud et al., 2013).  
Cyclophosphamide (CTX) is an important cancer drug. This alkylating agent is used for 
treating different kinds of cancer but also autoimmune diseases. It has the ability to initiate 
antitumor immune responses by stimulating the generation of TH1 and TH17 cells which in 
turn control cancer outgrowth (Viaud et al., 2011). Viaud and colleagues showed that 
treatment with antibiotics, for example vancomycin and colistin, decreases the efficacy of 
CTX against MCA205 sarcoma. Also, size reduction of the tumor due to CTX treatment 
was greater in SPF mice than in GF mice (Viaud et al., 2013). In fact, CTX decreases 
intestinal barrier integrity and facilitates translocation of specific Gram-positive bacteria 
into secondary lymphoid organs. Here, these bacteria stimulate an anticancer immune 
response (Viaud et al., 2013) (Figure 1.2.4).  
 
Figure 1.2.4: Influence of the GIT microbiome on tumor promotion and tumor management. GIT 
microbiome can drive tumor development. On the other hand, it can influence the efficacy of 
chemotherapeutic drugs, thus, influence tumor management, CTX = cyclophosphamide; CpG-ODN = CpG-
oligodeoxynucleotides (Modified from Perez-Chanona & Jobin, 2014). 
A similar effect was observed in a study by Iida and colleagues, where mice were 
pretreated with broad-spectrum antibiotics (vancomycin, imipenem and neomycin) before 
being inoculated with subcutaneous tumors and treated with immunotherapy or 
chemotherapy. Comparison of gene expression of three transplantable tumor models in 
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mice treated with these antibiotics showed a down-regulation of genes related to 
inflammation, phagocytosis, antigen presentation and adaptive immune response 
whereas genes related to tissue development, cancer and metabolism were upregulated 
(Iida et al., 2013). Mice treated with antibiotics and GF mice showed reduced tumor 
regression and survival when treated with oxaliplatin and cisplatin, two platinum salts, or 
with CpG-oligodeoxynucleotides (CpG-ODN) (Figure 1.2.4). Oxaliplatin damages tumor 
cells with ROS (Laurent et al., 2005). Mice treated with antibiotics and GF mice displayed 
immune cells producing less ROS-generating enzymes. The GIT microbiome seems to 
play a role in preparing the immune system and the antitumor immune response.  
Recently, two studies have shown that the efficacy of ICIs is also influenced by specific 
bacteria. In both studies, efficacy of ICI was reduced in GF mice and mice treated with 
antibiotics. Polysaccharide A produced by different species of Bacteroides spp. was found 
to induce maturation of intratumoral dendritic cells and TH1 cells. An increased antitumoral 
immune response could be observed when administering these bacteria to wild-type mice 
(Vétizou et al., 2015). In another study, different bifidobacteria were positively linked to the 
amount of antigen-presenting cells in tumors, leading to a better response to ICI treatment 
(Sivan et al., 2015).  
In vitro studies and subsequent in vivo murine studies have shown that the efficacy of 
several chemotherapeutic agents is increased or decreased due to interaction with 
specific bacteria. The available data suggests that specific bacterial enzymes are affecting 
the efficacy of the drugs (Lehouritis et al., 2015). These recent results indicate that the 
microbial composition and products in the intestine influence the efficacy of anticancer 
components, often by influencing the immune system. The ability to increase the efficacy 
of the anticancer treatment regimens would allow to use a less intense treatment or fewer 
cycles, possibly resulting in less adverse side effects and ultimately in a better outcome 
for patients. Altogether, this proves the importance of the microbiome in cancer treatment 
and therapeutic outcome and the perspective of incorporating microbiome in cancer 
treatment, but also the need for further investigations in the field. The GIT microbiome 
could be seen as an additional factor influencing cancer treatment and its outcome and 
should be modulated in a way that it could improve treatment outcome. However, 
currently, this is not possible. Rather, prophylactic broad-spectrum antibiotics are used, 
which do not distinguish between commensals and pathobionts and therefore can 
culminate in dybiosis, potentially eliminating bacteria that could have a beneficial effect on 
treatment outcome. 
 
1. Introduction 
!25 
1.3 Antibiotics, antibiotic resistance genes and alternative treatments 
Patients undergoing anticancer treatment are especially prone to infections, as they are 
often neutropenic or completely immunodeficient. Thus, antibiotic treatment is needed as 
prophylaxis or for the treatment of infections. However, the use of antibiotics may trigger 
dysbiosis by selection for pathogens expressing antibiotic resistance genes (ARGs) and 
lead to the emergence of multi-drug resistant (MDR) bacteria. 
The discovery of antibiotics has greatly impacted modern medicine and has helped to 
control infectious diseases that were major causes for morbidity and mortality. As many 
antibiotics and antimicrobial molecules are produced by microorganisms, resistance 
mechanisms have also been present in microbial communities, long before humans have 
started to use antibiotics in clinical settings. For example, ARGs have been identified in a 
cave in New Mexico that had been isolated for 4 million years (Bhullar et al., 2012), in an 
11th century AD mummy (Santiago-Rodriguez et al., 2015), and in 30,000 year-old 
permafrost sediments (D’Costa et al., 2011). This shows that antibiotic resistance 
predates selective pressure of antibiotics usage in clinical settings. However, the recent 
prevalence in the use of antibiotics drives the emergence of higher rate of antibiotic 
resistance by microorganisms and the appearance of MDR organisms, a problem that we 
are facing today (Goossens, Ferech, Vander Stichele, & Elseviers, 2005; Sun, Klein, & 
Laxminarayan, 2012). This in turn has led to an increased risk of fatal infections in 
susceptible patients, as for example in immune compromised cancer patients during 
therapy, who are usually treated with antibiotics as prophylactic agents. Also, antibiotics 
given to livestock or sprayed on fruit trees eventually affect the environmental microbiome 
and favour propagation of resistance mechanisms (Angenent, Mau, George, Zahn, & 
Raskin, 2008; Levy, 2002).  
Antibiotic resistance has recently been listed to one of the greatest threats to human 
health in the World Economic Forum Global Risks report (World Economic Forum, 2016), 
with 700,000 people dying of resistant infections each year (Neill, 2016). In Europe alone, 
around 25,000 patients die yearly as a result of MDR bacterial infections and this adds to 
€ 1.5 billion hospital and treatment costs (ECDC/EMEA, 2009). It is estimated that by 
2050, MDR pathogens will kill 10 million people a year (Neill, 2016). Therefore, there is an 
urgent need for discovery of new antibiotics and modification of existing antibiotics. 
Similarly, there is a high interest in new databases, which allow detection of ARGs in 
sequencing datasets. Updated databases as well as new tools, allowing detection of the 
genes in large MG datasets are currently being developed and published (Jia et al., 2016; 
Lakin et al., 2016). 
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Antibiotic resistance can be intrinsic or acquired. Intrinsic resistance is inherent to an 
organism and includes the absence of the antibiotic target, low cell permeability 
preventing access to the target, efflux or inactivation of the drug (Cox & Wright, 2013). 
Resistances can be acquired by mutation of pre-existing target genes or by horizontal 
gene transfer of ARGs via transformation, transduction or conjugation (Blair, J. M. A., 
Webber, M. A., Baylay, A. J., Ogbolu, D. O, Piddock, 2015; Huddleston, 2014). Although it 
is generally assumed that acquired ARGs represent a fitness cost, studies have shown 
that resistant populations can persist even four years after antibiotic treatment, showing 
that carrying these genes does not lead to a reduced fitness (Jakobsson et al., 2010; 
Jernberg, Löfmark, Edlund, & Jansson, 2007; Sjölund, Wreiber, Andersson, Blaser, & 
Engstrand, 2003). Studies have shown that the number of ARGs within an individual's 
microbiome increases over time as the person ages and is exposed to more antibiotics. 
But also in subjects that have never been treated with quinolones (one group of broad-
spectrum antibiotics), 40 % of the bacteria in humans and animals carry corresponding 
resistance genes (Field & Hershberg, 2015). Consequently, the human GIT microbial 
community, even of healthy individuals without antibiotic treatment, comprises a diversity 
of different ARGs (Bartoloni et al., 2004; Gibson, Forsberg, & Dantas, 2014; M. O. A. 
Sommer, Church, & Dantas, 2010).  
Alternatives to currently used traditional antibiotics could consist of bacteriocins, 
microcins, structurally nanoengineered antimicrobial peptide polymers (SNAPPs) and 
phage therapy. Bacteriocins and microcins largely target the same bacterial 
compartments and processes as conventional antibiotics (Cavera, Arthur, Kashtanov, & 
Chikindas, 2015). An advantage is that broad- but also narrow-spectrum bacteriocins 
exist, however as for traditional antibiotics, emergence of resistances is a threat (Cotter, 
Ross, & Hill, 2013). SNAPPs are antimicrobial agents, which interact with microbial 
membranes and therefore elicit less resistance development than traditional antibiotics, 
which act inside of bacterial cells. SNAPPs have recently been shown to be active against 
gram-negative bacteria, incuding different colistin-resistant and multidrug-resistant 
pathogens (Lam et al., 2016). One advantage of phages as treatment is that they usually 
only target a limited range of bacterial strains (Kuntz & Gilbert, 2017). Concerns regarding 
this treatment method however include the possibility of emergence of resistance 
mechanisms or a system able to degrade viral DNA (such as clustered regularly inter-
spaced palindromic repeats (CRISPRs)), as well as the risk of phages carrying and 
transferring ARGs into different bacteria via transduction (Nobrega, Costa, Kluskens, & 
Azeredo, 2015). Also, phages could be recognized and rapidly removed by the immune 
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system. Thus, several questions and concerns have to be solved before phage therapy 
could be applied to humans. 
Commensal bacteria prevent from overgrowth of pathogens in different ways, i.e. by 
activating the innate immune defences, via nutrient competition, occupation of specific 
niches or production of AMPs. Antibiotic treatment allows overgrowth of pathogens not 
only by selecting antibiotic-resistant bacteria, but also by killing bacteria that provide 
colonization resistance. Opening of ecological niches allows proliferation of pathogens. 
Loss of commensals also results in higher availability of nutrients, especially of sugars, 
which favors pathogen expansion. One important example is Clostridium difficile infection 
(CDI), which is a leading cause of hospital-associated diarrhea, causing an estimated cost 
of 5.4 billion US dollars annually (Desai et al., 2016). The two biggest risk factors for this 
infection are antibiotic intake and exposure to this organism (Slimings & Riley, 2014; 
Surawicz et al., 2013). CDI is also a major concern in patients who undergo an allo-HSCT 
(Alonso et al., 2012) with reported ratios of around 15 % or even 18 % (Chopra et al., 
2011; Trifilio, Pi, & Mehta, 2013). It is generally accepted that a severe perturbation 
(dysbiosis, caused by intake of broad-spectrum antibiotics) allows the expansion of 
pathogenic strains of C. difficile. The first treatment of CDI includes different antibiotics 
(metronidazole or vancomycin), however, many patients develop recurrent chronic CDI. 
Fecal microbiota transplantation (FMT) is recently being applied in the treatment of 
patients with recurrent CDI, where cure rates of 90 % have been reported (Brandt et al., 
2012). Intestinal domination of vancomycin-resistant Enterococcus (VRE) is often 
observed in patients undergoing allo-HSCT as result of nosocomial acquisition or 
extensive exposure to broad-spectrum antibiotics. VRE are one of the most frequently 
encountered bloodstream infections in patients undergoing allo-HSCT and this has been 
associated with high mortality in these patients (Kamboj et al., 2010; Y. Taur et al., 2012; 
Y Taur et al., 2014). 
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1.4 Aims of this work  
The GIT microbiome has recently gained a lot of interest and there is growing evidence, 
that this complex community of organisms can affect the efficacy of anticancer treatment, 
development or severity of severe side effects and influence overall treatment outcome. 
1.4.1 Identify changes in the GIT microbiome during treatment 
The first objective of this work is to describe in detail how the GIT microbiome changes 
during different chemotherapy regimens and myeloablative treatment followed by allo-
HSCT. As there is a tight interaction between the host intestinal mucosa and immune 
system and the commensal microbiome, changes in the status of the patient might be 
reflected in dynamics of the GIT microbiome community composition before, during and 
after treatment. 
1.4.2 Discern how the GIT microbiome might be involved in the development of 
anti-cancer treatment side effects 
Recent studies indicate that the GIT microbiome might be implicated in development or 
severity of important treatment side effects, such as mucositis and GvHD (Biagi et al., 
2015; Holler et al., 2014; Touchefeu et al., 2014). Patterns within the microbial community 
might be linked to development of these side effects. Importantly, this knowledge could 
help in the formulation of measures to prevent mucositis and GvHD development. 
1.4.3 Assess if and how metagenomic and metatranscriptomic sequencing could 
be used in personalized medicine 
In addition to taxonomic profiling of the GIT microbiome by 16S and 18S rRNA gene 
amplicon sequencing, this study includes MG and MT sequencing, which allows the 
description of the functional capacity and expression within the community. Additional 
information gathered from these methods could help in expanding our understanding of 
the complex interactions within the GIT microbiome and with its host. Ultimately, this 
knowledge might help in adjusting therapy regimens, thereby improving the overall 
outcome. 
 
To assess the structural and functional changes within the GIT microbiome throughout 
anticancer treatment, fecal samples from patients following different treatment regimens 
were collected at different time points throughout this treatment. An integrated-omics 
approach was used, including 16S, 18S rRNA gene amplicon sequencing, metagenomics 
and metatranscriptomics. 
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Phylogenetic marker gene sequencing (16S and 18S rRNA gene amplicon sequencing) 
allows taxonomic profiling of the microbial community. In addition to marker gene 
sequencing, this study also includes MG sequencing, as it provides information about the 
functional potential of the microbial community or individual taxa within the community. 
This gives further insights into the interaction between the host and the microbiome and 
analysis of for example antibiotic resistance genes, which might play an important role in 
this setting.  
Although culture-independent methods such as rRNA gene amplicon sequencing and 
whole MG sequencing are not yet part of clinical routine, these applications could in the 
future play an important role in diagnostics and in tailoring treatments to the specific 
individual needs. Drastic reductions in sequencing costs (Wetterstrand, 2016) but also in 
time and higher throughput sequencing technologies (Neelapu & Surekha, 2016) now 
permit to apply next-generation sequencing in the clinical setting as diagnostic tool. 
Recent studies have demonstrated how MG sequencing could be applied for example to 
identify and quickly treat foodborne outbreaks of Salmonella (Quick et al., 2015) and 
bioinformatic tools which help to identify pathogens have been developed (Flygare et al., 
2016; Greninger et al., 2015). 
This work gives first insights into the detailed information and knowledge that these 
methods provide and shows the importance of understanding the microbiome dynamics 
for future personalized strategies for anticancer treatment.  
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2 Materials and methods 
Parts of the materials and methods section are taken and modified from a manuscript that 
has been submitted to Translational Research. The respective manuscript is attached in 
the appendix: 
Appendix A.1: Anne Kaysen, Anna Heintz-Buschart, Emilie E. L. Muller, Shaman 
Narayanasamy, Linda Wampach, Cédric C. Laczny, Norbert Graf, Arne Simon, Katharina 
Franke, Jörg Bittenbring, Paul Wilmes, Jochen G. Schneider. (2017) Integrated meta-omic 
analyses of the gastrointestinal tract microbiome in patients undergoing allogeneic stem 
cell transplantation. Translational Research. (in revision). 
 
2.1 Study participants and collection of fecal samples 
The study was approved by the Ethics review board of the Saarland amendment 1 and 2 
(reference number 37/13), and by the Ethics Review Panel of the University of 
Luxembourg (reference number ERP-15-029). Fecal samples were collected by the 
pediatric oncology department and the hematology and oncology department of the 
Saarland University Medical Center. All patients, respectively their parent or guardian 
signed a written informed consent. Fecal samples were collected at different time points 
(TPs) throughout the anticancer treatment. The sampling plan is illustrated in Figure 2.1.1. 
The patients were grouped into different treatment groups (TGs) according to their 
treatment. Pediatric oncology patients with different types of cancer were included into 
TG1 – TG3. Patients within TG1 received a low intensity treatment, TG2 received a 
standard intensity treatment and TG3 underwent an intensive treatment followed by an 
autologous stem cell transplantation (auto-HSCT). In general, the first sample was taken 
at admission, before treatment was started. The second sample was collected after the 
first cycle of treatment at the nadir, the point where the leukocyte count was at its lowest. 
The third sample was taken when the blood counts recovered before the next cycle of 
treatment was started and the last sample was taken after the end of the therapy. For 
patients within TG3 or patients who were switched to TG3, samples were collected before 
and after the auto-HSCT.  
Patients recruited in the hematology and oncology department were grouped into TG4, 
whose treatment includes an intensive immune ablative treatment followed by an 
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allogeneic stem cell transplantation (allo-HSCT). Due to several reasons such as the 
overall health status of the patient or poor nutritional intake (due to loss of appetite, 
mucositis or GvHD), it was especially difficult to collect samples within this TG. Whenever 
possible, the first sample was collected before allo-HSCT (generally during the 
conditioning treatment). The next sample was taken directly after allo-HSCT, the third 
sample was taken around the engraftment period (around one month after allo-HSCT) and 
follow-up samples were taken at later time points. 
 
Figure 2.1.1: Sampling plan. Vertical arrows indicate sampling time points throughout treatment. Blue boxes 
and arrows represent treatment phases for pediatric patients grouped into three different treatment groups 
(TG1 – TG3). Red boxes and arrows indicate the treatment phases for adult patients with hematologic 
malignancies. Abbreviations: TG= treatment group; TP= time point; chemo=chemotherapy; ATG= 
antithymocyte globulin; Auto-HSCT: autologous stem cell transplantation; Allo-HSCT: allogeneic stem cell 
transplantation; GvHD: graft-versus-host disease. 
18 pediatric patients were recruited with the majority belonging to TG2. Anthropometric 
and clinical information on the study participants including age, sex, underlying disease, 
antimicrobial treatment, occurrence of severe mucositis as well as overall treatment 
outcome were collected (Table 2.1.1). As antimicrobial prophylaxis, 
trimethoprim/sulfamethoxazole (cotrimoxazole) was given twice a week, to prevent 
Pneumocystis jirovecii pneumonia. 
27 adult hematology patients were recruited. Anthropometric and clinical information on 
the study participants including age, sex, underlying disease, stem cell donor type, 
conditioning regimen, antimicrobial treatment, aGvHD development and grade as well as 
overall treatment outcome were collected (Table 2.1.2).  
TG1 
TG2 
TG3 
TG4 
Admission Chemo (light) Nadir 
Chemo and 
end of therapy Follow up 
Admission Chemo (standard) Nadir 
Chemo and 
end of therapy Follow up 
Admission Induction Chemo 
Mobilization 
Harvesting 
Chemo   
(high dose) Auto-HSCT Follow up 
Admission Conditioning:  Chemotherapy + ATG Allo-HSCT 
Recovery of 
blood counts 
GvHD 
Recovery 
Intensity 
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Table 2.1.1: Anthropometric and clinical information of the pediatric study cohort 
Patient Sex Age Underlying 
diseasea 
Treatment 
group 
Mucositis 
(min. grade 3) 
Antimicrobialsb Outcome 1.5 years 
after start of treatment 
P01 f 17 Hodgkin's lymphoma 2 no T/S, P-T alive  
P02 f 13 Ovarian germ cell 
tumor 
2 no T/S alive 
P03 f 16 Nephroblastoma 2 yes T/S alive 
P04 f 3 Nephroblastoma 1 yes T/S, P-T alive  
P05 f 8 Nephroblastoma 2 & 3 no T/S, C deceased day 521, 
tumor progression 
P07 f 4 Nephroblastoma 1 no T/S, C alive 
P08 m 4 Medulloblastoma 2 & 3 no T/S deceased day 364, 
respiratory failure 
P09 m 3 Neuroblastoma 3 yes T/S, P alive 
P10 f 14 Ewing sarcoma 2 no T/S, P-T, AF deceased day 504, 
tumor progression 
P11 f 12 Ewing sarcoma 2 no T/S, P-T deceased day 383, 
tumor progression 
P12 m 19 Relapsed ALL 2 no T/S alive  
P13 m 4 ALL 2 no T/S alive  
P14 f 8 Germ cell tumor of 
the brain 
2 & 3 no T/S alive 
P15 m 8 ALL 2 no T/S alive 
P16 m 14 NHL 2 no T/S alive 
P17 m 14 Large cell NHL 2 yes T/S alive  
P18 f 11 Hodgkin's lymphoma 2 no T/S alive 
P19 m 12 Relapsed ALL 2 yes T/S alive 
a: ALL: acute lymphoblastic leukemia, NHL: non-Hodgkin's lypmphoma 
b: T/S: trimethoprim/sulfamethoxazole, P-T: piperacillin-tazobactam, C: cefuroxime, P: phosphomycin, AF: antifungal 
!
! !
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Table 2.1.2: Anthropometric and clinical information of the study cohort recruited in the hematology department 
 
Patient Sex Age Underlying 
diseasea 
Donor 
relationship 
and HLAb 
Conditioning 
regimenc 
Antimicrobialsd GvHDe, f Outcome 1.5 years 
after allo-HSCT 
A01 m 43 lymphoma MRD FluBuCy F, M, P-T, V Skin I° alive  
A02 m 46 lymphoma MRD FluBuCy AF, M, P-T, V, 
other 
- deceased day 17, 
relapse 
A03 m 56 lymphoma MRD FluBuCy AF, F, M, P-T, 
other 
- deceased day 66, 
relapse 
A04 f 43 AML MUD BuCy AF, F, M, V Skin I° alive  
A05 m 49 lymphoma MMUD FluBuCy AF, F, M, P-T, V Skin II° deceased day 275, 
pneumonia 
A06 m 52 AML MRD BuCy AF, F, M, P-T, 
V, other 
- alive  
A07 f 63 AML MMUD FLAMSA-Bu AF, F, M, P-T, 
V, other 
Skin II°, 
GIT III° 
deceased day 268, 
GvHD 
A08 f 50 AML MUD BuCy AF, F, M, P-T, V  Skin I° alive  
A09 m 30 lymphoma MUD FluBuCy F, M, P-T - deceased day 212, 
pneumonia 
A10 m 54 AML MRD BuCy F, M, P-T Skin I°, 
GIT II° 
alive  
A11 m 58 AML MMUD BuCy AF, M, P-T, V, 
other 
Skin II° alive 
A12 m 57 lymphoma MUD FluBuCy F, M, P-T, V, 
other 
Skin III° alive  
A13 m 57 AML MRD BuCy AF, F, M, V Skin I°, 
lung II° 
alive  
A14 f 22 lymphoma MUD FluBuCy P-T, V, other - alive 
A16 m 67 AML MRD BuCy AF, M, P-T, V, 
other 
Skin II° alive 
2. Materials and methods 
!35 
A17 m 66 AML MUD BuCy F, M, V Skin II° alive  
A18 f 67 AML MUD FluBu F, M, P-T, V, 
other 
Skin III°, 
GIT III° 
deceased day 184, 
GvHD 
A19 f 58 myeloma MUD Treo/Flu F, M, P-T - deceased day 39, 
relapse 
A20 m 51 AML MMUD FLAMSA-Bu AF, F, M, P-T, 
V, other 
Skin II°, 
GIT II° 
alive  
A21 f 64 AML MUD Treo/Flu AF, M, P-T, V, 
other 
Skin II° alive  
A25 m 52 lymphoma MUD FluBuCy AF, F, M, P-T, 
V, other 
Skin III° alive 
A27 m 56 CML MRD BuCy AF, F, M, V, 
other 
Skin III°, 
GIT IV°, 
liver III 
deceased day 53, 
GvHD 
A29 f 60 ALL MRD TBI/Cy M, P-T, V - alive 
A34 m 52 AML MMUD Treo/Flu F, M, V, other - alive 
A35 m 45 lymphoma MMUD FluBuCy AF, M, P-T, V, 
other 
- alive 
A41 f 54 AML MMUD Treo/Flu F - alive 
A44 f 24 lymphoma MUD FluBuCy AF, F, M, V, 
other 
- deceased day 4, 
sepsis 
a: AML: acute myeloid leukemia, ALL: acute lymphoblastic leukemia, CML: chronic myeloid leukemia 
b: MRD: matched related, MUD: matched unrelated, MMUD: mismatched unrelated 
c: Bu: busulfan, Cy: cyclophosphamide, Flu: fludarabine, FLAMSA: fludarabine, cytarabine, amsacrine, Treo: treosulfan 
d: AF: antifungal, F: fluoroquinolone, M: meropenem; P-T: piperacillin-tazobactam, V: vancomycin 
e: Organ involvement, stages according to Glucksberg et al. (1974) 
f: Bold: GvHD with summed stages ≥ 4 considered as severe GvHD 
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2.2 Extraction of biomolecules from fecal samples 
Fecal samples were immediately flash-frozen in liquid nitrogen on-site and preserved at  
-80 °C to ensure integrity of the biomolecules of interest. The general workflow from 
sample collection to data integration is illustrated in Figure 2.2.1. 
 
Figure 2.2.1: General workflow from sample collection to data integration. Original graphics by Linda 
Wampach and from http://support.illumina.com/sequencing/sequencing_instruments/hiseq_2500.html (picture 
of the sequencer). 
Biomolecules were extracted from unthawed subsamples of 150 mg, after pre-treatment 
of the weighed subsamples with 1.5 ml RNAlater-ICE (LifeTechnologies) overnight at  
-20 °C. The biomolecules were extracted from the mixture as described in Roume, Muller, 
et al., 2013; Roume, Heintz-Buschart, Muller, & Wilmes, 2013. Briefly, the mixture was 
homogenized and biomolecules were extracted using the AllPrep DNA/RNA/Protein kit 
(Qiagen) as described in Roume, Heintz-Buschart, et al., 2013. To increase the overall 
yield, DNA fractions were supplemented with DNA extracted from 200 mg subsamples 
using the PowerSoil DNA isolation kit (MO BIO).  
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To samples with a very low yield, an adjusted protocol of the PowerSoil DNA isolation kit 
(MO BIO) was applied, which includes a few additional steps in comparison to the 
standard protocol. It starts with a phenol-chloroform-isoamyl treatment (200 µl) and an 
incubation at 65 °C for 10 minutes. Additional wash steps with ethanol were included. As 
this protocol elutes DNA and RNA, it was always followed by an RNA digestion. 1 µl of a 
100 µg/ml RNase A solution was added per 20 µl of DNA and incubated at 37 °C for 30 
min. Quality and quantity of the DNA were verified using 1 % agarose gel electrophoresis 
with Tris Acetate-EDTA running buffer (Sigma-Aldrich) and the MassRuler DNA Ladder 
Mix (Thermo Fisher Scientific), NanoDrop 2000c spectrophotometer (Thermo Fisher 
Scientific) or Qubit fluorometer (Life Technologies, Carlsbad, CA, USA), following the 
manufacturers' recommendations.  Quality and quantity of RNA extracts were verified 
using the Agilent 2100 Bioanalyzer (Agilent Technologies) or LabChip GXII Touch HT 
(PerkinElmer) following the manufacturers' recommendations. Only fractions with RNA 
integrity number (RIN, Agilent Technologies) > 7 or RNA Quality Score (PerkinElmer) > 6 
were sequenced. Extracted biomolecules were stored at -80 °C until shipment to the 
sequencing center on dry ice. 
2.3 16S and 18S rRNA gene amplicon sequencing 
Amplification and paired-end sequencing of extracted and purified DNA was performed at 
the Groupe Interdisciplinaire de Génoprotéomique Appliquée (GIGA, Belgium). 
Sequencing with 2 * 300 nt was performed using the V2 MiSeq kit on a MiSeq platform 
(Illumina). The V4 region of the 16S rRNA gene, which allows resolution of bacteria and 
archaea, was amplified using the primers listed in Table 2.3.1. Furthermore, the V4 region 
of the 18S rRNA gene, which allows resolution of eukaryotes, was amplified and 
sequenced using the primers listed in Table 2.3.1. 
Table 2.3.1: Primers used for 16S and 18S rRNA gene amplicon sequencing. 
Amplicon Primer name Sequence Reference 
16S rRNA 515F GTGBCAGCMGCCGCGGTAA L. W. Hugerth, Wefer, et al., 2014  
16S rRNA 805R GACTACHVGGGTATCTAATCC Herlemann et al., 2011 
18S rRNA 574*f CGGTAAYTCCAGCTCYV L. W. Hugerth, Muller, et al., 2014  
18S rRNA 1132R CCGTCAATTHCTTYAART L. W. Hugerth, Muller, et al., 2014 
 
The number of samples that have been sequenced per department are indicated in Table 
2.3.2. 
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Table 2.3.2: Number of patients and sequenced samples per department. 
Department Patients Samples  
Pediatrics 18 60 
Hematology 27 78 
 
2.4 16S and 18S rRNA gene amplicon sequencing data analysis 
16S rRNA gene sequencing reads were processed using the less operational taxonomic 
units scripts (LotuS) pipeline (version 1.34) (Hildebrand, Tadeo, Voigt, Bork, & Raes, 
2014) with default parameters. Within this pipeline, sequences are filtered with a C++ 
program, simple demultiplexer (sdm) and grouped into 'high-' and 'mid-' quality 
sequences. The high quality sequences are used by the software UPARSE (Edgar, 2013) 
to generate operational taxonomic unit (OTU) clusters, while the medium quality 
sequences are mapped to the established list of OTUs. Default sdm options for MiSeq 
sequences were used, consisting of a minimum sequence length (after primer removal 
and trimming) of 170 and a minimal average quality of 27 respectively 20 for high and 
medium quality sequences. Processed reads were clustered into OTUs, taxa with similar 
amplicon sequences at 97 % identity level. For taxonomic assignment, the Ribosomal 
Database Project (RDP) classifier (Q. Wang, Garrity, Tiedje, & Cole, 2007) was used. 
OTUs with a confidence level below 0.8 at the domain level were filtered out, as well as 
OTUs that were not represented by more than 10 reads in any given sample. OTUs that 
were unclassified on phylum level were selected and aligned to the NCBI nucleotide 
collection (nr/nt) database using the BLAST webservice (using program blastn). OTUs 
aligning to human, fungal or other eukaryotic genomes were removed. The final hand-
curated OTU table included 2,789 unique OTUs. Samples with a low number of reads 
(overall < 5,000 reads) were removed, concluding with an average (± standard deviation) 
of 208,000 ± 73,000 sequencing reads in each of the 134 samples.  
To process the 18S rRNA gene sequencing reads, a workflow specifically designed to 
process reads that are not overlapping was used (L. Hugerth, 2015). For classification, the 
PR2 database (Chevenet, Brun, Bañuls, Jacq, & Christen, 2006; Chevenet, Croce, 
Hebrard, Christen, & Berry, 2010; Guillou et al., 2013) was employed. After processing, 
OTUs represented by less than 10 reads in all samples were removed. OTUs belonging to 
the taxa Craniata and Streptophyta were removed, since they were most likely derived 
from human sequences or ingested food. Unclassified OTUs were aligned to the NCBI 
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nucleotide collection (nr/nt) database using the BLAST webservice (using program 
blastn). The results were hand-curated, removing OTUs that were related to human 
sequences, food, plants, viruses or phages. After removing samples from the 18S rRNA 
gene sequencing data due to a low number of reads (overall < 1,000 reads), 1381 unique 
OTUs were represented with an average (± standard deviation) of 69,000 ± 77,000 reads 
in each of the 103 samples.  
2.4.1 Diversity and statistical analyses  
Alpha-diversity describes within-sample diversity of a community. Different indices such 
as richness, evenness and the Shannon diversity index can be calculated to determine 
the diversity of a community within a sample. Richness quantifies how many different 
species or OTUs are present within a community, without taking into account different 
relative abundances. Evenness measures how species or OTUs are distributed in a 
community. The Shannon (or Shannon-Weaver) diversity index takes into account both 
richness and evenness. It is calculated as follows:  
! = !− !!!!"!!!!!!!!  
where pi is the relative abundance of species i and S is the total number of species in the 
community (Shannon & Weaver, 1948). 
Statistical analyses and plots were generated in R (version 3.2.1) (R Development Core 
Team, 2008). Alpha-diversity was determined at the OTU level, by calculating the 
Shannon diversity index and the Chao1 richness estimator after rarefaction, using the 
vegan package (Oksanen et al., 2015). The 16S and 18S rRNA gene sequencing data 
were rarefied to the lowest number of respective reads for any sample. Plots were 
generated using the R base graphics or the ggplot2 package (Wickham, 2009).  
Comparison of diversity and richness was carried out using the non-parametric Wilcoxon 
rank sum test, or, when applicable, Wilcoxon signed-rank test. When p values < 0.05 were 
observed, groups were considered as statistically significantly different. Differential 
analysis of taxa based on 16S rRNA gene sequencing data was performed using the 
DESeq2 package (Love, Huber, & Anders, 2014) and significant differences on taxonomic 
levels were determined using the Wald test, after multiple-testing adjustment with the false 
discovery rate (FDR) method after Benjamini and Hochberg. For further statistics, the 
Fisher's exact test, Spearman's rank correlation coefficient test and the Kolmogorov-
Smirnov test of the stats package were used (R Development Core Team, 2008).  
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2.5 Metagenomic and metatranscriptomic sequencing 
Metagenomic (MG) and metatranscriptomic (MT) sequencing of the extracted DNA and 
RNA fractions was conducted by GATC Biotech AG, European Genome and Diagnostics 
Centre, Germany. Ribosomal RNA (rRNA) was depleted from the RNA fractions using the 
Ribo-Zero Gold rRNA Removal kit (Epidemiology, Illumina) and a strand-specific cDNA 
library was prepared according to standard protocols, optimized by GATC. Libraries 
representing both nucleic acid fractions were sequenced using a 100 bp or 125 bp paired-
end approach on an Illumina HiSeq 2500 using HiSeq V3 reagents. A total of 97 samples 
from 17 pediatric and 21 hematology patients were sequenced. For 41 of those samples, 
MT and MG sequencing was possible, while for 56 samples, only the metagenome could 
be sequenced (Table 2.5.1). 
Table 2.5.1: Number of patients, samples, MGMT and MG only datasets per department. 
Department Patients Samples MGMT MG 
Pediatrics 17 54 32 22 
Hematology 21 43 9 34 
 
Detailed timelines indicating for each patient the day at which a sample was taken, as well 
as the sequencing method that could be applied to this sample are illustrated in Figure 
2.5.1 (pediatric department) and Figure 2.5.2 (hematology department). Vertical color 
shadings in Figure 2.5.2 indicate the time periods defined as specific TPs. 16S and 18S 
rRNA gene sequencing was performed for each sample, while it is indicated in the figures 
only if MG and MT sequencing were not possible.  
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Figure 2.5.1: Sampling timeline for pediatric patients. Timelines indicate the days samples were taken (in 
relation to the first sample). 16S and 18S rRNA gene amplicon sequencing was performed on all samples and 
additionally, applied metagenomic (MG) and metatranscriptomic (MT) sequencing is indicated for each 
sample. 
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Figure 2.5.2: Sampling timeline for patients recruited at the hematology department. The timeline 
indicates the day the samples were taken (in relation to allo-HSCT at day 0). 16S and 18S rRNA gene 
amplicon sequencing was performed on all samples and additionally, applied metagenomic (MG) and 
metatranscriptomic (MT) sequencing is indicated for each sample. 
2.6 Processing and assembly of metagenomic and metatranscriptomic 
datasets 
MG and MT datasets were processed using the Integrated Meta-omic Pipeline (IMP) 
(Narayanasamy et al., 2016a). For datasets from patient A07 (section 3.3), version 1.1 
was used. All other patient datasets were processed using version 1.2.2. Published 
human GIT microbiome MG and MT read data from four healthy individuals was obtained 
from the NCBI Sequence Read Archive [MG: SRX247379, SRX247391, SRX247401, 
SRX247405; MT: SRX247335, SRX247345, SRX247349, SRX247340] (Franzosa et al., 
2014). These sequencing reads were processed using IMP version 1.2.1 (Narayanasamy 
et al., 2016a). Data from the individuals 'X310763260', 'X316192082', 'X317690558' and 
'X316701492' are in the following referred to as the 'reference healthy microbiome', 
averaged as 'RHMs' or individually referred to as 'RHM1', 'RHM2', 'RHM3' and 'RHM4'. 
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Figure 2.6.1: Overview of the IMP workflow. Cylinders represent input and ouput. Rectangles represent 
processes. MG: metagenomic, MT: metatranscriptomic, NLDR-GS: genomic signature non-linear 
dimensionality reduction (Narayanasamy et al., 2016b). 
This fully automated pipeline comprises preprocessing of the reads, a customized iterative 
co-assembly of MG and MT reads, augmented visualizations of the resulting contigs 
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(Laczny et al., 2015; Laczny, Pinel, Vlassis, & Wilmes, 2014), variant calling, functional 
annotation of predicted genes, and provides information on the depth of coverage of 
genes based on the MG and MT datasets (Figure 2.6.1). 
In a first step, raw reads are being preprocessed, including removal of adapter 
sequences, bad quality reads, ribosomal RNA (for MT datasets) and reads mapping to the 
human genome. This is followed by the assembly of preprocessed MG and MT reads. 
This 'iterative assembly' includes several assembly rounds, each time including reads that 
were unmappable in the previous step, thereby increasing the amount of information used 
in the final set of contigs, the final assembly. The initial MG and MT reads are mapped 
back onto the final contigs, resulting alignment information is used in different analysis 
procedures such as variant calling and determination of depth of coverage. The average 
depth of coverage Dx of a gene or contig x is determined both for the metagenome and 
the metatranscriptome by calculating the average number of reads mapping to each 
nucleotide within a gene, respectively in a contig.  !! = ! !!!"#$%ℎ! 
where rx is the number of reads mapping to a gene or contig x at each nucleotide.  
Here, gene expression of a gene x is calculated as the ratio of average 
metatranscriptomic depth of coverage to the average metagenomic depth of coverage for 
individual genes x.  !! = !!!(!")!!(!") 
An additional output of the pipeline are VizBin maps, which will be explained in the 
following paragraph. 
2.7 Population-level binning of contigs from the co-assembly and 
inference of population size 
To analyze and compare the population-level structure of the microbial communities 
based on the assembled genomic information, contigs were binned into (partial) 
population-level genomes. Using VizBin (Laczny et al., 2015, 2014), 2D embeddings 
based on BH-SNE (Barnes-Hut Stochastic Neighborhood Embedding) of the pentamer 
frequency profiles of all contigs of at least 1,000 nt were produced, as part of IMP. In 
these embeddings, contigs with similar genomic signatures (pentamer frequencies) are 
closer together, hence, individual clusters of contigs represent individual populations 
(Muller et al., 2014). Population-level clusters were selected following the method 
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described in Heintz-Buschart et al., 2016. In short, the automatic workflow is based on 
DBSCAN (Ester, Kriegel, Sander, & Xu, 1996). Clusters were selected based on 
neighborhood points in a first step. Using a collection of 107 single-copy marker genes or 
'essential genes' (Albertsen et al., 2013), completeness and homogeneity of clusters were 
determined. By analyzing the MG depth of coverage of these essential genes, clusters 
with multiple copies of the same genes were further divided. Resulting bins are referred to 
as 'population-level genomes' in the following.  
Within a community, the relative population size of a cluster (i) was determined by dividing 
the number of MG reads mapping to the contigs forming this cluster (ci), by the total 
number of MG reads mapping to all the contigs used in the assembly (C) according to the 
following formula: !! = ! !! ∗ !100!  
2.8 Taxonomic affiliation of reconstructed population-level genomes 
Taxonomic affiliations of population-level genomes were determined using complementary 
methods. Contigs forming the population-level genomes were first aligned to NCBI 
nucleotide collection (nr/nt) database using the BLAST webservice (Madden, 2002). 
Parameters were left at default (using program megablast), and the output was analyzed 
using the MEtaGenome ANalyzer (MEGAN) (D. Huson, Mitra, & Ruscheweyh, 2011). 
Whenever the rpoB gene could be recovered within a population-level genome, the 
closest neighbor was determined in the nucleotide collection (nr/nt) database using the 
MOLE-BLAST webservice (Boratyn et al., 2014). Additionally, AMPHORA2 (Wu & Scott, 
2012) was used to identify the taxonomic affiliation of up to 31 bacterial or 104 archaeal 
phylogenetic marker genes. 
2.9 Reassembly 
Population-level genomes were reassembled using all MG and MT reads mapping to the 
contigs of the population-level genomes with the same taxonomic assignment. 
Reassembly of all recruited reads was carried out using SPAdes (Bankevich et al., 2012) 
(version 3.5.0) using standard parameters. MG and MT reads were subsequently mapped 
to the contigs forming this reassembly to determine expression levels and variant density. 
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2.10 Sequence comparison of population-level genomes 
The average nucleotide identity (ANI) calculator ('ANI Average Nucleotide Identity', at 
http://enve-omics.ce.gatech.edu/ani/; Goris et al., 2007) was used with standard settings 
to compare the reassembly from population-level genomes to publicly available reference 
genomes. A gene-wise protein sequence comparison of different population-level 
genomes was performed using the RAST server (Aziz et al., 2008) using standard 
parameters. 
2.11 Detection of antibiotic resistance genes 
Antibiotic resistance genes (ARGs) within a community or population were searched 
against Resfams version 1.2 (Gibson et al., 2014) using HMMer version 3.1b2 (Eddy, 
2011). We used the core version of the Resfams database, which includes 119 protein 
families. In accordance with the HMMer user manual, only identified genes with a bitscore 
higher than the binary logarithm of the total number of genes (of the community or 
population) were retained. 
2.12 Variant identification and density 
Variants were identified in population-level reassembled genomes using SAMtools 
mpileup (H. Li et al., 2009) with default settings, which include the calling of single 
nucleotide variants (SNVs) as well as the identification of small insertions/deletions 
(indels). The output was filtered using a conservative heuristic established in Eren et al., 
2015, which takes into account the ratio of the frequencies of both bases and the depth of 
coverage at the corresponding nucleotide position, in order to reduce the effect of 
sequencing errors. 
Variant density (V) in a population i was calculated by dividing the number of single 
nucleotide variant and indel positions (P) by the relative population size, more precisely 
the ratio between reads mapping to the population-level genomes (ci) and total number of 
reads (C). !! = ! !!!!!  
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2.13 Extraction, sequencing and analysis of bacterial DNA from a blood 
culture 
A bacterium was isolated from a patient's blood using the BD BACTEC FX system 
(Becton Dickinson) following the manufacturer's recommendations, by a consultant in 
medical microbiology from the institute for medical microbiology and hygiene of the 
Saarland University Medical Center. It was identified as a multidrug-resistant E. coli. 
Subcultures were grown on TSA blood agar plates and on MacConkey agar plates. DNA 
was isolated from a culture grown in standard growth medium (TSB, BHI or LB) using the 
Maxwell 16 Tissue LEV Total RNA Purification Kit on a Maxwell 16 MDx Instrument 
(Promega) according to manufacturer's instructions.  
DNA was sequenced on an Illumina MiSeq, 300 bp paired-end at GIGA. The genome was 
assembled using SPAdes (Bankevich et al., 2012) and ARGs were identified using 
Resfams, as described previously. Using ANI, nucleotide identity between E. coli 
genomes from GIT samples and the E. coli genome from the isolate were assessed. 
Using PanPhlAn (Scholz et al., 2016) and the provided database including 118 E. coli 
reference strains, their relation was assessed based on their gene set. While the 
PanPhlAn database includes 31,734 genes, only genes present in 10 or more genomes 
were included, resulting in 7,845 genes for comparison. 
2.14 Virus profiling 
The analysis tool ViromeScan (Rampelli et al., 2016) was separately applied to trimmed 
and filtered MG and MT reads to identify reads that map to eukaryotic viral genomes. 
Default parameters were used along with the eukaryotic DNA/RNA reference database 
which includes genomes of viruses that have the human as natural host, in addition to 
viruses of other vertebrates, invertebrates, fungi algae and plants. The database excluded 
bacteriophages. The relative abundance of the viral community in each sample was 
calculated as percentage of reads mapping to viral genomes of the total number of reads. 
2.15 Read-based taxonomic analyses 
Metagenomic operational taxonomic units (mOTUs) analysis for taxonomic profiling was 
performed on trimmed and filtered paired MG and MT reads individually using the MOCAT 
pipeline (Kultima et al., 2012; Sunagawa et al., 2013). This was used with standard 
parameters and the mOTU.v1.padded reference database including 10 single-copy 
marker genes (Sunagawa et al., 2013). 
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2.16 Functional analyses 
Within IMP, Prokka was used for functional annotation (Seemann, 2014), with Prodigal for 
gene prediction (Hyatt et al., 2010). Additionally, KEGG (Kyoto Encyclopedia of Genes 
and Genomes) orthologous groups (KOs) were annotated as described in Heintz-Buschart 
et al., 2016 (Kanehisa, Sato, Kawashima, Furumichi, & Tanabe, 2016). The featureCounts 
tool of the Subread package was used to count (MG or MT) reads mapping to the 
predicted genes (Liao, Smyth, & Shi, 2014). Differential analysis of functional gene 
categories and enzymes was performed using the DESeq2 package (Love et al., 2014) 
and significant differences on functional gene abundances were determined using the 
Wald test, after multiple-testing adjustment with FDR method after Benjamini and 
Hochberg. Additionally, KOs were grouped according to their KEGG pathway affiliation. 
Heatmaps were plotted using the heatmap.2 function from the gplots package.  !
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3 Results and discussion 
This chapter is divided into three sections, based on different patient cohorts that are 
focussed on in the individual sections. The first section focuses on patients from the 
pediatric department who underwent different anticancer treatments. The second section 
focuses on the adult hematology patients who underwent an allo-HSCT and the third 
section focuses on one specific adult patient. Each section first describes the general 
changes observed in the GIT microbiome community throughout the treatment, including 
assessment of alpha-diversity and changes on different taxonomic levels. The following 
parts describe the viral community and functional properties of the GIT microbiome, 
especially trends observed in the abundance of ARGs. The last part focuses on the 
possible link between the microbiome and development of mucositis or GvHD. 
 
3.1 Meta-omic analyses of the gastrointestinal tract microbiome in 
pediatric patients undergoing different anticancer treatments 
The first section focuses on the changes within the GIT microbiome of pediatric oncology 
patients undergoing anticancer treatment with different intensities and is based on 60 
fecal samples collected from 18 different patients. After processing and filtering of the 16S 
rRNA gene amplicon sequences (as described in section 2.4), 58 datasets were left for 
the following analyses, with 243,000 ± 75,000 (mean ± standard deviation) sequences per 
sample. Similarly, 67,500 ± 76,000 sequences per sample of the 40 sets of 18S rRNA 
gene sequencing data were retained. Of 32 samples, MG and MT combined datasets 
could be produced. Additionally, 22 MG-only datasets were produced. After processing 
with IMP (as described in section 2.6) which included filtering out low quality reads and 
reads mapping to the human genome, per dataset, 56,000,000 ± 21,000,000 MG 
sequences and 50,000,000 ± 15,000,000 MT sequences were kept for the following 
analyses. Co-assemblies of the preprocessed MG and MT reads were constructed which 
comprised longer contiguous sequences (contigs). For MG-only datasets, MG-only 
assemblies were contructed. Within the co-assemblies and MG-only assemblies, 158,500 
± 75,000 genes were predicted. 
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3.1.1 Patient characteristics and treatment 
Anthropometric and clinical information of the ten female and eight male patients included 
in the following analyses are provided in Table 2.1.1, and a summarized overview is 
presented in Table 3.1.1. At the start of the treatment, the patients aged between 3 and 19 
years (median 11.5). They were grouped into different treatment groups (TGs) according 
to the intensity of their treatment. Patients within TG1 received a treatment with low 
intensity, TG2 received a standard intensive treatment and TG3 underwent an intensive 
treatment followed by an autologous stem cell transplantation (auto-HSCT). Four patients 
were treated for nephroblastoma, four for acute lymphoblastic leukemia, two for Hodgkin's 
lymphoma, two for Ewing sarcoma, two for non-Hodgkin's lymphoma, one for ovarian 
germ cell tumor, one for germ cell tumor of the brain, one for neuroblastoma and one for 
medulloblastoma. Of the eighteen patients enrolled in the study, two were grouped into 
TG1, fifteen were grouped into TG2 and one into TG3. Three patients were changed from 
TG2 to TG3 during the course of their treatment. They first received a standard treatment 
and later an auto-HSCT. Five patients developed mucositis with minimum grade 3, 
meaning occurrence of severe, painful ulcers needing pain medication, with impaired 
intake of solid food. 1.5 years after start of the treatment, fourteen patients were still alive 
while four had deceased due to tumor progression or respiratory failure. 
Table 3.1.1: Summarized anthropometric and clinical information of the pediatric study cohort 
Underlying disease! Number of patients Treatment group! Age!
Nephroblastoma 4 2, 1, 2 & 3, 1 16, 3, 8, 4 
Acute lymphoblastic leukemia 4 2, 2, 2, 2 19, 4, 8, 12 
Hodgkin's lymphoma 2 2, 2 17, 11 
Ewing sarcoma 2 2, 2 14, 12 
Non-Hodgkin's lymphoma 2 2, 2 14, 14 
Ovarian germ cell tumor 1 2 13 
Germ cell tumor of the brain 1 2 & 3 8 
Neuroblastoma 1 3 3 
Medulloblastoma 1 2 & 3 4 !
3.1.2 Changes in the prokaryotic GIT microbiome in pediatric patients throughout 
cancer treatment 
Based on 16S rRNA gene amplicon sequencing of DNA extracted from 60 fecal samples 
of the patients, the prokaryotic (bacterial and archaeal) community was assessed. After 
filtering and removal of samples with a low number of reads (as described in section 2.4), 
58 of the sequenced samples were kept for the following analyses. The overall 14 most 
abundant genera within all 58 samples were identified to get an overview of the 
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composition of the GIT microbiome of the patients (Figure 3.1.1). The samples were 
usually dominated by few different genera, the most abundant ones being Bacteroides, 
Faecalibacterium and Parabacteroides. For some patients, the different samples taken at 
different time points (TPs) did not reveal drastic differences, but rather an individual 
specific composition, such as for example P02 revealing a high relative abundance of the 
genus Prevotella, at all four TPs, which expanded over a time period of over three 
months. For other patients, such as P15, strong differences in the composition between 
different TPs could be observed. 
 
Figure 3.1.1: Relative abundance of the 14 most abundant bacterial genera in fecal samples from 
pediatric cancer patients, grouped according to patient. Genera which were not comprised in the 14 most 
abundant genera are combined as 'others'. Operational taxonomic units (OTUs) which could not be classified 
at the genus level are grouped as 'unknown'. Patient ID and sampling time point (TP) are indicated below 
each respective bar and are colored according to the patient. 
In the following, the samples were grouped according to the TG and according to the TP 
within the TG (Figure 3.1.2). In TG1 and TG2, the first sample was taken at admission, 
before treatment was started. The second sample was collected after the first cycle of 
treatment at the nadir, the point where the leukocyte count is at its lowest. The third 
sample was taken when the blood counts recovered before the next cycle of treatment 
was started and the last sample was taken after the end of the therapy. For patients within 
TG3 or patients who were switched to TG3, samples were collected before and after the 
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auto-HSCT. No clear specificity of the relative abundance of bacteria distinct to individual 
TGs or TPs was apparent.  
 
Figure 3.1.2: Relative abundance of the 14 most abundant bacterial genera in fecal samples from 
pediatric cancer patients. Samples are grouped according to TPs within TG: (A) TG1, (B) TG2 and (C) TG3. 
Genera which were not comprised in the 14 most abundant genera are combined as 'others'. OTUs which 
could not be classified at the genus level are grouped as 'unknown'. Patient ID and sampling TP are indicated 
below each respective bar and are colored according to the patient. 
Differentially abundant OTUs between TP1 (before treatment) and TP2 (lowest leukocyte 
count after first cycle of treatment) were assessed. For this analysis, patients from TG2 
were included, as this TG comprised the highest number of patients. Between those TPs, 
27 differentially abundant bacterial OTUs were identified (absolute log2 fold change ≥ 1, 
FDR-adjusted p value < 0.05). Table 3.1.2 displays the 13 OTUs with the lowest adjusted 
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p value (< 0.02, Wald test, FDR-adjusted). A negative fold change indicates a lower 
relative abundance in samples collected after treatment (TP2).  
Table 3.1.2: Differentially abundant bacterial OTUs in samples from collection TP1 and TP2  
 
While the observed decrease in Clostridium cluster XIVa is in agreement with 
observations in other studies (Touchefeu et al., 2014), a different study observed an 
increase in the relative abundance of Akkermansia spp. after chemotherapy (Zwielehner 
et al., 2011), which is contrary to the current observation. Some members of the families 
Ruminococcaceae and Lachnospiraceae have beneficial, health-promoting properties 
(Ying Taur, 2016) and loss of these bacteria might have negative effects on the host. 
However, here, both decreases and increases in the relative abundance of different OTUs 
belonging to these families were observed. 
No correlations between the relative abundances of bacterial taxa (on any taxonomic 
level) and any clinical markers (including data such as calprotectin level, number or 
relative abundance of leukocytes, thrombocytes, CD3+ cells or C-reactive protein) were 
detected (Spearman's rank correlation test with multiple-testing adjustment). Similarly, no 
links between prokaryotic diversity and the clinical data were found. 
Bacterial Shannon diversity and Chao1 richness for each TP within each TG at OTU level 
were assessed after rarefaction (Figure 3.1.3). Quite drastic differences in diversity in TG1 
(Figure 3.1.3A) were observed with a median diversity of 2.6 at TP1, increasing to 3.3 at 
TP4. A similar pattern was observed for bacterial richness (Figure 3.1.3B). No statistically 
significant differences were found between different TPs in this TG. However, this TG 
comprised only two patients. With a higher number of patients and samples, the observed 
OTU Taxon log2 fold change adjusted p value 
OTU_17 Prevotella sp. -3.12 0.001 
OTU_135 Prevotella sp. -2.87 0.013 
OTU_46 Ruminococcaceae (family) -2.77 0.002 
OTU_76 Parasutterella sp. -2.62 0.002 
OTU_11 Akkermansia sp. -2.45 0.002 
OTU_194 Lachnospiraceae incertae sedis -2.37 0.002 
OTU_90 Clostridium cluster XIVa -2.22 0.002 
OTU_30 Flavonifractor sp.  1.49 0.013 
OTU_33 Clostridium cluster XVIII 1.49 0.013 
OTU_384 Clostridiales (order) 1.88 0.013 
OTU_31 Lachnospiraceae (family) 2.06 0.002 
OTU_52 Clostridium cluster XI 2.20 0.003 
OTU_35 Lactobacillus sp. 4.13 5.15E-07 
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pattern might look different, possibly more similar to the pattern observed in TG2. In TG2, 
a slight decrease in diversity throughout treatment was observed (Figure 3.1.3C). 
Bacterial richness displayed more pronounced changes with a significant decrease from 
TP1 to TP2 (samples of the same individuals: p value 0.017, Wilcoxon signed-rank test 
and over all patients: p value 0.018, Wilcoxon rank sum test, Figure 3.1.3D). In TG3, no 
drastic changes in diversity or richness could be observed (Figure 3.1.3E and Figure 
3.1.3F). Both diversity and richness were in general lower in this TG than in the other 
TGs. This might be due to the higher intensity of the treatment and due to previous 
treatments of these patients. 
 
Figure 3.1.3: Changes within gastrointestinal bacterial community structure in patients receiving 
different anticancer treatments. Boxplots depicting (A, C and E) diversity (Shannon diversity index) and (B, 
D and F) richness (Chao1 richness estimator) per collection time point (TP), for prokaryotes in (A, B) TG1, (C, 
D) TG2 and (E, F) TG3 (determined by 16S rRNA gene amplicon sequencing) The number of samples per 
collection TP is indicated above each box. Diversity and richness were determined after rarefaction of the 
dataset (* when p value < 0.05, Wilcoxon rank sum test).  
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As the GIT microbiome of infants and young children is unstable and reaches a state 
similar to that of adults at around 3-4 years (Greenhalgh et al., 2016; Voreades, Kozil, & 
Weir, 2014), I was wondering whether a difference in age of the patients was reflected in 
the microbiome. TG1 and TG3 displayed an overall lower richness than TG2 and included 
a higher ratio of younger patients. Both patients included in TG1, and one out of four 
patients in TG3, while only two out of fifteen patients in TG2, were 3 or 4 years old at 
beginning of treatment. In the following, patients were grouped according to their age with 
five patients belonging to the group with younger patients (3 or 4 years old). All remaining 
thirteen patients belonged to the group with older patients (8 years or older). A significant 
difference in richness was observed when grouping the samples independently of the TP 
(p value 0.0025, Wilcoxon rank sum test), with a lower richness for the samples from 
younger patients (Figure 3.1.4A). Richness was also plotted per TP as boxplots (Figure 
3.1.4B and Figure 3.1.4C) or as connected points (Figure 3.1.4D and Figure 3.1.4E) 
illustrating the development of richness per patient throughout the treatment. 
In general, a lower bacterial richness was observed in younger patients, and the richness 
was already lower at TP1, before treatment start. In the younger patients, a striking 
decrease in richness was observed at TP3. In the older patients, bacterial richness was 
generally higher and showed no specific pattern. In some of the older patients, a low level 
of richness was observed at some point during treatment, similar to the richness observed 
in samples from younger patients. These results indicate that richness was indeed related 
to age. In our study however, richness did change throughout the treatments indicating 
that the treatment also had a large effect on bacterial richness. 
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Figure 3.1.4: Bacterial richness in young and older children. Boxplots depicting richness (Chao1 richness 
estimator) in samples from (A) young (3-4 years, left) and older (8-19 years, right) patients. (B, C) Boxplots 
depicting richness of the same samples and patients per TP. (D, E) Richness per TP and patient indicated as 
point connected with lines. 
The GIT microbiome is usually temporally stable and inter-individual differences 
significantly higher than intra-individual differences (Brandt et al., 2012; Heintz-Buschart et 
al., 2016). Here, to compare the intra-individual to inter-individual distance between 
microbial profiles, Bray-Curtis dissimilarity was determined based on the OTUs obtained 
from 16S rRNA gene sequencing data. The intra-individual distance describes the 
variation between the microbial profiles of different TPs from each patient while the inter-
individual distance indicates the variation between the microbial profiles from different 
patients. A slightly higher inter-individual dissimilarity was observed (p value 0.024, 
Wilcoxon rank sum test, Figure 3.1.5).  
Earlier studies with healthy individuals have shown that without the influence of external 
factors, the inter-individual dissimilarity was significantly higher than intra-individual 
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differences, because of the stability of the GIT microbiome. Here, the intra-individual 
dissimilarity was high, indicating that the treatment did have a strong effect on the GIT 
microbial community. As the TGs were exposed to different intensities of treatment, a 
higher intra-individual distance in TGs with the more intense treatment might be expected. 
However, no statistically significant differences between the intra-individual distances in 
the three TGs were detected. Similarly, a higher diversity or richness at TP1 might be a 
predictor of a more stable bacterial community, which would be less affected by the 
following treatment. However, no correlation between the diversity or richness at TP1 and 
the following changes in terms of intra-individual dissimilarity was observed. Diversity or 
richness at TP1 is therefore not predictive of the level of changes within the GIT microbial 
community throughout treatment. 
 
Figure 3.1.5: Comparison of intra-individual to inter-individual distances between bacterial profiles 
3.1.3 Changes in the microeukaryotic populations of pediatric patients throughout 
cancer treatment 
While other studies have focussed on the prokaryotic community only, here, also the 
microeukaryotic community composition was assessed using 18S rRNA gene amplicon 
sequencing of DNA extracted from 60 fecal samples of the patients. During the filtering 
steps, food related reads, such as reads mapping to plants (e.g the genera Fragaria 
(strawberry) or Solanum (potato and tomato)) as well as reads mapping to the human 
genome were removed. For some samples, the majority of the reads were human or food 
related, hence, these datasets were removed due to a low number of reads after filtering. 
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38 samples were kept for further analyses. The 14 most abundant taxa were identified to 
get an overview of the composition of the GIT microeukaryotic community of the patients 
(Figure 3.1.6). Most samples were dominated by the taxon Ascomycota, which includes 
the most common microeukaryotic representatives within the human GIT, such as 
Candida spp. and Saccharomyces spp. Some samples included other taxa, for example 
P01_TP3 showed relative high levels of Blastocystis spp., a unicellular, nonflagellated 
member of the Stramenopiles belonging to the taxon Opalinata (Scanlan et al., 2014), 
which is a common member of the GIT microbiome. In P18_TP1, a common flagellate 
protozoan parasite, Dientamoeba fragilis belonging to the taxon Parabasalia was 
detected. BLAST analysis revealed that some of the abundant OTUs included in the group 
'unknown' also represented Dientamoeba fragilis. Infections with Dientamoeba fragilis can 
remain asymptomatic but can also cause abdominal symptoms such as pain, nausea and 
diarrhea (Elbakri, Al-qahtani, & Samie, 2015). 
 
Figure 3.1.6: Relative abundance of the 14 most abundant microeukaryotic taxa in fecal samples from 
pediatric cancer patients grouped according to patient. Taxa which are not comprised in the 14 most 
abundant taxa are combined as 'others'. OTUs which could not be classified at any taxonomic level are 
grouped as 'unknown'. Patient ID and sampling TP are indicated below each respective bar and are colored 
according to the patient. 
In the following, the samples were grouped according to the TG and according to the TP 
within the TG (Figure 3.1.7). In some samples, a large proportion of reads was grouped as 
'unclassified', meaning that those OTUs could not be classified at the genus level. They 
could however be classified at higher levels and the largest part of these OTUs belonged 
to the taxon Ascomycota. No clear differences in the relative abundance of 
microeukaryotes specific to individual TGs or TPs were apparent. Some patients (such as 
P07, in Figure 3.1.7A and P15, in Figure 3.1.7B) showed similar microeukaryotic 
community compositions at each TP while others (such as P01 in Figure 3.1.7B) revealed 
a more unique community composition at different TPs. 
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Figure 3.1.7: Relative abundance of the 14 most abundant microeukaryotic genera in fecal samples 
from pediatric cancer patients. Samples are grouped according to TPs within TG: (A) TG1, (B) TG2 and (C) 
TG3. Taxa which were not comprised in the 14 most abundant genera are combined as 'others'. OTUs which 
could not be classified at the genus level are grouped as 'unclassified'. OTUs which could not be classified at 
any taxonomic level are grouped as 'unknown'. Patient ID and sampling TP are indicated below each 
respective bar and are colored according to the patient. 
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In order to determine whether the microeukaryotic community evolved in the same way as 
the prokaryotic community, diversity and richness of the microeukarotic community were 
determined on the OTU level after rarefaction (Figure 3.1.8). No statistically significant 
differences in diversity or richness between different TPs within the TGs were determined. 
Overall, the microeukaryotic community exhibited a lower diversity and richness than the 
prokaryotic community. No correlation between prokaryotic and eukaryotic diversity or 
richness was detected (Spearman's rank correlation test). Development over time of both 
diversity and richness of the microeukaryotic community was different from the 
development of the prokaryotic community (Figure 3.1.3), which indicates that both 
communities were differently affected by the treatment.  
 
Figure 3.1.8: Changes in the gastrointestinal microeukaryotic community structure in patients 
receiving different anticancer treatments. Boxplots depicting (A, C and E) diversity (Shannon diversity 
index) and (B, D and F) richness (Chao1 richness estimator) per collection time point (TP), for 
microeukaryotes in (A, B) TG1, (C, D) TG2 and (E, F) TG3 (determined by 18S rRNA gene amplicon 
sequencing). The number of samples per collection TP is indicated above each box. Diversity and richness 
were determined after rarefaction of the dataset. 
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3.1.4 Variability of GIT microbiome trajectories throughout treatment 
As apparent from the overview of the prokaryotic community composition in each sample 
(Figure 3.1.1), the GIT microbiome from some patients underwent pronounced changes 
throughout treatment while the microbiome of other patients stayed relatively stable. A 
principal component analysis (PCA) on the genus level revealed similar trends (Figure 
3.1.9). One patient whose samples clustered relatively closely together (P02, marked in 
light brown in Figure 3.1.9) and one patient whose samples were quite dispersed on the 
PCA plot, especially in regards to PC1 (P05, marked in blue in Figure 3.1.9) were selected 
for a closer evaluation. Their respective samples are encircled in Figure 3.1.9. Overall, the 
samples also did not group according to the collection TP, or according to parameters 
characterizing the patient's status, such as the occurrence of mucositis, a low number of 
leukocytes, a reduced overall status or overall outcome. 
 
Figure 3.1.9: Principal component analysis (PCA) for GIT prokaryotic community composition. Each 
dot represents a sample colored according to which patient it derived from. PCA was performed on genus 
level, based on 16S rRNA gene amplicon sequencing.  
In P02, the most abundant OTUs (such as Prevotella sp., Dialister sp. and 
Faecalibacterium sp.) were the same at each TP (Figure 3.1.10A), diversity stayed quite 
high (Figure 3.1.10C), as did the richness (ranging between 445 and 610). Within the 
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cohort, patient P02 displayed the lowest mean Bray-Curtis dissimilarity between the TPs 
(0.22). In P05, the most abundant OTUs differed at each TP (Figure 3.1.10B) and there 
were important changes in diversity between the TPs (Figure 3.1.10D) as well as in 
richness (ranging from 188 to 526). Mean intra-individual dissimilarity for this patient was 
0.54. 
 
Figure 3.1.10: Variation of the microbial community structure over the course of the treatment in 
pediatric patients. (A) and (B) Relative proportions of the 14 most abundant operational taxonomic units 
(OTUs) based on 16S rRNA gene sequencing. The remaining OTUs are summarized as 'others'. (C) and (D) 
Prokaryotic diversity represented by Shannon diversity index at sampling TPs throughout the treatment. (E) 
and (F) Relative proportions of the 14 most abundant metagenomic operational taxonomic units (mOTUs) 
based on MG sequencing. The remaining mOTUs are summarized as 'others'. Plots represent the 
corresponding results for patient P02 (panels A, C and E) and patient P05 (panels B, D and F).  
For the 54 samples where MG sequencing data was available, metagenomic operational 
taxonomic units (mOTUs) were identified for taxonomic profiling. For most of the abundant 
mOTUs, classification at species level was possible. While the bacterial abundance profile 
based on 16S rRNA gene sequencing and MG sequencing largely coincide for P02 
(Figure 3.1.10A and Figure 3.1.10E), more differences are observed for P05 (Figure 
3.1.10B and Figure 3.1.10F). For example, the most abundant OTU at TP4 based on 16S 
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rRNA gene sequencing was classified as Escherichia/Shigella sp., while this seemed to 
be only lowly abundant at TP4 in the MG sequencing dataset. 
MG sequencing does not only allow taxonomic profiling but also functional profiling, which 
will be described in the next parts.  
3.1.5 Detection of antibiotic resistance genes 
Many cancer patients are immunocompromised, either due to the underlying disease, or 
due to the anticancer treatment. Therefore, they are often prone to infection, hence, 
prophylactic antibiotics or an antibiotic treatment during neutropenia or at occurrence of 
fever are often given. However, antibiotic resistance and especially the emergence of 
multi-drug resistant bacteria represent a threat. For the 54 samples with available MG 
datasets, antibiotic resistance genes (ARGs) were detected within the predicted genes 
using the Resfams database (section 2.11) and their relative abundance (percentage of 
ARGs relative to the total number of genes) was calculated (Figure 3.1.11A). The mean 
relative abundance and standard deviation within these 54 samples was 0.26 ± 0.06 %.  
While most patients received only trimethoprim/sulfamethoxazole (cotrimoxazole) 
regularly to prevent Pneumocystis jirovecii pneumonia, some patients received also other 
antibiotics. For example, patient P01 was treated with piperacillin/tazobactam before TP1, 
patient P07 before TP3, patient P04 before TP2 and TP3 and patient P05 was treated 
with cefuroxime before TP1 and TP2. For the majority of patients, a slight increase in 
relative abundance of ARGs was observed (Figure 3.1.11A and Figure 3.1.11C), however, 
also other patterns were observed as for example a decrease for P01, and a decrease 
followed by an increase for P07 and P14 (Figure 3.1.11A). Within TG1 (Figure 3.1.11B) 
the relative abundance of ARGs stayed relatively constant while a decrease followed by 
an increase was observed in TG3 (Figure 3.1.11D). However, due to the low number of 
samples within these TGs, these observations cannot be fully attributed to the respective 
treatments. In TG2, a statistically significant increase from TP1 to TP2 (p value 0.034, 
Wilcoxon rank sum test) and from TP1 to TP3 (p value 0.045, Wilcoxon rank sum test) 
was observed (Figure 3.1.11C). To summarize, especially in TG2 (which included the 
highest number of patients), an increase in the relative abundance of ARGs throughout 
treatment was observed. 
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Figure 3.1.11: Relative abundance of antibiotic resistance genes in fecal samples from pediatric 
cancer patients. (A) Samples grouped according to patient. IDs are colored according to the patient. (B – D) 
Samples combined according to TP within (B) TG1, (C) TG2 and (D) TG3. (B-D) The number of samples per 
collection TP is indicated above each plot (* when p value < 0.05, Wilcoxon rank sum test). 
3.1.6 Virome profiling within the GIT microbiome of pediatric cancer patients 
Apart from prokaryotes and eukaryotes, the GIT community also harbors viruses which 
play a part in human health and disease (Popgeorgiev, Temmam, Raoult, & Desnues, 
2013). Even viruses which are usually not harmful for their host can pose a serious threat 
in immunocompromised patients (Sahin et al., 2016). Shotgun sequencing may allow their 
detection and treatment, before they become harmful. On average, 0.014 ± 0.012 % MG 
and 0.033 ± 0.058 % MT reads were mapped onto viral genomes within the 54 (for MG) 
and 32 (for MT) samples.  
 
TP1 TP2 TP3 TP4
0.0
0.1
0.2
0.3
0.4
0.5
0.6
AR
Gs
/to
ta
l n
um
be
r o
f g
en
es
 [%
]
n= 2 n= 2 n= 2 n= 2
●
TP1 TP2 TP3 TP4
0.0
0.1
0.2
0.3
0.4
0.5
0.6
AR
Gs
/to
ta
l n
um
be
r o
f g
en
es
 [%
]
n= 12 n= 11 n= 11 n= 4
B C D 
A 
   * 
    * 
0.0
0.1
0.2
0.3
0.4
0.5
0.6
P0
1_
TP
1
P0
1_
TP
2
P0
1_
TP
3
P0
1_
TP
4
P0
2_
TP
1
P0
2_
TP
2
P0
2_
TP
3
P0
2_
TP
4
P0
3_
TP
1
P0
3_
TP
3
P0
4_
TP
1
P0
4_
TP
2
P0
4_
TP
3
P0
4_
TP
4
P0
5_
TP
2
P0
5_
TP
3
P0
5_
TP
4
P0
5_
TP
5
P0
7_
TP
1
P0
7_
TP
2
P0
7_
TP
3
P0
7_
TP
4
P0
8_
TP
1
P0
8_
TP
2
P0
8_
TP
3
P0
8_
TP
4
P0
9_
TP
1
P0
9_
TP
2
P0
9_
TP
3
P1
0_
TP
1
P1
0_
TP
2
P1
0_
TP
3
P1
1_
TP
1
P1
1_
TP
3
P1
2_
TP
1
P1
2_
TP
2
P1
2_
TP
3
P1
3_
TP
1
P1
3_
TP
2
P1
3_
TP
3
P1
3_
TP
4
P1
4_
TP
1
P1
4_
TP
2
P1
4_
TP
3
P1
4_
TP
4
P1
4_
TP
5
P1
5_
TP
2
P1
5_
TP
4
P1
6_
TP
1
P1
6_
TP
2
P1
7_
TP
1
P1
7_
TP
3
P1
8_
TP
1
P1
8_
TP
2
AR
G/
to
ta
l n
um
be
r o
f g
en
es
 [%
]
TP1 TP2 TP3
0.0
0.1
0.2
0.3
0.4
0.5
0.6
AR
Gs
/to
ta
l n
um
be
r o
f g
en
es
 [%
]
n= 3 n= 3 n= 2
3. Results and discussion 
!65 
 
Figure 3.1.12: Relative abundance of reads mapping to viral genomes. Boxplots depict MG (A, C and E) 
or MT (B and D) reads mapping to viral genomes grouped per TP within TG1 (A and B), TG2 (C and D) and 
TG3 (E). The number of samples per collection TP is indicated above each box. For TG3, only two MT 
datasets from one patient were available, hence it was not possible to construct boxplots. 
Compared to the average, one sample (P01_TP1, Figure 3.1.12C) contained many reads 
mapping to viral DNA genomes (0.087 %). The most abundant viruses found in this 
sample included viruses with large genomes belonging to the clade Megaviridae, such as 
the Phaeocystis globosa virus (Santini et al., 2013), which infects the unicellular algae 
Phaeocystis (however this was not detected in the 18S rRNA gene sequences), or the 
Acanthamoeba polyphage moumouvirus infecting the amoeba Acanthamoeba polyphage 
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(which was also not detected in the 18S rRNA gene sequences) (Yoosuf et al., 2012). 
Different Entomopoxviriniae were detected, which infect insects (Afonso et al., 1999).  
Sample P01_TP4 (Figure 3.1.12D) contained many reads (0.31 %) mapping to RNA 
viruses, compared to the average. Tobamovirus, the pepper mild mottle virus (PMMoV) 
was found to account for 96 % of the RNA reads mapping to viral genomes within this 
sample. This is among the most important pathogens of peppers (Capsicum spp.) and is 
commonly detected in high abundance in fecal samples (Colson et al., 2010; Zhang et al., 
2006). Although it is generally assumed that plant-associated viruses do not become 
resident in the GIT and are not pathogenic for humans, it cannot be completely excluded 
(Balique, Lecoq, Raoult, & Colson, 2015). In one study, the presence of PMMoV was 
linked to clinical symptoms such as abdominal pains and fever (Colson et al., 2010). 
However, abdominal pain could simply be linked to the consumption of pepper. 
As for some samples, the majority of the reads mapping to viral genomes contained plant-
associated viruses which were taken up via nutrition, or viruses, which infect insects or 
amoeba, the same analyses were repeated but mapping against human-associated 
viruses only (Figure 3.1.13). On average, 0.0004 ± 0.0003 % MG and 0.0009 ± 0.0006 % 
MT reads were mapped onto viral genomes within the 54 (for MG), respectively 32 (for 
MT) samples. 
Sample P14_TP5 contained the highest ratio of MG reads (0.002 %) mapping to human-
associated viral genomes, compared to the other samples. 66 % of those reads mapped 
to Betapapillomavirus. This virus has previously been detected in fecal samples (Di Bonito 
et al., 2015; Ma et al., 2014) and does not necessarily provoke any symptoms in the host. 
Patient P14 developed herpes zoster, a painful skin rash, directly after collection of the 
third sample. This is caused by the human herpesvirus 3, or herpes zoster virus. This 
virus was detected in P14_TP3 (2.24 * 10-5 % of the total number of reads), P14_TP4 
(8.22 * 10 -6 %) and P14_TP5 (1.79 * 10-4 %).  
One sample with a high RNA viral load was P15_TP2, where the human Coronavirus was 
detected. This virus commonly infects the human respiratory tract or GIT, has been 
isolated from fecal samples and has been observed to be shed for many months (Clarke, 
Caul, & Egglestone, 1979; Zhang et al., 2006). In P13_TP1 (69 %), P13_TP2 (2 %) but 
not in P13_TP3, Enterovirus of the order Picornaviridae was detected. This virus is 
thought to be swallowed, followed by replication in the intestinal mucosa, crossing the 
intestinal barrier to reach the blood. Most infections are asymptomatic, but symptoms can 
present as symptoms of a common summer cold to a threatening encephalitis (Tapparel, 
Siegrist, Petty, & Kaiser, 2013).  
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To summarize, shotgun sequencing allows deep profiling of the GIT microbiome, including 
the virome and might enable their detection and treatment, before they become harmful. 
 
Figure 3.1.13: Relative abundance of reads mapping to human-associated viral genomes. Boxplots 
depict MG (A, C and E) or MT (B and D) reads mapping to human-associated viral genomes grouped per TP 
within TG1 (A and B), TG2 (C and D) and TG3 (E). The number of samples per collection TP are indicated 
above each box. For TG3, only two MT datasets from one patient were available, hence it was not possible to 
construct boxplots. 
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3.1.7 Does the microbiome influence development of mucositis? 
3.1.7.1 Differences on taxonomic level 
It has been hypothesized that the GIT microbiome might be involved in development of 
mucositis, a severe side effect of anticancer treatment. In the next part, I will focus on this 
subject. Mucositis is generally associated with the treatment, with intensive chemotherapy 
and/or radiation leading to higher incidence of mucositis. Five out of eighteen patients 
developed severe mucositis, three of these belonged to TG2, one to TG1 and one 
belonged to TG3. No link between the TG and occurrence of severe mucositis could be 
made. Similarly, no link between prokaryotic diversity or richness and development of 
mucositis was found.  
Differentially abundant prokaryotic taxa between patients who developed mucositis and 
those who did not were identified based on 16S rRNA gene datasets. Since a specific 
microbial community profile might possibly play a part in the development of mucositis, 
and the community could also be altered after the active phase of mucositis, not only 
samples from TPs with active mucositis (n=3), but all the samples from patients who 
developed mucositis (n=13), were included for the following analyses and compared to 
samples from patients who did not develop severe mucositis (n=45). 68 different OTUs 
were observed to be differentially abundant. Table 3.1.3 includes 34 OTUs with the lowest 
adjusted p value (< 0.02, Wald test, FDR-adjusted). A negative fold change indicates a 
lower relative abundance in samples from patients with mucositis.  
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Table 3.1.3: Differentially abundant OTUs in relation to mucositis  
OTU Taxon log2 fold change adjusted p value 
OTU_54 Phascolarctobacterium sp. -4.91 5.88E-11 
OTU_94 Lachnospiracea incertae sedis -3.35 4.03E-05 
OTU_278 Alistipes sp. -3.18 0.001 
OTU_28 Bacteroides sp. -2.92 1.75E-04 
OTU_366 Anaerorhabdus sp. -2.81 0.003 
OTU_135 Prevotella sp. -2.8 0.017 
OTU_466 Phascolarctobacterium sp. -2.8 0.02 
OTU_488 Oxalobacter sp. -2.79 0.006 
OTU_82 Prevotella sp. -2.74 0.004 
OTU_72 Ruminococcus sp. -2.61 0.003 
OTU_52 Clostridium cluster XI -2.47 1.02E-04 
OTU_78 Lachnospiracea incertae sedis -2.39 0.003 
OTU_139 Sutterella sp. -2.32 0.013 
OTU_17 Prevotella sp. -2.3 0.016 
OTU_55 Clostridium sensu stricto -2.23 9.37E-05 
OTU_191 Roseburia sp. -2.23 0.002 
OTU_262 Clostridium cluster XlVa -2.2 0.02 
OTU_203 Escherichia/Shigella sp. -2.16 0.002 
OTU_92 Clostridium sensu stricto -1.98 0.006 
OTU_33 Clostridium cluster XVIII -1.85 0.001 
OTU_359 Clostridium cluster XVIII -1.81 0.006 
OTU_32 Clostridium cluster XI -1.73 0.003 
OTU_12 Erysipelotrichaceae incertae sedis -1.58 0.003 
OTU_45 Blautia sp. -1.58 0.02 
OTU_3 Escherichia/Shigella sp. -1.41 0.004 
OTU_286 Erysipelotrichaceae incertae sedis -1.41 0.016 
OTU_242 Clostridium cluster XlVa 1.23 0.006 
OTU_532 Eggerthella sp. 1.42 0.004 
OTU_75 Eggerthella sp. 1.55 0.003 
OTU_160 Clostridium cluster IV 1.59 0.016 
OTU_10 Clostridium cluster XlVa 1.64 2.41E-04 
OTU_115 Clostridium sensu stricto 2.81 0.005 
OTU_127 Erysipelotrichaceae incertae sedis 3.12 8.22E-05 
OTU_376 Alistipes sp. 3.36 0.004 
 
While OTU_278, belonging to the genus Alistipes was observed to be less abundant in 
samples from patients with mucositis, OTU_376, also classified as the genus Alistipes, 
showed increased levels in these patients. Similarly, different OTUs classified into the 
genus Clostridium or Clostridium cluster XIVa showed differing directions of change. 
Some of the OTUs that were less abundant in the samples from patients with mucositis 
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belonged to genera which are among the most common members of the GIT microbiome, 
such as the genera Bacteroides, Prevotella, Ruminococcus and Escherichia (Arumugam 
et al., 2011). Other OTUs with a lower relative abundance in patients with mucositis were 
bacteria, which are usually considered to have health-promoting properties, such as the 
acetate- or butyrate-producing genera Blautia and Roseburia.  
When comparing only the samples that were collected when patients had active severe 
mucositis (n=3) against all the other samples (n=55), a significant decrease in only one 
genus, Akkermansia, was observed (log2 fold change -3.35, FDR-adjusted p value 0.04, 
Figure 3.1.14). Akkermansia muciniphila is a mucin-degrading bacterium which resides in 
the mucus layer and uses the proteins of the epithelial mucus layer as its main source of 
carbon and nitrogen (Reunanen et al., 2015). Lower levels of A. muciniphila have been 
observed in patients with ulcerative colitis and Crohn's disease, indicating that this 
organism is important for human GIT health and inversely correlated with inflammation 
(Derrien, Belzer, & de Vos, 2016; Png et al., 2010; Schneeberger et al., 2015; Wu & Scott, 
2012). Also, it was observed that A. muciniphila strengthens the epithelial barrier function 
(Reunanen et al., 2015). On the one hand, loss of this bacterium could add to the 
impaired integrity due to treatment-provoked damage and facilitate translocation of 
bacteria and bacterial products such as LPS. On the other hand, chemotherapy induced 
damage of the intestinal epithelial wall and a concomitant decrease of mucin, could lead 
to a decrease in relative abundance of A. muciniphila, as the mucus layer is its most 
important nutrient source (Yamamoto, Ishihara, Takeda, Koizumi, & Ichikawa, 2013). In 
this scenario, the decrease in relative abundance of A. muciniphila would only represent a 
consequence of the treatment and the damage, rather than being a cause of mucositis 
development or its aggravation.  
 
Figure 3.1.14: Relative abundance of the genus Akkermansia in samples from TPs with active 
mucositis compared to TPs without mucositis (* FDR-adjusted p value < 0.05, Wald test).  
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3.1.7.2 Differences on the functional level 
Recently, several studies have stressed the importance of SCFAs, especially of butyrate, 
as energy source for colonocytes, possibly reinforcing epithelial barrier function 
(Mathewson et al., 2016; Peng et al., 2009). The list of differentially abundant OTUs 
(Table 3.1.3) includes many known important SCFA producers. Therefore, I was 
interested in whether a difference in the potential for production of butyrate by the 
microbiome was apparent in the samples of patients who developed severe mucositis and 
those who did not. Presence and expression of the genes coding for the three enzymes 
catalyzing the final step in butyrate production (buk, but and ato) were compared (Vital, 
Howe, & Tiedje, 2014). Median copy number of the three genes on MG level was higher in 
the samples from patients with mucositis (0.029 % relative abundance) than in the 
samples from patients without severe mucositis (0.016 %). On MT level, transcript levels 
were slightly higher in samples from patients without mucositis (0.027 % compared to 
0.025 %). However, both on MG and on MT level, no statistically significant differences 
were observed between both groups. 
In the 54 MG and 32 MT datasets, differentially expressed functions between samples 
from patients with mucositis and those without were detected. Genes from different 
bacterial genomes with the same functions were grouped together. These will in the 
following be referred to as 'functional gene categories'. Differential analysis of functional 
gene categories in the MG datasets between both groups resulted in 15 differentially 
abundant functional gene categories including an apparent increase in the peptidoglycan-
associated lipoprotein precursor in samples from patients without mucositis (log2 fold 
change ≥ 1, FDR-adjusted p value < 0.05, Figure 3.1.15). This precursor contains a 
characteristic LVAC motif, which is cleaved during translocation across the cytoplasmic 
membrane. One role of this lipoprotein is to link the outer membrane to the peptidoglycan 
layer. The peptidoglycan-associated lipoprotein is a TLR2 agonist and is highly conserved 
in different genera (Liang et al., 2005). Lipoproteins are PAMPS, which are usually 
associated with bacterial pathogenicity and the possibility to cause inflammatory 
responses and even sepsis. It seems counter-intuitive that a gene associated with this 
should be found to be increased in samples from patients who did not develop severe 
mucositis. Possibly, the intestinal barrier in these patients was more resistant, less 
damaged by the treatment and therefore these patients did not develop severe mucositis 
despite the risk posed by these PAMPs.  
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Figure 3.1.15: One differentially abundant functional gene category on MG level when grouping 
according to development of severe mucositis (* FDR-adjusted p value < 0.05, Wald test). 
In the MT dataset, 59 functional gene categories were differentially expressed when 
grouping according to occurrence of severe mucositis. Some of these genes, which could 
possibly be implicated in the development of the side effect are illustrated in Figure 3.1.16. 
One functional gene category with higher expression in samples from patients with 
mucositis was the integration host factor (IHF) subunit alpha (Figure 3.1.16A). IHF is a 
DNA-binding protein and plays a role in several cellular functions in gram-negative 
bacteria. It was shown to positively regulate virulence gene expression in different 
bacteria (Porter & Dorman, 1997; Stonehouse, Kovacikova, Taylor, & Skorupski, 2008). 
The alpha subunit of this gene showed a higher expression level in samples from patients 
with mucositis. Similarly, the type II secretion system protein F expression was higher in 
samples from patients with mucositis (Figure 3.1.16B) and this secretion system has also 
been associated with bacterial virulence (Sandkvist, 2001). Both functions being 
implicated in bacterial virulence could initiate a cascade of inflammatory processes and 
therefore be involved in the development of mucositis. 
Other functional gene categories which were more highly expressed in samples from 
patients without severe mucositis were associated with bacteriophages (such as the 
phage P2 GpU, the phage tail tube protein FII and the baseplate J-like protein, Figure 
3.1.16C, D and E) or with the prokaryotic defense mechanism against bacteriophages 
(such as the CRISPR-associated protein Cas6, Figure 3.1.16F), indicating that 
bacteriophages might play a role in the prevention of mucositis. Studies have shown that 
bacteriophages can decrease the level of ROS produced by phagocytes (Przerwa et al., 
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2006). This process involves not only phages and phagocytes, but an intermediate step 
with phage-LPS interaction, thus, implicating the GIT microbiome as well as the host 
immune system (Kaur et al., 2012). ROS are believed to play a role in the first and second 
stages of mucositis development, initiation and the primary damage response (Sonis, 
2004). Presence of bacteriophages as well as the bacteria in the patients' GIT might have 
resulted in lower ROS production and therefore contributed towards the prevention of 
severe mucositis in these patients.  
As phages cannot actively move toward their host, the targeted bacterial community has 
to be above a so called 'replication threshold', allowing the phage to encounter its host by 
chance. This scenario is also called 'kill the winner', where more abundant bacteria are 
targeted. In this scenario, bacteriophages could possibly act as regulator of the microbial 
ecosystem, maintaining bacterial diversity (De Paepe, Leclerc, Tinsley, & Petit, 2014). 
Functional gene categories detected in these samples (phage tail tube protein FII, phage 
P2 GpU and baseplate J-like protein, Figure 3.1.16B, C and D) are associated with the 
bacteriophage P2. This is a temperate phage, meaning that it can insert its genome into 
the host genome and be maintained as prophage (lysogenic cycle) or use the host cell to 
produce phage progenies and finally lyze the host cell (lytic cycle). This phage has been 
shown to infect E. coli, as well as Shigella, Klebsiella, Yersinia and Serratia (Kahn et al., 
1991). Phage therapy has been suggested as alternative to antibiotics to fight bacterial 
infections. Here, patients who did not develop severe mucositis might have had higher 
titers of these bacteriophages, helping to maintain a diverse bacterial community. As this 
was detected in the MT dataset, the presence of viral RNA indicates active production of 
phage progenies, thus a lytic cycle with lysis of the bacterial host cell.  
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Figure 3.1.16: Selection of differentially abundant functional gene categories on MT level when 
grouping according to development of severe mucositis. Relative abundances of (A) integration host 
factor subunit alpha (B) putative type II secretion system protein F (C) phage P2 GpU (D) phage tail tube 
protein FII (E) baseplate J-like protein and (F) CRISPR associated protein Cas6 (* FDR-adjusted p value < 
0.05, Wald test). 
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3.1.8 Functional changes in the GIT microbiome in relation to the overall health 
status 
At each TP, the status of the patient was defined either as 'stable' or as 'reduced'. The 
reduced status could include different clinical symptoms such as fever, neurological 
symptoms (for example agitation), efflorescence of the skin or other symptoms. In the MG 
dataset, 136 functional gene categories were differentially abundant when accounting for 
the status of the patient, with p value < 0.01. These included many functional gene 
categories with normal bacterial cellular functions, where a link to the status of the patient 
could not be made. Examples of functional gene categories which could possibly be 
implicated in the patient's overall condition are illustrated in Figure 3.1.17. These include 
two genes associated with bacterial pathogenicity and one gene playing a part in the 
prokaryotic defense mechanism against phages. Type IV secretion systems can for 
example mediate injection of virulence proteins into mammalian cells or contribute to the 
spread of ARGs among pathogenic bacteria (Fronzes, Christie, & Waksmas, 2009; 
Wallden, Rivera-Calzada, & Waksman, 2010). Type IV pili are involved in adherence to 
different surfaces and in pathogenicity (Bieber et al., 1998). Both genes were more 
abundant in patients whose status was reduced which indicates the possible activity of 
pathogens and their implication in the overall health status of the patients (Figure 3.1.17A 
and Figure 3.1.17B). The CRISPR-associated gene Csn2 (Figure 3.1.17C) is involved in 
spacer acquisition in the type II CRISPR system, so in the first stage of the immune 
response against bacteriophages (Nam, Kurinov, & Ke, 2011; Sapranauskas et al., 2011). 
So far, this gene has not been detected in a wide range of bacterial species. A higher 
bacterial diversity in the GIT microbiome of patients with a stable health status could 
possibly be linked to a higher detection of this functional gene category. Incidentally, the 
median diversity of the bacterial community was higher in samples from patients with a 
stable health status than in samples from patients with reduced health status (2.77 in 
stable, 2.30 in reduced, p value 0.024, Wilcoxon rank sum test). However, there was no 
statistically significant correlation between the relative abundance of this functional gene 
category and the bacterial diversity. 
On MT level, grouping according to the status of the patient did not reveal differentially 
abundant functional gene categories. 
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Figure 3.1.17: Selection of differentially abundant functional gene categories on MG level when 
grouping according to the status of the patient. Relative abundances of (A) type IV secretion lipoprotein 
(B) type IV pilin biogenesis protein and (C) CRISPR-associated protein Cas_Csn2 (** FDR-adjusted p value < 
0.01, Wald test). 
3.1.8.1 Case study – a patient with severe mucositis 
In the following, I will focus on a patient who developed severe mucositis, patient P04. 
This patient, 3 years old at diagnosis, was treated with a light chemotherapy (TG1) for 
nephroblastoma. Fecal samples were collected at day 0 (TP1, beginning of treatment), 16 
(TP2, after first cycle of treatment, lowest leukocyte count), 55 (TP3, before next cycle of 
treatment) and 359 (TP4, after end of therapy). The patient received 
trimethoprim/sulfamethoxazole to prevent Pneumocystis jirovecii pneumonia and 
piperacillin-tazobactam around TP2 and TP3 (for 2, respectively 3 days) because the 
patient had developed a fever (reason unknown). At TP2, when the leukocyte count was 
low (500/µl), the patient developed severe mucositis, which included impaired intake of 
solid food and needing pain medication. From this patient, MG and MT data from four TPs 
were produced. Although this patient received antibiotics, including a broad spectrum 
antibiotic (piperacillin-tazobactam), no drastic changes were observed in the bacterial 
community composition (Figure 3.1.18A). The biggest differences in the relative 
abundances of the most common mOTUs in P04 between TP1 and TP4 were an increase 
in relative abundance of Bacteroides dorei/vulgatus and Bacteroides fragilis (from 8.2 % to 
29.7 %, respectively from 1.4 % to 14.8 %), an increase in relative abundance of 
Roseburia intestinalis (from 1.0.3 % to 8.0 %) and a decrease in relative abundance of 
Bifidobacterium longum (from 26.7 % to 0.5 %). There was an interval of almost one year 
between TP1 and TP4, which is the largest time span within this cohort (Figure 2.5.1). 
However, the Bray-Curtis dissimilarity index between TP1 and TP4 was 0.36, which is 
lower than the median intra-individual variability (Figure 3.1.5), indicating that the GIT 
microbial community within this patient was nonetheless quite stable. The genus 
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Akkermansia was detected in each sample and accounted for 2.70 %, 0.01%, 5.89 % and 
0.01 % relative abundance, respectively. The observed changes in the microbial 
community including the evolution of high abundance of the genus Bifidobacterium to 
higher abundance of the genus Bacteroides might have been age related (Ottman, Smidt, 
de Vos, & Belzer, 2012). Shannon diversity of the bacterial population, both on MG and on 
MT level stayed relatively high throughout the treatment with values ranging between 2.8 
and 3.4 (Figure 3.1.18B). 
 
Figure 3.1.18: Variation of the microbial community structure over the course of the treatment in a 
patient who developed severe mucositis. (A) Relative proportions of the 14 most abundant metagenomic 
OTUs (mOTUs), based on MG and (C) MT reads. The remaining OTUs are summarized as 'others'. (B) 
Bacterial diversity represented by Shannon diversity index at sampling TPs throughout the treatment, based 
on MG (circle) and MT (square) reads. (D) Ratio of the MT to MG relative proportion of the 13 most abundant 
mOTUs (in both datasets). The size of the dot indicates the ratio. Absence of a dot indicates that the organism 
was not detected in the MT dataset. 
Compared to the median intra-individual variability as indicated by the Bray-Curtis 
dissimilarity index (Figure 3.1.5), patient P04 showed relatively little variation between 
different TPs with a Bray-Curtis dissimilarity index of 0.23 between TP1 and TP2, 0.33 
between TP2 and TP3 and 0.43 between TP3 and TP4. Although this patient developed 
severe mucositis, the core microbiome appears to have stayed relatively unaffected and 
stable, indicating that the colonic microbiome might not be strongly affected by the 
treatment and mucositis. Treatment and mucositis might have stronger effects on bacteria 
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such as the mucin-degrading Akkermansia muciniphila, which adheres to the intestinal 
epithelium (Reunanen et al., 2015).  
Comparing the 14 most abundant mOTUs on MG and on MT levels (Figure 3.1.18A and 
Figure 3.1.18C), 13 mOTUs were found to agree. Some mOTUs (such as Bacteroides 
dorei/vulgatus and Bacteroides fragilis) were even positioned at the same rank on MG and 
MT level. For most mOTUs however, their abundance rank was not exactly the same on 
MG and MT level. In Figure 3.1.18D, the ratio of the MT to MG reads that were mapped 
onto a specific mOTU, is represented. This representation indicates that the relative 
activity of the mOTUs varied over time and that the organism displaying the highest 
activity differed at each TP. This also demonstrates that the organism showing the highest 
relative abundance in a sample cannot be expected to also display the highest activity. 
Thus, the most abundant organisms might not be the most important ones within an 
ecosystem. This new layer of information (MT sequencing) might be important in order to 
reveal the microbial activity and its possible implications in human health. 
 
 ! !
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3.2 Meta-omic analyses of the gastrointestinal tract microbiome in adult 
patients undergoing allogeneic stem cell transplantation 
The second section focuses on the changes within the GIT microbiome of hematology 
oncology patients undergoing an allogeneic stem cell transplantation (allo-HSCT). The 
results within this chapter are based on 78 fecal samples collected from 27 patients. After 
processing and filtering of the 16S rRNA gene amplicon sequences, 76 datasets were left, 
with 183,000 ± 55,000 (mean ± standard deviation) reads per sample. 73,000 ± 79,000 
18S rRNA gene amplicon sequences per sample were retained for 61 datasets. 
In order to compare the changes within the GIT during and following treatment, specific 
time frames relative to the day of transplantation were defined as time points (TP). These 
time frames are visualized in (Figure 2.5.2 in section 2.5). The first TP (TP1) includes 
samples that were taken up to two weeks before the transplantation. TP2 includes 
samples that were collected within one week after transplantation, TP3 includes samples 
that were collected around engraftment (3-6 weeks after transplantation). TP4 includes 
samples that were taken later, between 100 and 260 days after transplantation. Together, 
these TPs included 62 samples from 24 different patients. 
Of 9 samples, MG and MT combined datasets could be produced. Additionally, 34 MG 
datasets were produced. After processing with IMP which included filtering out low quality 
reads and reads mapping to the human genome, per dataset 47,000,000 ± 18,000,000 
MG sequences and 61,000,000 ± 23,000,000 MT sequences were kept for the following 
analyses and assembly. From the assemblies, 92,000 ± 71,500 genes per sample were 
predicted. 
 
3.2.1 Patient characteristics and treatment 
Anthropometric and clinical information of the seventeen male and ten female patients 
included in the following analyses are provided in Table 2.1.2. The patients were between 
22 and 67 years old (median 54). Fourteen patients were treated for acute myeloid 
leukemia (AML), ten were treated for lymphoma, one for acute lymphoblastic leukemia 
(ALL), one for chronic myleloid leukemia (CML) and one for myeloma. Eleven patients 
received stem cells from a matched unrelated donor, nine donors were matched and 
related and seven were mismatched and unrelated. Ten patients were conditioned with 
fludarabine (Flu), busulfan (Bu) and cyclophosphamide (Cy). Nine patients were treated 
with BuCy, one with FluBu, three with treosulfan (Treo) and Flu, one with total body 
irradiation (TBI) and Flu, one with TBI and Cy and two with FLAMSA-Bu (Flu, cytarabine, 
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amsacrine, Bu). Of the 27 patients, sixteen developed GvHD. Of those, six developed 
GvHD with implication of two or more organs and of those, four patients developed severe 
GvHD (with summed stages ≥ 4). 1.5 years after allo-HSCT, nine patients had deceased; 
three due to relapse, three due to GvHD, two due to pneumonia and one due to sepsis. 
The sex of the patient was not determined as risk factor for higher GvHD grade 
(Kolmogorov-Smirnov test). No correlation between the sex or the age of the patient and 
the overall outcome was determined (Fisher's exact test). In this cohort, the ratio of 
patients who deceased was higher in lymphoma patients than in leukemia patients 
compared to a random distribution. The grade of GvHD was positively correlated with the 
age of the patient (p value 0.042, Spearman's rho 0.393).  
3.2.2 Changes in the prokaryotic GIT microbiome of patients undergoing allo-
HSCT 
The prokaryotic (bacterial and archaeal) community composition was assessed based on 
16S rRNA gene amplicon sequencing of DNA extracted from 78 fecal samples from 27 
patients. After filtering and removal of samples with a low number of reads (as described 
in section 2.4), 76 of the sequenced samples were kept for the following analyses. The 
overall 14 most abundant orders within all 76 samples were identified to get an overview 
of the composition of the GIT microbiome of the patients (Figure 3.2.1). Overall, the 
majority of the samples displayed a high relative abundance of Bacteroidales, often in 
combination with a high abundance of Clostridiales. Some samples were almost 
completely dominated by Lactobacillales (such as A05_4, A08_2, A13_1, A18_4, A20_2, 
A27_3, A29_3 and A35_3), while others displayed high relative abundance of 
Enterobacteriales (as A05_5, A07_2, A08_3 and A11_1). Even on this taxonomic level, 
drastic changes in the GIT microbiome composition in different samples from one patient 
were observed. For example, A03 displayed high relative abundance of Burkholderiales in 
the second sample (90 %), which made up only 0.01 % in the first sample, or A41 which 
showed a high relative abundance of Verrucomicrobiales in the first sample (40 %) which 
decreased to 0.03 % and 0.23 % in the second and third sample, respectively. For other 
patients such as A21, no drastic changes from one sample to the next were observed. 
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Figure 3.2.1: Relative abundance of the 14 most abundant bacterial orders in fecal samples from patients undergoing an allogeneic stem cell transplantation 
(allo-HSCT), grouped according to patient. Orders which were not comprised in the 14 most abundant orders are combined as 'others'. OTUs which could not be 
classified at the order level are grouped as 'unknown'. Patient ID and number of the sample are indicated below each respective bar and colored according to the 
patient.  
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In the following, the samples were grouped according to the TP (Figure 3.2.2). Only 
samples for which the collection fell into one of the defined time periods (as displayed in 
Figure 2.5.2) were included and designated TP1-4. Analyses based on these TPs 
included 62 samples from 24 different patients. In these barplots, the 14 most abundant 
genera are displayed. For some samples, dominance of one genus was observed, often 
by Enterococcus spp.(e.g. A08_TP2 and A29_TP4), Escherichia/Shigella spp. (e.g. 
A08_TP3 and A29_TP3) and sometimes by Lactobacillus spp. (A27_TP3). On this 
taxonomic level, the drastic changes between TPs from one patient are even more 
apparent than on the level of orders. Similarly, large changes between samples from 
different patients were observed, indicating that both the initial composition of the GIT 
microbiome but also the changes throughout treatment are individual-specific. No clear 
specificity of the relative abundance of bacteria specific to individual TGs or TPs was 
apparent. 
Overall, the majority of the reads were assigned to the domain bacteria, with only an 
average of 0.06 % ± 0.42 % reads over the 62 samples being assigned to the domain 
archaea. Archaea were detected in 21 out of 62 samples and comprised three different 
genera, the most abundant genus being Methanobrevibacter, followed by Methanosarcina 
and Methanosaeta.  
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Figure 3.2.2: Relative abundance of the 14 most abundant bacterial genera in fecal samples from 
patients undergoing an allo-HSCT. Samples are grouped according to TPs: (A) TP1, (B) TP2, (C) TP3 and 
(D) TP4. Genera which were not comprised in the 14 most abundant genera are combined as 'others'. OTUs 
which could not be classified at the genus level are grouped as 'unknown'. Patient ID and sampling TP are 
indicated below each respective bar and are colored according to the patient. 
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As the taxonomic overview revealed drastic changes within the community, I wondered 
whether this was also reflected in diversity and richness. Figure 3.2.3 represents bacterial 
Shannon diversity and Chao1 richness for each TP, which were assessed after 
rarefaction. Drastic changes both in diversity (Figure 3.2.3A) and richness (Figure 3.2.3B) 
were observed. A decrease in median diversity from 2.9 at TP1 to 1.7 at TP2 (samples of 
all patients: p value 0.007, Wilcoxon rank sum test and samples from the same 
individuals: p value 0.02, Wilcoxon signed-rank test) and a further decrease to 1.6 at TP3 
(TP1 to TP3: p value 0.0006, Wilcoxon rank sum test, p value 0.001 Wilcoxon signed-rank 
test) were observed, followed by an increase to 2.2 at TP4. The variation of the diversity 
within each TP was high, ranging for example between 0.43 and 3.89 at TP1 and from 
0.09 to 3.59 at TP4.  
The same trends were observed for the bacterial richness, decreasing from median 
richness of 280 to 229 (p value 0.04, Wilcoxon rank sum test, 0.03 Wilcoxon signed-rank 
test), to 155 (TP1 to TP3: p value 0.001, Wilcoxon rank sum test, 0.002 Wilcoxon signed-
rank test, TP2 to TP3: p value 0.03, Wilcoxon rank sum test and Wilcoxon signed rank-
test) and increasing to 204 at TP4. 
 
Figure 3.2.3: Changes within gastrointestinal bacterial community structure in patients undergoing 
allo-HSCT. Boxplots depicting (A) diversity (Shannon diversity index) and (B) richness (Chao1 richness 
estimator) per collection time point (TP), for prokaryotes (determined by 16S rRNA gene amplicon 
sequencing). The number of samples per collection TP is indicated above each box. Diversity and richness 
were determined after rarefaction of the dataset. (* when p value < 0.05, ** when p value < 0.01, Wilcoxon 
rank sum test) 
In the following, the same patients and corresponding samples were grouped according to 
the overall outcome and to their collection TP (as visualized in Figure 2.5.2 in section 2.5). 
This included 24 patients of whom, 17 patients had survived (1.5 years after allo-HSCT) 
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while 7 patients had deceased due to different reasons, such as relapse, GvHD or 
pneumonia.  
 
Figure 3.2.4: Shannon diversity indices of samples from patients who survived 1.5 years after allo-
HSCT (S) compared to those who deceased (M). The samples are grouped per collection TP. The number 
of samples per collection TP is indicated above each box. Diversity was determined  after rarefaction of the 
(16S rRNA gene amplicon sequencing) dataset. 
For both groups, a statistically significant decrease in diversity from TP1 to TP3 was 
observed (Figure 3.2.4). No statistically significant difference between diversity in both 
groups at any TP was detected. However, at TP3 (around engraftment), a trend towards 
lower diversity in patients who later deceased compared to those who survived, was 
observed. This link between lower diversity at engraftment and higher mortality rate was 
also seen in a study including 80 patients (Y Taur et al., 2014). Possibly, antibiotic usage 
led to a lower diversity and its pressure selected pathogens, which could result in sepsis 
or infection. It is however not known whether this link between microbial diversity and the 
outcome is directly causal. An intermediate link in the form of infection and antibiotics 
might exist, meaning that possibly a severe infection required intensive antibiotic 
treatment, resulting in a lower bacterial diversity. Hence, the link between infection and 
outcome would only be indirectly reflected in the diversity index. Also, microbial diversity is 
more likely to be linked to mortality due to for example infection, pneumonia, sepsis or 
GvHD, than to mortality due to relapse. Due to the low number of patients in this group (7) 
however, I did not further discern the reasons for mortality in this analysis.  
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Similarly, the patients were in the following grouped according to development of severe 
GvHD (with summed stages ≥ 4) or no GvHD at all (Figure 3.2.5).  
 
Figure 3.2.5: Shannon diversity indices of samples from patients who did not develop GvHD (-) 
compared to those who developed severe GvHD (+). The samples are grouped per collection TP. The 
number of samples per collection TP is indicated above each box. Diversity was determined after rarefaction 
of the (16S rRNA gene amplicon sequencing) dataset. 
A statistically significant decrease in diversity from TP1 to TP2 in patients without GvHD 
(p value 0.006, Wilcoxon rank sum test) was observed. At TPs 1, 2 and 3, median 
diversity in both groups was similar, while at TP4, patients who had developed severe 
GvHD displayed a higher bacterial diversity. However, at TP4, both groups included only 2 
samples, each. No link between bacterial diversity at TP1 and subsequent development of 
severe GvHD was identified. Hypothesizing that a GIT microbial dysbiosis (possibly 
caused by usage of several broad-spectrum antibiotics) with selection of pathogens would 
be implicated in initiation of GvHD (Khoruts et al., 2016), a lower Shannon diversity index 
in patients who developed severe GvHD would be expected. This was however not the 
case, median diversities in both groups stayed similar. GIT microbial diversity was 
therefore not predictive of development of severe GvHD. As the risk of developing GvHD 
is influenced by different factors such as the number of HLA-mismatches and sex disparity 
between donor and recipient, one should also account for these factors. Further grouping 
according to this was however not done due to the low number of patients with severe 
GvHD.  
As drastic changes on different taxonomic levels and in bacterial diversity and richness 
had been observed, I wondered whether this was also reflected in the intra-individual and 
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inter-individual distance between microbial profiles. Bray-Curtis dissimilarity was 
determined based on the OTUs obtained from 16S rRNA gene sequencing data. High 
intra-individual dissimilarities were observed, reflecting the marked changes in individual 
microbial profiles. Still, a statistically significantly higher inter-individual dissimilarity (p 
value 0.003, Wilcoxon rank sum test) was observed (Figure 3.2.6). Both the intra- and the 
inter- individual dissimilarity in the adult hematology patients were higher than the ones 
observed in patients from the pediatric department (Figure 3.1.5) indicating even stronger 
perturbations in the GIT microbial community compositions in this patient cohort as well as 
strong effects of the intensive treatments on the GIT microbial community. Prokaryotic 
diversity at TP1 was negatively correlated with the dissimilarity index between TP1 and 
the following TP (p value 0.028, Spearman's rho -0.452). This indicates that a diverse 
microbiome was more stable and less affected by the treatment, while a GIT community 
with a low diversity underwent more drastic changes due to the treatment. 
 
Figure 3.2.6: Comparison of intra-individual to inter-individual distances between bacterial profiles. 
As the biggest changes in diversity and richness were observed from TP1 to TP3, I 
wondered whether this was reflected by general changes in relative abundance of specific 
taxa over the whole cohort. Between those TPs, 30 differentially abundant bacterial 
genera were identified (absolute log2 fold change ≥ 1, FDR-adjusted p value < 0.05, Table 
3.2.1). A negative fold change indicates a decrease in abundance in samples from TP3 
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(n=16) compared to TP1 (n=24). Of those 30 genera, 14 genera decreased and 16 genera 
increased in relative abundance from TP1 to TP3. Figure 3.2.7 illustrates examples of 
bacterial genera, which decreased in relative abundance from TP1 to TP3.  
Table 3.2.1: Differentially abundant bacterial genera in samples from collection TP1 and TP3 
Genus log2 fold change adjusted p value 
Roseburia -2.32 1.90E-10 
Dorea -2.20 1.20E-04 
Barnesiella -2.15 0.002 
Butyricicoccus -1.89 1.20E-04 
Blautia -1.58 4.11E-05 
Dialister -1.55 0.012 
Gemella -1.55 0.012 
Collinsella -1.42 0.016 
Lachnospiracea incertae sedis -1.38 0.004 
Parabacteroides -1.26 0.004 
Ruminococcus -1.25 0.002 
Bifidobacterium -1.20 0.005 
Gemmiger -1.06 0.022 
Faecalibacterium -1.03 0.022 
Flavonifractor 1.02 0.020 
Prevotella 1.13 0.045 
Enterococcus 1.15 0.045 
Lactobacillus 1.16 0.008 
Streptophyta 1.40 0.020 
Corynebacterium 1.45 0.008 
Clostridium sensu stricto 1.53 0.002 
Acinetobacter 1.69 0.008 
Lactococcus 1.87 3.25E-04 
Rothia 2.07 1.58E-04 
Elizabethkingia 2.29 0.015 
Clostridium cluster XI 2.29 1.39E-06 
Brevundimonas 2.30 0.025 
Erysipelotrichaceae incertae sedis 2.44 1.06E-09 
Flavobacterium 2.45 1.20E-04 
Staphylococcus 2.51 5.87E-06 
 
After treatment, a decrease in the abundance of several bacterial genera that are 
considered to have health-promoting properties, such as Blautia spp., and the butyrate 
producers Roseburia spp. and Faecalibacterium spp., was observed. These, as well as 
Dorea spp. have been shown to diminish inflammation by modulation of the NF-κB 
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pathway (Lakhdari et al., 2011). Another decreased genus, Barnesiella, was shown to 
confer resistance to domination by vancomycin-resistant Enterococcus (Ubeda et al., 
2013). On the other hand, an increase in for example the genera Enterococcus, 
Clostridium cluster XI, Lactobacillus and Staphylococcus was observed. Overall, the GIT 
microbiome composition after treatment might harbor a higher risk for infection and GvHD. 
 
Figure 3.2.7: Examples of differentially abundant genera in samples from TP1 (n=24) and TP3 (n=16). 
Relative abundances of (A) Roseburia, (B) Blautia, (C) Faecalibacterium and (D) Dorea (* FDR-adjusted p 
value < 0.05, ** < 0.01, Wald test).  
3.2.3 Changes in the microeukaryotic GIT microbiome of patients undergoing allo-
HSCT 
The microeukaryotic community composition was assessed using 18S rRNA gene 
amplicon sequencing of DNA extracted from 78 fecal samples of the patients. During the 
filtering steps, food-related reads as well as reads matching to the human genome were 
removed. Samples with a low number of reads after this filtering step were removed. 41 
datasets were kept for further analyses. The 14 most abundant taxa were identified to get 
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an overview of the composition of the GIT microeukaryotic community of the patients 
(Figure 3.2.8). Overall, the most abundant taxon was Ascomycota. Sample A12_1 
contained mostly Dinophyceae. Some samples (A05_3, A11_2, A18_3, A18_5, A19_1 
and A21_1) displayed a similar combination of different taxa (including 
Oligohymenophorea, Prostomatea, Phylopharyngea and others). 
 
 
Figure 3.2.8: Relative abundance of the 14 most abundant microeukaryotic taxa in fecal samples from 
patients undergoing allo-HSCT, grouped according to patient. Taxa which were not comprised in the 14 
most abundant taxa are combined as 'others'. OTUs which could not be classified at any taxonomic level are 
grouped as 'unknown'. Patient ID and number of the sample are indicated below each respective bar and are 
colored according to the patient. 
In the following, the samples were grouped according to the TPs and different sequencing 
control data were included in this representation (Figure 3.2.9). The first four controls 
included extraction controls from different extraction batches. The last control (NTC) 
included a sequencing control (no template control, Figure 3.2.9E). The first extraction 
control (NC) contained only few human associated reads, which were removed during the 
filtering steps. The other controls included many reads that could not be classified at the 
genus level, as well as genera that were not or only lowly abundant in the patients' 
samples. Most samples from the patients included mainly the genus Saccharomyces, next 
to organisms, which could not be classified at this taxonomic level. On higher taxonomic 
levels, they were mostly assigned to Ascomycota.  
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Figure 3.2.9: Relative abundance of the 14 most abundant microeukaryotic genera in fecal samples 
from patients undergoing allo-HSCT. Samples are grouped according to TPs: (A) TP1, (B) TP2, (C) TP3 
and (D) TP4. Taxa which were not comprised in the 14 most abundant genera are combined as 'others'. 
OTUs which could not be classified at the genus level are grouped as 'unclassified'. OTUs which could not be 
classified at any taxonomic level are grouped as 'unknown'. Patient ID and sampling TP are indicated below 
each respective bar and are colored according to the patient. (E) includes the relative abundance of 
microeukaryotes sequenced in different extraction and sequencing controls. 
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Some samples, such as A34_TP1, A08_TP2, A27_TP3 and A21_TP4 mostly contained 
reads assigned to the genus Candida. No clear difference in the relative abundance of 
microeukaryotes specific to individual TPs was apparent. As in the previous 
representation, several samples displayed a similar taxonomic composition including a 
high ratio of unclassified microeukaryotic genera, as well as reads assigned to the genera 
Vorticella, Prorodon and others. However, the different extraction and sequencing controls 
included in Figure 3.2.9E did not show this specific composition of genera, indicating that 
it was not artifactual. No explanation for this peculiar composition of microeukaryotic taxa 
in different samples was found.  
As the prokaryotic community displayed drastic changes in terms of diversity and richness 
from one TP to another, I wondered whether the microeukaryotic community showed 
similar trends. Diversity and richness of the microeukarotic community were determined 
on OTU level after rarefaction (Figure 3.2.10). No statistically significant differences in 
diversity or richness between different TPs were observed. Overall, in the microeukaryotic 
community, a lower median diversity (ranging between 1.3 and 1.7) and lower median 
richness (ranging between 65 and 90) than in the prokaryotic community (Figure 3.2.3) 
were observed. No drastic changes between different TPs were observed, indicating that 
the microeukaryotic community was not strongly affected by the treatment.  
 
Figure 3.2.10: Changes in the gastrointestinal microeukaryotic community structure in patients 
undergoing allo-HSCT. Boxplots depicting (A) diversity (Shannon diversity index) and (B) richness (Chao1 
richness estimator) per collection time point (TP), for microeukaryotes (determined by 18S rRNA gene 
amplicon sequencing). The number of samples per collection TP is indicated above each box. Diversity and 
richness were determined after rarefaction of the dataset. 
When grouping the patients according to antifungal treatment, a slightly lower median 
diversity at TP2 (1.24 against 1.41) in patients who were treated with antifungals, 
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compared to no antifungal treatment was observed. However, this difference was not 
statistically significant. 
3.2.4 Virome profiling within the GIT microbiome of hematology cancer patients 
Besides 16S and 18S rRNA gene amplicon sequencing, which allow identification of 
prokaryotes and eukaryotes, this project also included MG and MT shotgun sequencing of 
the samples. This allows identification of viruses, which are also numerous in the GIT 
community. While many of them do not pose problems in healthy individuals, they might 
represent a serious threat in immunocompromised and immunosuppressed patients 
(Sahin et al., 2016). 
On average (± standard deviation), 0.017 % ± 0.014 % MG and 0.089 % ± 0.171 % MT 
reads were mapped onto viral genomes within the 43 MG, respectively 9 MT samples 
(Figure 3.2.11A and Figure 3.2.11B). One of the highest ratios of MG reads mapping onto 
viral genomes was found in A18_3 (0.055 %), with 25 % of those reads mapping to the 
torque teno virus, which is very common in the human population and has been 
suspected to cause several pathologies. However, due to its ubiquitous state in the 
population, it is difficult to discern its pathogenic potential (Kincaid, Burke, Cox, de Villiers, 
& Sullivan, 2013; Okamoto, 2009). The highest ratio of MT reads mapping to viral 
genomes was detected in A11_2 (TP4), adding up to 0.54 %. 98 % of these reads 
mapped to Tobamovirus genomes, including the tomato mosaic virus and the pepper mild 
mottle virus. 
As many reads mapped to plant-associated viruses, the same analyses were repeated, 
but with human-associated viral genomes only (Figure 3.2.11C and Figure 3.2.11D). On 
average, 0.0012 % ± 0.0036 % MG and 0.005 % ± 0.012 % MT reads were mapped onto 
human-associated viral genomes within the 43 MG, respectively 9 MT samples. The 
highest ratio of MG reads mapping to human-associated viruses was detected in A18_4 
(0.018 %), with 86 % of those reads mapping to the BK polyomavirus. This is a widepread 
virus and infections are usually harmless. However, infection in immunocompromised 
individuals can have severe consequences, such as hemorrhagic cystitis (Bennett, 
Broekema, & Imperiale, 2012; Dropulic & Jones, 2008). In sample A34_4, 42 % of the 
viral reads mapped to cytomegalovirus, which can cause severe colitis in 
immunosuppressed patients with symptoms similar to those of GIT GvHD such as 
diarrhea and abdominal pain (Jacobsohn & Vogelsang, 2007; Sahin et al., 2016).  
Within the MT datasets, one sample showed a drastically higher ratio of reads mapping to 
viral genomes than the average: A07_3 (0.039 %). These reads mainly mapped to the 
Torque teno virus (89 %), which has a ssDNA genome which should not be detected in 
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the MT datasets. However, during an active phase in which the virus replicates, viral RNA 
of this virus might also be detected. Incidentally, this virus was also detected within the 
MG dataset of this sample and accounted for 78 % of the viral reads. Other human RNA 
viruses detected include for example the human enteric coronavirus (in A06_1).  
To summarize, shotgun sequencing allows deep profiling of the GIT microbiome, including 
the virome and might enable detection of for example the cytomegalovirus, which can 
cause serious infections after allo-HSCT which are difficult to treat (Kharfan-Dabaja et al., 
2012). 
 
Figure 3.2.11: Relative abundance of reads mapping to viral genomes. Boxplots depict MG (A, and C) or 
MT (B and D) reads mapping to viral genomes grouped per TP. (A and B) include reads mapping to all 
eukaryote-associated viruses. (C And D) include reads mapping to human-associated viruses. The number of 
samples per collection TP is indicated above each box.  
3.2.5 Variability of GIT microbiome trajectories in patients throughout treatment 
In the following, I will focus on the 43 MG datasets obtained from 21 patients. Within those 
43 MG datasets, after filtering out reads mapping to the human genome, on average, 
82.88 % (median 94.24 %) ± 24.90 % reads were retained, which were of microbial origin. 
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Only for few samples (A05_4, A18_3, A27_3, A29_3 and A35_3), less than 50 % of the 
reads were retained as the rest mapped to the human genome. This high amount of 
human DNA within the sequenced sample indicates the presence of human cells in the 
corresponding fecal samples, which could be due to the presence of intestinal epithelial 
cells and might indicate a bad health status of the patient. The detection of high amounts 
of human DNA did not always coincide with the occurrence of GIT GvHD and did not 
correlate with the overall outcome.  
The overview of the most abundant bacteria in different samples (Figure 3.2.1) as well as 
the intra-individual dissimilarity index (Figure 3.2.6), both based on 16S rRNA gene 
sequencing, indicated big changes from one collection TP to the next. A principal 
component analysis (PCA) based on metagenomic OTUs (mOTUs) identified in MG 
sequencing data revealed similar trends (Figure 3.2.12) as samples from the individual 
patients do not cluster together. 
 
Figure 3.2.12: Principal component analysis (PCA) for GIT prokaryotic community composition. Each 
dot represents a sample colored according to the corresponding patient. PCA was performed based on the 
metagenomic operational taxonomic units (mOTUs) identified in MG sequencing data. Samples from patient 
A21 and from patient A27 are highlighted. 
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In the following, I will focus on two patients (A21 and A27) who displayed strongly 
diverging evolutions of their health status. The corresponding samples are highlighted in 
Figure 3.2.12 and Figure 3.2.13. 
 
Figure 3.2.13: Variation of the microbial community structure over the course of the treatment in two 
hematology patients. (A) and (B) Relative proportions of the 14 most abundant metagenomic operational 
taxonomic units (mOTUs) based on MG sequencing. The remaining mOTUs are summarized as 'others'. (C) 
and (D) Bacterial diversity represented by Shannon diversity index in different samples taken throughout the 
treatment. Days of the collection TP relative to allo-HSCT are indicated below the plot. Plots represent the 
corresponding results for patient A21 (panels A and C) and patient A27 (panels B and D). 
Patient A21 was 64 years old at the beginning of treatment and was treated with a 
treosulfan/fludarabine conditioning regimen for acute myeloid leukemia. The graft was 
from a matched unrelated donor. The patient developed light GvHD with implication only 
of the skin (stage II°) and was still alive two years after allo-HSCT. The most abundant 
mOTUs in all four samples included different species of the genera Bacteroides, as well 
as Veillonella and Ruminococcus (Figure 3.2.13A). Enteroccocus faecium was detected in 
each sample, however never in high abundance. This patient was already treated with 
many different antibiotics (piperacillin/tazobactam, meropenem, vancomycin, linezolid) 
before the first sample was collected and the intensive antibiotic treatment was continued 
for some time, which might have lead to the overall relatively low bacterial diversity 
(Shannon diversity index), ranging between 0.9 (A21_2) and 1.9 (A21_4) (Figure 
3.2.13C). Although one species was dominating in sample A21_2, the majority of the 
other bacteria did not disappear completely but were still detectable. The number of 
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different mOTUs detected from sample 1 to sample 4 evolved from 31, over 48, to 41 and 
finally 34.  
Patient A27 was 56 years old at beginning of the treatment and was treated with a 
busulfan/cyclophosphamide conditioning regimen for chronic myeloid leukemia. The graft 
was harvested from a matched related donor. 22 days after allo-HSCT, the patient 
developed severe GvHD (skin stage III°, GIT IV°, liver III°). The patient deceased 53 days 
after allo-HSCT due to steroid-resistant GvHD. Some of the most abundant taxa in the 
first two samples included different species of the genus Bacteroides, Alistipes sp. and 
Parabacteroides distasonis. Bacterial diversity was relatively high at the beginning of the 
treatment with a Shannon diversity index of 2.6 in the first sample and 2.4 in the second 
sample. The third sample (collected three days after onset of GvHD) had an extremely low 
diversity (0.3), in which only eight different taxa could be detected (Figure 3.2.13D). Of the 
eight different taxa identified in the third sample, only the lowest abundant (Clostridium 
butyricum, 0.04 %) was a strictly anaerobic bacterium. All the other bacteria were 
facultative anaerobic bacteria (such as Lactobacillus johnsonii, L. rhamnosus, 
Enterococcus faecium and Streptococcus thermophilus).  
After quality filtering, 84 % of the MG reads from the third sample were removed, as they 
mapped to the human genome. The collection of this sample coincided with severe 
aGvHD implicating the GIT. Thus, the sample could have contained human cells, possibly 
intestinal epithelial cells. This sample was dominated by L. jonhsonii, which was also 
detected in the first samples but in low relative abundance. Considering that the third 
sample contained a large proportion of human DNA and the microbial community 
composition is represented in relative abundance, in relation to the total bacterial DNA 
within the sample, this probably means that there were only very little bacteria left in the 
GIT and almost only facultative aerobic bacteria were able to survive, which can possibly 
be linked to aGvHD (Jenq et al., 2012).  
This detailed look at the taxonomic GIT community profiles of two patients again makes 
clear how drastic but also how individual-specific the changes within the microbial 
community can be, especially in such a heterogeneous cohort undergoing intensive 
treatments. 
As in the PCA plot (Figure 3.2.12), the samples did not cluster according to the patients, I 
wondered whether the samples clustered according to their collection TP. Figure 3.2.14 
represents the same analysis, a PCA plot based on the mOTUs identified in MG 
sequencing data. Here, the samples are colored according to their collection TP. No clear 
clustering is observed in this plot. However, the TP1 samples (dark blue) tend to be 
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separate from samples from other TPs. The main drivers are indicated and show that the 
main driver for TP1 samples was Ruminococcus sp. 5_1_39BFAA. One sample from TP1 
is closer to the samples from later TPs. This is A13_TP1, which has a very high relative 
abundance of Enterococcus spp. (Figure 3.2.2), which is the main driver guiding the 
samples from later TPs in this opposite direction of the plot. Different species of the genus 
Bacteroides act as additional drivers. Loss of health-promoting bacteria such as 
Ruminococcus spp. as well as expansion of Enterococcus spp. after allo-HSCT has been 
observed in several studies (Biagi et al., 2015; Holler et al., 2014; Ubeda et al., 2010).  
 
 
Figure 3.2.14: Principal component analysis (PCA) for GIT prokaryotic community composition. Each 
dot represents a sample colored according to the collection TP. PCA was performed based on the 
metagenomic operational taxonomic units (mOTUs) identified in MG sequencing data. The main drivers are 
indicated. 
Besides taxonomic profiling, MG sequencing also allows functional profiling, which will be 
described in the next parts.  
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3.2.6 Detection of antibiotic resistance genes 
Due to the underlying disease and/or the intensive conditioning treatment, hematology 
patients undergoing an allo-HSCT are immunocompromised, at least from the day the 
conditioning treatment takes effect, until engraftment takes place. As they are prone to 
infection, they are usually treated with prophylactic antibiotics, and treatment is continued 
during neutropenia or at occurrence of fever. Intensive antibiotic treatment can favor 
emergence of multi-drug resistant (MDR) bacteria. For the 43 samples where MG data 
was available, ARGs were detected (as described in section 2.11) and their relative 
abundance (percentage of ARGs relative to the total number of genes) was calculated 
(Figure 3.2.15). The mean relative abundance and standard deviation within these 43 
samples was 0.33 % ± 0.11 %. As indicated in Table 2.1.2, the patients were treated with 
several antibiotics including broad-spectrum antibiotics such as fluoroquinolones and 
meropenem. Treatment with these antibiotics sometimes continued for several weeks. For 
almost all of the patients, an increase in the ratio of ARGs from one TP to the next is 
observed (Figure 3.2.15). Only in patient A08, a strong decrease was observed between 
A08_3 and A08_4. These samples were collected more than 7 months apart, during which 
the patient was only heavily and regularly treated with antibiotics for around a month. 
Except for four samples (A05_1, A27_1, A27_3 and A18_3), the ratio of ARGs within the 
samples from patients was higher than the ratio within four reference microbiomes from 
healthy individuals (RHM1-4). All of the ARGs identified within the sample with the highest 
ARG ratio, A29_3, belonged to one population-level genome. This was the only 
population-level genome that could be reconstructed within this sample. It was classified 
as Enterococcus faecium. During processing of this MG dataset, only 5.22 % of the 
(quality filtered) reads were retained, as the rest mapped to the human genome.  
 
Figure 3.2.15: Relative abundance of antibiotic resistance genes in fecal samples from patients 
undergoing allo-HSCT. Samples are grouped according to patient. The labels are colored according to the 
patient. RHM1-4 represent the relative abundance of ARGs in 4 reference microbiomes from healthy 
individuals. 
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A drastic increase in the relative abundance of ARGs from TP1 to TP2 was observed 
(Figure 3.2.16), although the difference was not statistically significant, which might be 
due to the low number of samples at TP2 (n=4). Significant increases were observed from 
TP1 to TP3 (samples from all the patients: p value 0.013, Wilcoxon rank sum test and 
samples from the same individuals: p value 0.014, Wilcoxon signed-rank test) and from 
TP1 to TP4 (p value 0.008, Wilcoxon rank sum test). The biggest increase was observed 
from TP1 to TP2, probably because the intensive antibiotic treatment had begun in the 
time span between collection of both samples. The median ARG ratio at TP3 was lower 
than at TP2, (but still higher than at TP1). Here, the range of ARG ratio between different 
samples was high, going from 0.20 % to 0.54 %. This might be due to different intensities 
and duration of antibiotic treatment in the patients. Also at TP4, median ARG ratio was 
higher than at TP1 but lower than at TP2.  
 
Figure 3.2.16: Relative abundance of antibiotic resistance genes in fecal samples from patients 
undergoing allo-HSCT. Samples are combined according to TP. The number of samples per collection TP is 
indicated above each plot. 
3.2.7 Changes in the functional potential of the GIT microbiome during treatment 
As the biggest changes in bacterial diversity and richness were observed from TP1 to TP3 
(Figure 3.2.3), I wondered whether this was reflected in the functional potential of the GIT 
microbiome. Within the MG datasets, functions were detected. Genes with similar 
functions from different bacterial genomes were grouped together. These will in the 
following be referred to as 'functional gene categories'.  
A total of 12,917 different functional gene categories were detected. Large differences in 
the number of functional gene categories between different TPs were detected. The 
** 
* 
●
●
TP1 TP2 TP3 TP4
0.0
0.2
0.4
0.6
0.8
AR
Gs
/to
ta
l n
um
be
r o
f g
en
es
 [%
]
n= 17 n= 4 n= 10 n= 7
3. Results and discussion 
!101 
number of different functional gene categories (measured by the Chao1 richness 
estimator) at each TP indicated a decrease from a median value of around 7,000 at TP1 
to 5,400 at TP2 (TP1 to TP2: p value 0.014, Wilcoxon rank sum test) and further to around 
5,000 at TP3 (TP1 to TP3: p value 0.0005, Wilcoxon rank sum test).  
 
Figure 3.2.17: Richness of functional gene categories at different TPs. Boxplot depicting richness (Chao1 
richness estimator) per collection time point (TP) of different functional gene categories. The number of 
samples per collection TP is indicated above each box. Richness was determined after rarefaction of the 
dataset. (* when p value < 0.05, ** when p value < 0.01, Wilcoxon rank sum test)  
730 functional gene categories were found to be differentially abundant in the MG 
datasets between TP1 (n=17) and TP3 (n=10), with FDR-adjusted p values < 0.05 and 
absolute log2 fold change ≥ 1. Of those, 530 were decreased at TP3. As seen in Figure 
3.2.17, in samples from TP3, there was a loss of around 2000 functional gene categories. 
Results of the differential analysis indicate, that the functional gene categories that were 
lost, were not always the same in every sample, which again shows that there is a large 
inter-individual variation and can probably be linked to the high taxonomic inter-individual 
variation within the GIT microbiome. 
Upon further filtering, 64 functional gene categories were found to be differentially 
abundant with FDR-adjusted p value < 0.01 and absolute log2 fold change ≥ 3 (Figure 
3.2.18). Of those, only 1 functional gene category (the putative carnobacteriocin-B2 
immunity protein) were found to be increased, all the other functional gene categories 
displayed a decreased abundance at TP3. In healthy humans, even if there are changes 
within the composition of the GIT microbiome, the functional profile usually stays relatively 
stable (The Human Microbiome Project Consortium, 2012). Contrary to this, the functional 
capacity of the GIT microbiome of the adult hematology patients underwent drastic 
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changes throughout treatment. The decrease in abundance of a high number of functional 
gene categories at TP3 can probably be linked to a loss in diversity and richness of the 
GIT microbiome (Figure 3.2.3). In the less complex ecosystems in samples collected 
around one month after allo-HSCT, also the functional potential of this community seems 
to be decreased. The functional gene categories that displayed a statistically significantly 
lower abundance at TP3 included various functions such as genes needed for flagella 
construction, chaperones, spore formation, metabolic pathways (such as cellobiose 
degradation, sulfur metabolism) and many others, which is probably linked to loss of 
several bacterial populations.  
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Figure 3.2.18: Heatmap of differentially abundant functional gene categories between collection TP1 
and TP3 with FDR-adjusted p value < 0.01 and absolute log2 fold change ≥ 3. Samples from collection 
TP3 are highlighted in green. Heatmap of normalized functional gene category abundances is scaled as 
indicated in the color key. The dendrogram represents a hierarchical clustering with Ward's minimum variance 
method of the euclidian distance between the abundances displayed in the heatmap. 
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3.2.8 Does the microbiome influence development of GvHD? 
One aim of this project was to assess whether the GIT microbiome is involved in 
development or aggravation of GvHD. Of the 27 patients, sixteen developed GvHD. Of 
those, four patients developed severe GvHD (with summed stages ≥ 4), considered as 
severe GvHD. 
Previously detected differences of relative genus abundances between TP1 and TP3 
(Table 3.2.1) encompassed a shift towards a GIT microbiome composition that might lead 
to a more inflammatory environment, thereby potentially harbouring a higher risk for GvHD 
development. As a specific composition of the GIT microbiome could potentially play part 
in development of GvHD, I compared the early samples (TP1 and TP2) from patients who 
later developed severe GvHD (n=12), to those who never developed GvHD (n=14). Ten 
genera were found to be differentially abundant with five being decreased in samples from 
patients who later developed severe GvHD (Table 3.2.2). The highest difference in 
relative abundance was seen for the genus Akkermansia, with a 10-fold reduction in 
samples from patients who did develop GvHD. As previously described in relation to 
mucositis development (section 3.1.7.1), this bacterium strengthens the epithelial barrier 
function and is inversely correlated with onset of inflammation (Derrien et al., 2016; Png et 
al., 2010; Schneeberger et al., 2015; Wu & Scott, 2012). Thus, loss of this bacterium 
could have led to impaired integrity and higher translocation of microbial products, 
possibly adding to initiation of GvHD. On the other hand, damage of the intestinal 
epithelial wall might have led to a decrease in the availability of the main nutrient source 
for Akkermansia (mucin), and thereby caused this decrease in relative abundance of 
Akkermansia. In this scenario, possibly a higher damage of the intestinal epithelial wall in 
these patients would represent a factor leading to GvHD development. In general, the 
differences observed in the GIT microbiome between both groups do not point towards a 
higher microbiome-induced inflammatory environment in the GIT of patients who later 
developed severe GvHD. 
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Table 3.2.2: Differentially abundant bacterial genera in (TP1 and TP2) samples from patients with 
severe GvHD compared to those who never developed GvHD 
 
 
In the following, I compared samples that were collected while or after the patient had 
developed severe GvHD (n=3) against samples from patients who did not develop GvHD 
(n=21), including all TPs. Only two genera were differentially abundant, the genus 
Lactobacillus being more abundant in samples from patients with GvHD (2.71 log2 fold 
change, FDR-adjusted p value 0.013) and the genus Streptococcus less abundant (-2.36 
log2 fold change, FDR-adjusted p value 0.013). In patients with GvHD, an increase in 
facultative anaerobic (aerotolerant) Lactobacillales has been observed and it was 
suggested, that they might be able to occupy this opening niche, in contrast to obligate 
anaerobes (Jenq et al., 2012). Here however, contradicting trends were observed, with 
increase in one facultative anaerobe and decrease in another facultative anaerobe. In the 
samples from early collection TPs from patients who later developed severe GvHD (Table 
3.2.2), both genera were decreased. This indicates that, rather than being involved in 
development of GvHD, physiological changes within the GIT during onset of GvHD might 
have enabled an expansion of Lactobacillus spp.  
When comparing samples collected from patients during or after onset of severe GvHD 
(n=3) to samples from patients who did not develop GvHD (n=15), 797 functional gene 
categories (with FDR-adjusted p value < 0.01 and absolute log2 fold change ≥ 2) were 
found to be differentially abundant. Of those, only 5 functional gene categories were more 
abundant in samples from patients with GvHD. Similar to the changes in the functional 
profile throughout treatment in general, a drastic loss in the functional potential was 
observed in samples from patients during or after onset of severe GvHD. 
To get a better overview of what pathways those functions belong to, the functional gene 
categories were annotated for corresponding KEGG orthologous groups (KOs). Applying 
Genus log2 fold change adjusted p value 
Akkermansia -3.32 1.29E-06 
Bilophila -2.67 0.006 
Lachnoanaerobaculum -1.88 0.040 
Streptococcus -1.61 0.005 
Lactobacillus -1.56 0.030 
Parabacteroides 1.45 0.034 
Coprococcus 1.70 0.040 
Mogibacterium 1.83 0.050 
Alistipes 2.18 0.001 
Barnesiella 2.31 0.034 
3. Results and discussion 
!106 
the same analysis on these KOs as previously, 646 were found to be differentially 
abundant (FDR-adjusted p value < 0.05 and absolute log2 fold change ≥ 1), with only 41 
being higher abundant in samples from patients with GvHD and 605 lower abundant. The 
KOs with lower abundance are illustrated in Figure 3.2.19. The corresponding pathways 
which were enriched (meaning that a significantly higher number of KOs belonging to this 
pathway were observed in the differentially abundant set than expected by chance, 
adjusted p value < 0.05, hypergeometric test) are indicated with colored lines.  
 
Figure 3.2.19: Heatmap of differentially abundant KOs between samples from patients with severe 
active GvHD and samples from patients who never developed GvHD (with FDR-adjusted p value < 0.05 
and negative log2 fold change ≥ 1). Heatmap of normalized gene abundances is scaled as indicated in the 
color key. Pathway correspondence of the KOs is indicated next to the heatmap. At the top of the heatmap, 
samples from patients with severe GvHD are marked in red, samples from patients without GvHD are marked 
in white. Samples from patients without GvHD are ordered according to the patient ID. 
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Figure 3.2.20A represents the ratio of KOs with significantly decreased abundance in 
samples from patients with GvHD compared to the total number of KOs per pathway. 
Figure 3.2.20B represents the number of significantly differentially abundant KOs in 
samples from patients with GvHD compared to the total number of KOs detected in the 18 
samples included in this analysis. A higher ratio of differentially abundant KOs belonging 
to these mentioned pathways (Figure 3.2.20A and Figure 3.2.19) than the overall ratio of 
differentially abundant KOs (Figure 3.2.20B), is observed. 
 
Figure 3.2.20: Barplots indicating number of differentially abundant KOs in samples from patients with 
GvHD, compared to the total number of KOs per pathway. (A) Ratios of KOs with decreased abundance 
are represented in red, total numbers of KOs per pathway are represented in blue. Corrresponding pathways 
are indicated below each bar. (B) Ratio of differentially abundant KOs (red) compared to the total number of 
KOs (blue). 
These pathways included some that are generally needed by bacterial cells, such as two-
component systems or the carbon metabolism. However, also genes belonging to the 
propanoate and the butanoate metabolism pathway were overrepresented within the 
functions with lower abundances in samples from patients with GvHD. This might indicate 
lower production of butyrate and propionate, two SCFAs, which are associated with 
important health-related functions, for example promoting absorption of electrolytes and 
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fluid (Scheppach, 1994). As mentioned above, a higher relative abundance of the genus 
Lactobacillus was detected in samples from patients with GvHD, which mainly produce 
lactate. This is usually converted by other bacteria into acetate, propionate and butyrate. If 
these bacteria and the corresponding pathways are missing or down-regulated however, 
lactate might accumulate in the GIT. In feces from individuals with ulcerative colitis for 
example, high concentrations of lactate have been detected and linked to diarrhea 
(Hashizume, Tsukahara, Yamada, Koyama, & Ushida, 2003; Vernia et al., 1988). Thus, 
changes within the GIT microbiome community and functional capacity during GvHD 
could further worsen the status of the patient. 
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3.3 Case study: Patient A07 – severe GvHD and dysbiosis 
This section focuses on a specific patient who underwent an allo-HSCT, developed 
severe GvHD in parallel with a marked GIT microbial dysbiosis. Parts of the results and 
discussion section focussing on this are taken and slightly modified from a manuscript that 
has been submitted to Translational Research. The respective manuscript is attached in 
the appendix: 
Appendix A.1: Anne Kaysen, Anna Heintz-Buschart, Emilie E. L. Muller, Shaman 
Narayanasamy, Linda Wampach, Cédric C. Laczny, Norbert Graf, Arne Simon, Katharina 
Franke, Jörg Bittenbring, Paul Wilmes, Jochen G. Schneider. (2017) Integrated meta-omic 
analyses of the gastrointestinal tract microbiome in patients undergoing allogeneic stem 
cell transplantation. Translational Research. (in revision). 
 
3.3.1 Patient A07 – description of treatment and status of the patient 
We chose to focus on patient A07, a patient who displayed a marked reduction in bacterial 
diversity with high relative abundances of opportunistic pathogens (Figure 3.3.1A and 
Figure 3.3.1B) and a fatal treatment outcome. This 63 year old patient had acute myeloid 
leukemia with deletion 7q. The patient was refractory to conventional induction (3+7) and 
salvage chemotherapy with high-dose cytarabine and mitoxantrone and therefore needed 
further treatment. FLAMSA-Bu (Schmid, Schleuning, Ledderose, Tischer, & Kolb, 2005), a 
modified sequential conditioning regimen for refractory acute myeloid leukemia was used 
(Fludarabine 30 mg/m² day -11 to -8, Cytarabine 2000 mg/m² day -11 to -8, Amsacrine 
100 mg/m² day -11 to -8 and Busulfan 3,2 mg/kg day -7 to -4) for remission induction and 
transplantation. She received peripheral blood stem cells from a single HLA-C antigen 
mismatched unrelated donor. After engraftment on day 26, bone marrow was 
hypocellular, but free of leukemia. Planned immunosuppression consisted of 
antithymocyte globulin (ATG) on day -4 to -2, mycophenolate mofetil until day 28 and 
cyclosporine until day 100.  
A high level of C-reactive protein (CRP) before and around allo-HSCT was observed 
which decreased slightly but stayed considerably high throughout the entire observation 
period (Figure 3.3.1C). After leukocyte depletion around allo-HSCT, the count increased 
to around 3600/µl 20 days after allo-HSCT and further increased to a normal value around 
80 days after-HSCT. However, high fluctuations and later a decrease in the leukocyte 
count were observed (Figure 3.3.1C).  
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As the patient had prolonged neutropenia due to refractory leukemia and intensive 
chemotherapy, various antibiotics and antifungals were used to treat infectious 
complications before and during transplantation. More specifically beginning from day -17 
she received piperacillin/tazobactam for neutropenic fever and this was changed to 
meropenem on day -14 for refractory fever. On day -11, vancomycin was added and on 
day -4, meropenem was exchanged for tigecycline. Additionally, the patient was treated 
with a fluoroquinolone (levofloxacin), ceftazidime and liposomal amphotericin B (Figure 
3.3.1D).  
 
Figure 3.3.1: Variation of the microbial community structure over the course of the allo-HSCT 
treatment in patient A07. (A) Relative proportions of the 10 most abundant operational taxonomic units 
(OTUs) based on 16S rRNA gene sequencing. The remaining OTUs are summarized as 'others'. Similar 
shades of the colors represent genera belonging to the same phylum. (B) Prokaryotic (triangle) and eukaryotic 
(circle) diversity represented by Shannon diversity index at sampling TPs throughout the treatment. (C) C-
reactive protein (CRP) blood levels (green line) and leukocyte blood count (blue line). (D) Drugs (antibiotics, 
antifungals and antithymocyte globulin) administered throughout the treatment. Along the x-axis, days relative 
to the day of transplantation are indicated. Abbreviations: Vancom=vancomycin; Tigecycl=tigecycline; 
Fluoroq=fluoroquinolone; Antif=antifungal; ATG=antithymocyte-globulin. 
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74 days after allo-HSCT, the patient developed aGvHD overall grade III, skin stage II and 
GIT stage III. As the patient did not respond to 2 mg/kg prednisolone and deteriorated 
rapidly, ATG (5 mg/kg body weight) was administered for four days as second line GvHD 
treatment. A partial remission of intestinal GvHD was noted with reduction of diarrhea 
from > 20 stools per day to 4-5 per day. She was bedridden with general fatigue and 
malaise. With continuous signs of infection and lower back pain an MRI scan of the spine 
showed a paravertebral abscess which was removed surgically on day 126.  
A MDR Escherichia coli was isolated both from the abscess and from a blood culture, and 
was analyzed further. After surgery the patient's health status improved, she was able to 
walk again and could be discharged from hospital at day 209. She was readmitted on day 
260 with suspected sepsis. The patient deceased at day 268 due to GvHD and systemic 
inflammatory response syndrome suspected to be bacterial sepsis. However, no pathogen 
could be recovered from blood cultures. 
In order to explore the treatment-induced effects on the GIT microbiome in more detail 
and relate them to the detrimental treatment outcome, we used a meta-omic approach 
including MG and MT analyses in addition to rRNA gene amplicon sequencing. For this 
patient, samples at later time points were available, i.e. four months after allo-HSCT, 
which allowed investigation of the GIT microbiome over an extended period of time.  
3.3.2 Patient A07 – changes in the microbial community structure during the 
treatment 
Fecal samples were taken, as indicated in Figure 3.1.1D, at days -13 (sample A07-1), day 
75 (sample A07-2) and day 119 (sample A07-3). The prokaryotic diversity decreased 
markedly after allo-HSCT (Figure 3.3.1B). Similarly, in sample A07-1 177 different OTUs 
were detected, while A07-2 and A07-3 only contained 62 and 79 OTUs, respectively.  
Dominant OTUs of sample A07-1 reappeared in A07-3, more precisely several OTUs 
representing Bacteroides spp., Escherichia/Shigella sp. and Enterococcus sp. (Figure 
3.3.1A). However, many of the less abundant OTUs, belonging to 25 different genera, 
disappeared entirely, including for example Anaerostipes and Clostridium cluster IV. 
OTUs with decreased abundance in sample A07-3 (compared to sample A07-1) 
represented 50 genera, for example Alistipes, Barnesiella, Blautia, Clostridium cluster 
XIVa and cluster XI, Prevotella, Roseburia and Ruminococcus. In addition, OTUs 
belonging to the genus Lactobacillus exhibited a 10-fold increase in relative abundance. 
Furthermore, different OTUs belonging to the genus Bacteroides increased in relative 
abundance resulting in a total relative abundance of Bacteroides spp. in A07-3 of 63 % 
compared to a total relative abundance of 27 % in A07-1 (Figure 3.3.1A). This difference 
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was mainly due to the increase in relative abundance of two Bacteroides OTUs, with an 
increase from 2.2 % to 23.5 % and from 0.9 % to 11.1 %, respectively. In total, 19 different 
OTUs belonging to the genus Bacteroides were detected in the first sample, 23 different 
OTUs in the last sample, and only 5 different Bacteroides OTUs were identified in the 
second sample which accounted for 0.07 % overall. One OTU belonging to the domain 
archaea could be identified, Methanobrevibacter smithii, which accounted for 3.4 % total 
relative abundance in A07-1. Similar to the short-term developments observed in the 
whole cohort and described before, the eukaryotic microbial community did not exhibit 
pronounced changes over time (Figure 3.2.10 and Figure 3.3.1B). Taken together, a 
drastic decrease in prokaryotic diversity, with relative expansion of few bacteria, including 
potential pathogens, was observed.  
Only one study so far has followed the GIT microbiome trajectories up to three months 
after allo-HSCT (Biagi et al., 2015). Contrary to this study, which observed that the 
richness and metabolic capacity of the microbial community recovered after two months 
(Biagi et al., 2015), our study found that the GIT microbial community in patient A07 did 
not regain its initial composition even four months after allo-HSCT, which is likely linked to 
the detrimental treatment outcome. Diversity was still decreased and many bacterial taxa 
remained absent or at drastically decreased relative levels. Taxa with decreased relative 
abundance were mainly bacteria whose presence in the human GIT is associated with 
health-promoting properties (such as butyrate production) and whose absence has been 
linked to negative consequences (such as inflammation) (Abreu & Peek, 2014; Jiang et 
al., 2015; Perez-Chanona & Jobin, 2014). The genus Blautia for instance, has been linked 
to reduced aGvHD-associated death and improved overall survival (Jenq et al., 2015) and 
the genus Barnesiella with resistance to intestinal domination with vancomycin-resistant 
enterococci in allo-HSCT patients (Ubeda et al., 2013). On the other hand, potential 
pathogens like Fusobacterium sp. and Proteus sp. appeared in the post-treatment 
sample, which were not detected in the first sample. Consecutive loss in intestinal barrier 
integrity could have allowed a GIT-borne E. coli to cause a paravertebral abscess. 
Coinciding with the development of severe aGvHD (expressed by severe diarrhea) 75 
days after allo-HSCT, 16S rRNA gene amplicon sequencing revealed a GIT microbiome in 
a notably dysbiotic state with a low diversity and dominance of two opportunistic 
pathogens, E. coli and E. faecium. The dominance of E. faecium has been observed to be 
quite common in allo-HSCT recipients and has been linked to higher occurrence of 
bacteremia and/or GIT GvHD (Holler et al., 2014; Y. Taur et al., 2012). A high relative 
abundance of E. faecium is also observed in sample A07-2. Broad-
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therapy, which has been associated with higher GvHD-related mortality (Shono et al., 
2016), can reduce mucosal innate immune defences through elimination of commensal 
microbes, thereby allowing the expansion of specific bacterial taxa, such as E. faecium, 
which carry multiple antibiotic resistance mechanisms (Brandl et al., 2008; Ubeda & 
Pamer, 2012). Our findings suggest that this specific population expanded in response to 
antibiotic treatment.  
Bacteroides spp. are normal commensals of the human GIT microbiome, they usually 
make up around 25 % of the community, as it is the case in sample A07-1 (Figure 3.3.1A). 
However, they can also cause infections with associated mortality (Wexler, 2007). 
Bacteroides spp. might be able to penetrate the colonic mucus and persevere within crypt 
channels. These reservoirs might persist even during antibiotic treatment (S. M. Lee et al., 
2013). Different species of the genus Bacteroides produce bacteriocins (Avelar et al., 
1999; Booth, Johnson, & Wilkins, 1977; Nakano, Ignacio, Fernandes, Fukugaiti, & Avila-
campos, 2006), a trait that might have made it possible for these bacteria to repopulate 
the GIT and expand after the dysbiosis in A07-2, occupying specific niches, resulting in a 
relative abundance of 63 % in A07-3 (day 119).  
3.3.3 Population-level structure of the pre- and post-treatment microbial 
community 
Coupled MG and MT datasets of samples A07-1 (pre-treatment) and A07-3 (post-
treatment) were generated and analyzed in order to inspect the changes in the GIT 
microbiome and the effects of allo-HSCT and concurrent antibiotics use after an extended 
period of time. As a comparison, samples from four healthy individuals (referred to as 
'reference healthy microbiomes' or 'RHMs') were analyzed in the same way.  
To gain a comprehensive overview of the populations present in either sample, a method 
for automated binning of the contigs based on the BH-SNE embedding was employed. 
This binning method allowed the identification of 134 and 14 individual population-level 
genomic complements, representing individual populations, in the pre-treatment and post-
treatment samples, respectively (Figure 3.3.2). The visual impressions of the two 
embeddings reflect the drastic change in the GIT microbiome, in particular the decrease in 
diversity with the representation of the post-treatment sample A07-3 being exceptionally 
sparse (Figure 3.3.2B). The most abundant populations were identified as Escherichia 
coli, Enterococcus faecium, Lactobacillus reuteri, Lactobacillus rhamnosus and several 
species assigned to the genus Bacteroides, which is in agreement with the 16S rRNA 
gene sequencing-based results (Figure 3.3.1A).  
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Representation of both samples within a single plot allows visual discrimination of clusters 
that are specific to one sample, or present in both samples (Figure 3.3.2C). In accordance 
with the results from 16S rRNA gene sequencing (Figure 3.3.1A), the majority of the 
clusters were only found in the pre-treatment sample, while other clusters comprised 
contigs from both samples and two clusters in the post-treatment sample were identified 
as Lactobacillus reuteri and Lactobacillus rhamnosus, which were either not present, or 
lowly abundant in sample A07-1 (Figure 3.3.2C).  
Facultative anaerobes such as members of the orders Lactobacillales and 
Enterobacteriales are often observed to increase in relative abundance after treatment 
while obligate anaerobes such as members of the order Clostridiales often decrease in 
abundance (Jenq et al., 2012). Lactobacillus rhamnosus and Lactobacillus reuteri (which 
were detected in sample A07-3) are both often combined in probiotic formulations and are 
commonly considered safe and even beneficial through inhibition of potential pathogen 
(such as E. coli and E. faecium) expansion (Borriello et al., 2003; Servin, 2004; Spinler et 
al., 2008). Bacteria found in probiotic formulations, especially Lactobacillus species have 
occasionally also caused bloodstream infections (Cohen et al., 2016). Our data suggest 
that probiotics should be administered with great caution and should be subject to further 
investigations to clearly ensure safety of their usage. 
Given the potential role of opportunistic pathogens in aGvHD (Penack et al., 2010), we 
were specifically interested in two opportunistic pathogens that were found in both 
samples and whose genomes could be recovered with high completeness. We identified 
populations of Escherichia coli and Enterococcus faecium, which were inspected further. 
The population-level genomes from both samples were reassembled to allow direct 
comparison of identified variants as well as of the complement of ARGs encoded by them 
and detected in each sample.  
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Figure 3.3.2: BH-SNE-based visualization of genomic fragment signatures of microbial communities 
present in samples of patient A07. Points represent contigs ≥ 1000 nt. Clusters are formed by contigs with 
similar genomic signatures. (A) Visualization of pre-treatment sample contigs. (B) Visualization of post-
treatment sample contigs. (A and B) Points within clusters are colored according to the cluster completeness, 
based on the number of unique essential genes. Lines within the colored bar indicate the number of clusters 
at each percentage of completeness. (C) Combined visualization of contigs derived from pre-treatment 
sample (A07-1, blue squares) and post-treatment (A07-3, red crosses) samples. The inset displays a 
magnification of a section of the plot representing two populations (Lactobacillus reuteri and Lactobacillus 
rhamnosus), which are only present in the post-treatment sample. In each representation, clusters 
representing Escherichia coli and Enterococcus faecium are indicated. 
3.3.4 Evidence for selective pressure at the strain-level 
To uncover evidence of possible selective sweeps in the populations of interest (the 
opportunistic pathogens Escherichia coli and Enterococcus faecium), caused by 
administration of antibiotics, we performed a gene-wise protein sequence comparison of 
the different population-level genomes. This analysis revealed that 97.4 % of the genes 
found in the different population-level genomes of E. coli, reconstructed from samples 
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A07-1 and A07-3, were 100 % identical and only 1.1 % of the genes were less than 95 % 
identical. In E. faecium, only 76 % of the genes were completely identical and 13.2 % of 
the genes showed less than 95 % identity.  
The average MG depths of coverage indicated that the population size of E. coli was 
smaller after allo-HSCT (Figure 3.3.3A), while the population size of E. faecium remained 
rather constant (Figure 3.3.3C). In E. coli, a similarly high number of variants was 
identified in both the pre- and post-treatment samples, with an important overlap of 
variants identified in both populations (Figure 3.3.3C), whereas only a few variants were 
present in E. faecium of both samples (Figure 3.3.3D). A similar pattern of variant 
distributions in both samples was observed for E. coli (Figure 3.3.3E and Figure 3.3.3G), 
while the variant pattern in E. faecium (Figure 3.3.3F and Figure 3.3.3H) changed 
between both samples. Observed nucleotide variant frequencies and patterns of variant 
distributions indicated that the E. coli populations were composed of different strains in 
both samples, which persisted over the course of the treatment. In contrast, E. faecium 
was mainly represented by a single strain in each sample, and the strain of the first 
sample was replaced by a different strain in the second sample.  !!
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Figure 3.3.3: Number and distribution of variants in Escherichia coli and Enterococcus faecium. (A 
and C) Violin plots representing distribution of depth of coverage of the contigs contained in each population-
level genome. (B and D) Venn diagrams indicating the number of variant positions exclusive to each sample 
respectively the number of variant positions found in both samples. (E and F) Representation of exemplary 
sections of the reassembled population-level genomes with aligned reads of both samples highlighting 
occurrences of variants in each population, visualized with the Integrative Genomics Viewer. Length of the 
represented section is indicated as well as the average MG depth of coverage of each reconstructed 
population-level genome. (G and H) Histogram of the variant frequencies of the minor nucleotide at all variant 
positions. Panels on the left represent results for E. coli, panels on the right represent results for E. faecium. 
Blue figure elements refer to the pre-treatment sample (A07-1), red figure elements refer to the post-treatment 
sample (A07-3). 
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3.3.5 Coupled metagenomic and metatranscriptomic analysis of antibiotic 
resistance genes in the pre- and post-treatment samples from patient A07 
The relative abundance of detected ARGs (percentage of ARGs relative to the total 
number of genes, Figure 3.3.4A) in the post-treatment sample (0.39 %) was significantly 
higher than the relative abundance of ARGs in the pre-treatment sample (0.28 % ARGs, p 
value 6.9 *10-4, Fisher's exact test) while the relative abundances of ARGs of both the pre- 
and post-treatment sample were higher than the average relative abundance in the RHMs 
(0.20 % ± 0.01 %, p value 5.601 * 10-7 and 3.278 * 10-10). Moreover, the expression of 
ARGs was higher in both samples from patient A07 when compared to the RHMs (Figure 
3.3.4B).  
 
Figure 3.3.4: Expression levels and relative abundances of antibiotic resistance genes (ARGs). (A) 
Percentage of identified ARGs (in relation to total number of genes) in the pre-treatment (A07-1) and post-
treatment (A07-3) sample and in the GIT microbiomes of four healthy untreated individuals (RHMs; ** p value 
< 0.01, Fisher's exact test). (B) Histogram of the ratios of metatranscriptomic (MT) to metagenomic (MG) 
depths of coverage of ARGs in the pre-treatment and post-treatment sample and in the RHMs. (C) 
Histograms of the ratios of MT to MG depths of coverage of ARGs in population-level genomes of Escherichia 
coli and of Enterococcus faecium in the pre- and post-treatment samples. Bars representing the number of 
ARGs at a specific expression rate in the pre-treatment sample are blue, bars representing the genes in the 
post-treatment sample are red. For the RHMs, the average of four datasets is represented with standard 
deviation as error bar.  
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3.3.6 Identification of antibiotic resistance genes in population-level genomes of 
opportunistic pathogens 
Given the higher number and expression of ARGs in the post-treatment sample of patient 
A07, we were interested whether this could also be detected in the specific populations E. 
coli and E. faecium. Within the population-level genome of E. coli, 31 ARGs were 
identified in both samples and 2 additional genes were detected in the post-treatment 
sample only. In E. faecium, 25 ARGs were identified in both samples of which 21 genes 
were identical in both samples (summaries of the ARGs identified in each population-level 
genome are listed in Table 3.3.1 and Table 3.3.2). In E. coli, 20 of the 31 ARGs that were 
found in both samples, exhibited higher levels of expression in the post-treatment sample 
while in E. faecium, 18 out of 21 ARGs showed higher expression post-HSCT (Figure 
3.3.4C). Although patient A07 was only treated with antibiotics until day 18 (Figure 
3.3.1D), expression of the ARGs was in general higher in the post-treatment sample, both 
in the whole sample (Figure 3.3.4B), as well as in the specific populations (Figure 3.3.4C).  
Table 3.3.1: ARGs identified in population-level genomes of GIT E. coli from patient A07. 
Resfams_ID 
Number of 
Genes Resfam Family Name Mechanism 
RF0005 1 AAC6-Ib 
Aminoglycoside Modifying 
Enzyme 
RF0007 3 ABCAntibioticEffluxPump ABC Transporter 
RF0027 1 ANT3 
Aminoglycoside Modifying 
Enzyme 
RF0035 1 baeR Gene Modulating Resistance 
RF0053 1 ClassA Beta-Lactamase 
RF0055 1 ClassC-AmpC Beta-Lactamase 
RF0056 1 ClassD Beta-Lactamase 
RF0065 1 emrB MFS Transporter 
RF0088 1 macA ABC Transporter 
RF0089 1 macB ABC Transporter 
RF0091 1 marA Gene Modulating Resistance 
RF0098 1 MexE RND Antibiotic Efflux 
RF0101 1 MexX RND Antibiotic Efflux 
RF0112 1 phoQ Gene Modulating Resistance 
RF0115 6 RNDAntibioticEffluxPump RND Antibiotic Efflux 
RF0121 1 soxR Gene Modulating Resistance 
RF0147 1 tolC ABC Transporter 
RF0168 6 TE_Inactivator Antibiotic Inactivation 
RF0172 1 APH3'' Phosphotransferase 
RF0173 1 APH3' Phosphotransferase 
RF0174 1 ArmA_Rmt rRNA Methyltransferase 
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Table 3.3.2: ARGs identified in population-level genomes of GIT E. faecium from patient A07. 
Resfams_ID 
Number of 
Genes Resfam Family Name Mechanism 
RF0004 1 AAC6-I 
Aminoglycoside Modifying 
Enzyme 
RF0007 9 ABCAntibioticEffluxPump ABC Transporter 
RF0033 1 APH3 
Aminoglycoside Modifying 
Enzyme 
RF0066 1 emrE Other Efflux 
RF0067 1 
Erm23SRibosomalRNAMethylt
ransferase rRNA Methyltransferase 
RF0104 1 MFSAntibioticEffluxPump MFS Transporter 
RF0134 1 
Tetracycline_Resistance_MFS
_Efflux_Pump Tetracycline MFS Efflux 
RF0154 1 vanR Gylcopeptide Resistance 
RF0155 2 vanS Gylcopeptide Resistance 
RF0168 1 TE_Inactivator Antibiotic Inactivation 
RF0172 2 APH3'' 
Aminoglycoside Modifying 
Enzyme 
RF0173 2 APH3' 
Aminoglycoside Modifying 
Enzyme 
RF0174 6 ArmA_Rmt Aminoglycoside Resistance 
 
In E. coli, three different genes conferring resistance against β-lactams were identified, 
one of which was only detected in the post-treatment sample, which might have been 
acquired due to selective pressure given the administration of three different β-lactam 
antibiotics during the treatment.  
Observed nucleotide variant frequencies and patterns of variant distributions indicated 
that the treatment may have constituted a genetic bottleneck for E. faecium, culminating in 
the observed lower genetic diversity. This also suggests that two different mechanisms 
influenced the respective compositions of E. coli and E. faecium populations. While the E. 
coli population remained relatively unaffected, the E. faecium population underwent a 
selective sweep in response to the antibiotic treatment with selection of a specific 
genotype expressing ARGs. Overall, our observations indicate that antibiotic pressure and 
associated selection of bacteria encoding ARGs are likely essential factors in governing 
the observed expansion in opportunistic pathogens. 
3.3.7 Genomic characterization of a blood culture E. coli isolate and comparison 
to GIT populations 
The genomes of a blood culture isolate and GIT population-level genomes of E. coli from 
patient A07 exhibited an average nucleotide identity of 100 %. A heatmap and 
corresponding dendrogram based on the E. coli pangenomes indicated that the genomes 
of the E. coli isolated from patient A07 and genomes from the GIT MG data were closer 
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related to each other than to any other reference E. coli (Figure 3.3.5). In the genome of 
the E. coli isolate, the same ARGs as in the pre- and post-treatment GIT E. coli could be 
identified, with 4 additional ARGs compared to the post-treatment GIT E. coli.  
The overlap of ARGs identified in each genome further indicates their association. These 
findings are a proof for the potential fatal effects of dysbiosis associated pathogen 
dominance in the GIT and subsequent systemic infections on patient survival. 
 
Figure 3.3.5: Gene set profiles of the 118 reference strains and 3 E. coli isolated from patient A07 
(marked in red). Each row represents a gene (blue: present, yellow: absent), each column represents a 
strain.  
 
Gene
absent
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4 Conclusion and perspectives 
4.1 Is there a general response of the GIT microbiome to anticancer 
treatment and is the GIT microbiome implicated in development of treatment 
side effects? 
Different studies analyzing the GIT microbiome using 16S rRNA gene amplicon 
sequencing, in relation to changes in response to different anticancer treatments have 
been published (Biagi et al., 2015; Montassier et al., 2014). However, these studies have 
included different cohorts with several underlying diseases, various treatments and also 
varying analysis methods. Therefore, it is not surprising that the results are not 
necessarily in complete agreement. A systematic review (Touchefeu et al., 2014) lists a 
decrease in Bifidobacterium spp., Clostridium cluster XIVa, Faecalibacterium prausnitzii 
and an increase in Enterobacteriaceae and Bacteroides spp. as the most commonly 
observed changes after different anticancer treatments, including different combinations of 
cytotoxic and radiation therapies. In the current study, the changes within the GIT 
microbiome of the pediatric patients did not agree with these findings, except for a slight 
decrease in one member of the Clostridium cluster XIVa (Table 3.1.2).  
In samples from patients who developed mucositis, a decrease in one OTU classified in 
the Clostridium cluster XIVa and a decrease in Bacteroides sp. was observed, among 
other changes (Table 3.1.3). This was observed over all TPs including the TP before the 
treatment, thus, these differences were not likely due to the treatment. However, these 
GIT microbiome profiles might have contributed to mucositis development. In samples 
from patients who had severe mucositis, Akkermansia muciniphila was decreased. This 
bacterium was shown to strengthen the epithelial barrier function and is assumed to have 
anti-inflammatory properties (Derrien et al., 2016; Reunanen et al., 2015; Schneeberger et 
al., 2015). Thus, loss of this bacterium could lead to increased translocation of microbial 
molecules and favor an inflammatory response, thereby contributing to mucositis 
development. On the other hand, the decrease could represent a consequence of the 
damaged epithelium and a degradation of the mucus layer, which is its most important 
nutrient source (Yamamoto et al., 2013). In this case, the observed decrease in relative 
abundance of this bacterium would only represent a consequence of mucositis. 
To this date, this is the first study of MG and MT datasets of fecal samples from cancer 
patients. On the MT level, differentially abundant functional gene categories in samples 
from patients with mucositis were detected, which included functions associated with 
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bacteriophages, suggesting a potential role of these entities in the development of 
mucositis. Further investigations are needed in order to validate this finding and elucidate 
a mechanism.  
In the adult patient cohort, a decrease in many bacterial genera that are generally 
associated with health-promoting properties, such as Bifidobacterium spp., 
Faecalibacterium spp., Dorea spp., Roseburia spp., Blautia spp. and Barnesiella spp. was 
observed, along with many other changes (Table 3.2.1), which is partly in agreement with 
results commonly found in previous studies (Touchefeu et al., 2014). 
Similar to the observations in the pediatric cohort, the relative abundance of Akkermansia 
municiphila was decreased in samples from patients who later developed severe GvHD. 
As mentioned before, lower levels of this bacterium might have contributed inflammation 
or to a weaker intestinal epithelial barrier and thus enabled translocation of bacterial 
components and activation of the pro-inflammatory cascade. In other studies, onset of 
GvHD was accompanied by an increase in the abundance of Enterococcus spp. (Biagi et 
al., 2015; Holler et al., 2014) and a reduction in Faecalibacterium spp. and Ruminococcus 
spp. (Biagi et al., 2015; Jenq et al., 2012). In this study, trends in the abundance of these 
taxa were not observed with regards to GvHD but more generally over time. In the current 
study, Ruminococcus spp. was shown to be characteristic of samples collected at TP1 
(Figure 3.2.12), while Enterococcus spp. was more abundant in later TPs.  
One general response to treatment that was observed in both cohorts was a decrease in 
alpha-diversity of the prokaryotic GIT community (measured by the Shannon diversity 
index and the Chao1 richness estimator in Figure 3.1.3 and Figure 3.2.3). This decrease 
was substantially more pronounced in the adult patients undergoing allo-HSCT, which 
could be due to the intensive conditioning treatment, but also due to the antibiotic 
treatment. Furthermore, a general decrease in the functional potential was observed 
including a decrase in relative abundance or loss of various metabolic and cellular 
functions, which is probably linked to the decrease in microbial diversity and associated 
loss in bacterial populations (Figure 3.2.17 and Figure 3.2.18). This is the first study to 
show this decrease in functional capacity in these patients' GIT microbiomes. Overall, a 
detailed look at changes in samples from patients who have been sampled more 
frequently might help to discern and detect mechanisms that are involved in development 
of treatment side effects. Therefore, it might be useful to add this layer of information in 
future studies.  
A decrease in alpha-diversity after allo-HSCT (Figure 3.2.3) was also observed in other 
studies and lower diversity at engraftment was linked to higher transplant-related mortality 
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(Y Taur et al., 2014). This was also observed in this study (Figure 3.2.4). This raises 
questions and concerns regarding intensive antibiotic treatment after allo-HSCT, which of 
course has a drastic effect on microbial diversity. Based on the observation, one strategy 
to avoid a treatment-induced intestinal domination by pathogens could consist in the 
tailored administration of several, rather than single probiotic strains, composed based on 
the individual GIT microbiome changes during therapy. A different approach to restore 
specific beneficial microbes could consist in fecal microbiome transplantation, either as 
'autologous' (transplanting the pre-transplant microbiome) or 'allogeneic' graft (from the 
donor of the stem cells or a relative of the patient). A randomized trial of autologous fecal 
microbiome transplantation (FMT) for prevention of Clostridium difficile infection after allo-
HSCT is currently recruiting participants (https://clinicaltrials.gov/ct2/show/NCT02269150). 
This auto-FMT could possibly also prevent other treatment-related side effects. FMT with 
the patient's spouse or relative as donor was successfully performed on four allo-HSCT 
patients with steroid-resistant aGvHD of the GIT. In three cases, a complete response 
was observed along with one partial response (Kakihana et al., 2016). Preservation or re-
establishment of a diverse microbiome able to inhibit expansion of potential pathogens 
might be a new approach to avoid treatment related side effects. Bacteria with anti-
inflammatory properties, such as several members of the class Clostridia, might help in 
regulating the immune response by induction of Treg and IL-10 and lower the incidence or 
severity of GvHD and mucositis. Specifically Blautia spp. (a member of the class Clostridia 
with anti-inflammatory properties) was linked to lower GvHD-related mortality and 
improved overall survival after allo-HSCT (Jenq et al., 2015). 
In both cohorts, the microeukaryotic and the archaeal community did not display drastic 
changes in response to the treatment (section 3.1.3, section 3.2.2 and section 3.2.3). No 
correlation between bacterial diversity and microeukaryotic diversity was found which 
indicates that the individual microbial communities were differently affected by the 
treatment. 
In both cohorts, a high intra-individual dissimilarity but also inter-individual dissimilarity 
between different GIT bacterial profiles were observed (Figure 3.1.5 and Figure 3.2.6). 
Here, individual-specific changes rather than general trends within the GIT microbiome 
following treatment were observed. Additionally, as there is a high complexity within this 
ecosystem including numerous interactions between the GIT microbiome, the host 
immune system, treatment and dietary changes, it is not possible to relate development of 
mucositis or GvHD to one factor (the microbiome) alone. In this study, it was not possible 
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to detect changes in the GIT microbiome leading to development or aggravation of the 
side effects. 
4.2 How important are SCFAs? 
Numerous studies have focused on and discovered new effects of short-chain fatty acids 
(SCFAs), especially of butyrate, on the human body and implications in human health. For 
example, butyrate is important for maintenance of the intestinal barrier and it is a histone 
deacetylase inhibitor (Davie, 2003). Thereby, butyrate acts as an anti-inflammatory agent, 
inhibiting NF-κB activation (Inan et al., 2000). In patients with inflammatory bowel 
diseases, similar GIT microbial profiles were found as in patients with GvHD; marked by 
reduced richness, lower abundance of butyrate producers (such as members of the 
Clostridium clusters IV and XIVa) (Kolho et al., 2015; Zama et al., 2016). In a recent 
murine study, butyrate or a bacterial community including butyrate-producing Clostridia, 
were shown to mitigate GvHD (Mathewson et al., 2016), suggesting an important role of 
butyrate and butyrate-producers in relation to GvHD. 
In this project, in general, a decrease in the relative abundance of many SCFA producers 
was observed, in response to the allo-HSCT (Table 3.2.1). However, this was not 
observed when grouping according to development of severe GvHD (section 3.2.8). On 
this level, no link between SCFA-producers and GvHD was found. In both cohorts within 
the metagenome and metatranscriptome, no statistically significant differences in the copy 
number of the genes coding for the three enzymes catalyzing the final step in butyrate 
production were detected when grouping according to the occurrence of severe mucositis 
or GvHD (section 3.1.7.2). In samples from patients with active GvHD, a statistically 
significant decrease in the relative abundances of some genes belonging to different 
SCFA biosynthetic pathways was observed. These pathways included the propionate and 
butyrate biosynthesis pathway (Figure 3.2.19). Still, with the current study results, no 
direct link between the SCFA-producers in the GIT microbiome and occurrence of 
treatment side effects can be made. As it seems, there are more factors playing a role in 
development of these side effects and the interconnection between the microbiome, the 
health status of the patient and especially the immune system is more complicated. 
4.3 Could shotgun sequencing of the GIT microbiome revolutionize 
personalized medicine? 
Metagenomic sequencing allows description of the composition of the GIT microbiome 
including identification of potential pathogens. One advantage in comparison to 16S 
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and/or 18S rRNA gene amplicon sequencing is that with MG sequencing, genomic 
fragments from all domains of life and even of DNA viruses are contained within one 
dataset. 16S rRNA gene sequencing, in contrast, does not allow to draw conclusions on 
the actual composition of the GIT community as eukaryotes and viruses are not resolved. 
In addition, the total community size or the proportion of human DNA content are not 
measured. All of this information is retained in MG sequencing datasets. In this project, for 
example the presence of high amounts of human DNA in several samples was noticed 
(sample A27_3, Figure 3.2.13 and section 3.2.5), which in turn indicates that the overall 
microbial content was low. 
MG sequencing allows identification of potential pathogens without culturing. Culturing 
can lead to false negatives, as some bacteria are difficult to culture (Vartoukian et al., 
2010). Also, culturing does not reflect relative abundance. In addition, MG sequencing 
allows identification of all the ARGs comprised within the microbial community, i.e. the 
resistome. As observed in this study, there was an important increase in the ratio of ARGs 
within the community throughout treatment (Figure 3.1.11 and Figure 3.2.15), which was 
especially pronounced in the adult hematology patients and this can probably be linked to 
the intensive antibiotic treatment. A specifically tailored treatment could then be chosen, in 
response to the detected pathogens and corresponding ARGs. Although this may sound 
good in theory, we are still far away from being able to apply this workflow in the clinical 
setting. Especially immunocompromised patients are in a critical state, where timely 
actions and direct treatments are a necessity. At the onset of fever, indicating an infection, 
immediate action is crucial. At this point, it is not possible to wait for results of processed 
sequencing data, identifying the infecting pathogen and corresponding ARGs. However, if 
the first choice of treatment (empiric treatment) fails, these results may help to find a 
suitable medication (informed treatment). Furthermore, if next-generation sequencing 
became cheaper and faster, the changes in the microbiome of patients could be 
monitored and dangerous bacteria could be recognized and kept at bay before a fever or 
infection were to develop. Implementation of screening of ARGs and potential pathogens 
in baseline samples (at admission) as well as at sign of infection could possibly help to 
find the appropriate treatment and infection control measures, thereby improve patient 
treatment. Such a workflow could potentially result in faster and more reliable diagnostics 
(Figure 4.3.1). 
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Figure 4.3.1: Workflow suggesting possible usage of shotgun sequencing in personalized medicine to 
compile individually tailored treatments. 
Furthermore, MG sequencing allows detection and identification of viruses before they 
pose a threat to the patient. Often, symptoms of viral infections can vary and be quite 
unspecific, making it difficult to discern the virus causing the symptoms. For example, the 
symptoms of cytomegalovirus colitis, diarrhea and abdominal pain, are very similar of 
those of aGvHD. Therefore, a biopsy is advised at suspicion of infection (Jacobsohn & 
Vogelsang, 2007). Another method to detect viral infection is an antibody assay, however, 
in immunocompromised patients this test might result in a false negative result due to a 
low antibody response (Woods, 2013). Similarly, culturing of viruses (in cell culture) can 
be difficult and lead to false negatives if only a low number of viruses is present, which 
would then be growing slowly and take up to weeks to eventuate in a positive result. 
Shotgun sequencing allows early detection of viruses in a non-invasive and exhaustive 
way (section 3.1.6 and section 3.2.4).  
As seen in this study and mentioned previously, shotgun sequencing allows identification 
of ARGs (section 3.1.5 and section 3.2.6). A suggested response following this would be a 
specifically tailored antibiotic treatment. The majority of the currently used antibiotics 
however, are not specific to particular pathogens. Modes of action for example are the 
inhibition of cell wall synthesis (e.g. meropenem) or the inhibition of nucleic acid synthesis 
(e.g. fluoroquinolones). Generally, the fact that antibiotics have broad-spectrum activity is 
seen as an advantage. However, treatment with prophylactic broad-spectrum antibiotics 
will not only kill pathogenic and opportunistic bacteria, but also important beneficial and 
commensal bacteria. Resulting antibiotic pressure can lead to microbial dysbiosis and 
emergence of MDR bacteria, a threat that is well known. Therefore, development of other 
narrow-spectrum treatments is indispensable. Alternatives to currently used traditional 
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antibiotics have been presented in section 1.3. Another option for changing the 
composition of the microbiome may be the ingestion of specific beneficial microbes, i.e. 
probiotics. Generally, probiotics are defined as living microbes, which confer benefits to 
the host. Mainly lactobacilli and bifidobacteria are used as probiotics. In this study, the 
relative abundance of Lactobacillus spp. was in general higher in patients with severe 
aGvHD than in those without GvHD (section 3.2.8), as for example in A27_3 (Figure 
3.2.13) and A07_3 (Figure 3.3.1). The results in this project suggest, that the high relative 
abundance of this bacterial genus was a consequence of GvHD, rather than a cause. 
Bloodstream infection with Lactobacillus spp. has been observed in patients, including 
patients after allo-HSCT (Cohen et al., 2016; Salminen et al., 2004). Although their 
administration is generally considered safe (Ladas et al., 2016), these organisms and their 
interaction in particular with the immunocompromised host should be further investigated. 
Similarly, FMT is recently being applied in the treatment of patients with multiple recurrent 
Clostridium difficile infections (CDI), where cure rates of 90 % have been reported (Brandt 
et al., 2012). However, FMT has yet to be further investigated and improved before 
becoming a standard therapy option. In order to apply this method to patients undergoing 
cancer treatment, mechanisms of action need to be better understood. This is especially 
important in immunocompromised patients such as patients undergoing an allo-HSCT. 
After allo-HSCT, immunologic recovery occurs gradually, over time. On one hand, it might 
be beneficial to have an 'intact' GIT microbiome from a healthy donor, which could 
positively influence development of the hematopoietic cells and immune recovery. On the 
other hand, it is not known how the patient's newly acquired immune system might react 
to a completely foreign microbiome, even though the donor might be in good health. 
In short, if cost and turnaround time of shotgun sequencing could be addressed, it could 
potentially allow exhaustive profiling of the GIT microbiome of patients including members 
of all domains of life, as well as viruses and ARGs and thereby enable individually tailored 
treatments. 
4.4 General challenges for GIT microbiome studies in the clinical setting 
Numerous studies applying high-throughput sequencing such as rRNA gene amplicon 
sequencing on fecal samples have characterized the human GIT microbiome in detail and 
suggested that the GIT microbiome performs many important functions for the host, and 
that alterations and disorders in the microbial community can be associated to different 
diseases. Eventually, this deep insight into the human-microbiome interaction might 
enable the application of high-throughput sequencing in the clinical setting. However, a 
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standardized procedure and methodology should be put in place before it can be used in 
personalized medicine. Several recent studies have compared how different steps in 
microbiome studies influence the results (Blekhman et al., 2016; Gerasimidis et al., 2016; 
Walker et al., 2015). These factors include: storage (flash-freezing samples versus 
keeping them at room temperate, addition of preservation buffers, storage at -20 °C or  
-80°C), the period of storage, the extraction method, sequencing method (including the 
choice of primers for example for amplicon sequencing) and the pipeline used for 
processing of the reads (for example mothur (Schloss et al., 2009), QIIME (Caporaso et 
al., 2010) or LotuS (Hildebrand et al., 2014)). All of those steps have been shown to 
introduce bias and influence the final output. Within individual studies therefore, one is 
usually mindful to use the same strategy for all of the samples, which allows comparison 
of the results within the study. However, it is a general aim in research to share the gained 
knowledge and build upon it. Usage of different strategies makes it difficult or impossible 
to truly compare results from different studies. However, it is difficult to establish a general 
workflow that accounts for everybody's needs. While the majority of the studies only focus 
on DNA, it would be crucial to add and integrate different omic data (such as RNA, 
proteins or metabolites). In this case, a framework that allows extraction of all of those 
biomolecules from one undivided subsample would be ideal (Roume, Muller, et al., 2013; 
Roume, Heintz-Buschart, et al., 2013).  
To reduce some of the introduced bias, the same storage method, and a generally applied 
lysis protocol, allowing disruption of the cell walls of the different organisms present in one 
sample could be set in place. After lysis, subsequent extraction of DNA only or of different 
biomolecules (DNA, RNA, proteins and metabolites), according to the needs of the 
individual project would be possible. Additionally, if raw sequencing data of individual 
projects were publicly available, they could be processed using different pipelines, making 
the results from different studies more comparable. 
In the GIT microbiome field, fecal samples are generally used as proxy for the content of 
the large intestine, as they are easier to collect than for example biopsies. However, they 
might not accurately reflect the microbial community in the colon as for example 
organisms living in the mucus layer might be underrepresented in the sample. 
Additionally, transit time and stool consistency influence microbial richness (Vandeputte et 
al., 2016). Thus, it has to be kept in mind that fecal samples might not represent the exact 
reality. A solution to get a more representative overview of the actual microbial community 
within the colon is the IntelliCap (MediMetrics), an electronic capsule, which allows 
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sampling within the GIT in a non-invasive way. The included pH temperature sensors 
enable position tracking and thereby sampling from different locations within the GIT. 
Also, different subsamples from one fecal sample result in high variability of the different 
microbial taxa (Gorzelak et al., 2015; D. H. Huson et al., 2016). In order to circumvent 
some of these difficulties in this study, we applied an extraction method that allows 
extraction of DNA and RNA from one undivided sample was applied (Roume, Muller, et 
al., 2013; Roume, Heintz-Buschart, et al., 2013). Also, the same sequencing 
methodologies were applied for individual samples and each dataset type was processed 
using the same pipeline, in order to allow comparison of the different results. Different 
omic layers (rRNA gene amplicon sequencing, metagenomic and metatranscriptomic 
datatsets) were produced and analyzed, allowing higher confidence. In addition, 
metagenomic sequencing is less bias prone than rRNA gene amplicon sequencing, as 
this method does not include PCR amplification (Shakya et al., 2013). 
4.5 Challenges in this study 
In this project, two different departments were included to be able to include a higher 
number of patients, resulting in two different patient cohorts, each cohort displaying high 
levels of heterogeneity in itself. The patients in these cohorts had different underlying 
diseases and received different antibiotic and anticancer treatments. Thus, many 
confounding factors could have influenced the GIT microbiome, which makes it difficult to 
link the observed changes to one factor alone. For example, the GIT microbiome has 
been shown to evolve throughout lifetime and to display different patterns according to the 
age of the host. Even within the pediatric department, where the age of the patients 
ranged only from 3 to 19 years, this effect could be observed. Younger children (3-4 
years) displayed a microbial community with a lower diversity and richness (Figure 3.1.4 
(Ringel-Kulka et al., 2013)). It was noticed that the lower richness was not related to the 
treatment group, but mainly to the age of the patient. The treatment however did also 
have an influence on richness. 
It has been observed that the GIT microbiome of healthy individuals is strikingly stable 
over time and also capable of reverting roughly to its initial state, even after external 
influences have induced changes in the complex ecosystem (David et al., 2014; Heintz-
Buschart et al., 2016). However, in this study, a high inter-individual but also a high intra-
individual variation and dissimilarity between different GIT microbial profiles were 
observed (Figure 3.1.5 and Figure 3.2.6). Currently, large-scale studies including a higher 
number of patients usually conduct analyses based solely on the mean or median over 
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the whole cohort or individual study groups. Considering the huge variation that was 
observed between different patients and the very individual-specific patterns that were 
observed in this study (for example illustrated in Figure 3.1.10), averages were often not 
representative of any member of the cohort. Therefore, detailed personalized profiles 
were presented and discussed. The compelling individual-specific results suggest, that 
one way to resolve the dynamics within the microbiome following treatments should 
include studies focussing on patient dynamics individually. Similary, in the future, 
treatments should be more individually tailored (as suggested in Figure 4.3.1). 
In this study, high fluctuations in different blood counts, as well as in the GIT, especially in 
patients undergoing an allo-HSCT, were observed (for example in patient A07, Figure 
3.3.1). In order to relate changes in the composition of the GIT microbiome to the status of 
the immune system, a more frequent sampling scheme (ideally daily), would have to be 
adopted. For future studies, it would be interesting to include only a low number of 
patients, but to sample them frequently, over a longer time period. This has been done in 
other studies, focusing for example on the GIT microbiome of healthy individuals or of 
newborn babies (David et al., 2013, 2014; Palmer, Bik, DiGiulio, Relman, & Brown, 2007). 
4.6 Perspectives 
As observed in this study, many factors influence the complex microbial ecosystem in the 
GIT. Already in a simple bacterial population with a single taxon, there is a complicated 
interconnection and signalling network between the microorganisms resulting in 
responses of the population to simple parameters such as nutrient availability, 
temperature and pH. In general in the clinical setting, as it was the case in this project, a 
complex ecosystem of microorganisms, interacting with each other, but being also 
influenced by factors such as dietary changes of the host, drastic changes of the status of 
the immune system and treatment with chemotherapeutics and antibiotics, is studied. In 
this system, new layers and levels of interconnections are added, resulting in a highly 
intricate network.  
To get an overview of the mechanisms within the microbiome, in this project, in addition to 
taxonomic profiling, assessment of the functional potential within the microbial community 
was included, adding a whole new level of information. However, the current study design 
does not allow identification of causality. It was not possible to identify whether changes in 
the GIT microbiome composition led to the development or aggravation of adverse effects, 
a worse outcome, or changes in the status of the immune system, or, if the latter resulted 
in further changes in the microbiome. In order to find out specific causalities and 
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mechanisms, a much more simplified and controlled system might be more suitable. 
Mouse studies allow a more controlled environment with less confounding factors, 
frequent sampling and also the analysis of the GIT content instead of the stool samples. 
However, as for example mice are different from humans in anatomy, genetics and 
physiology, murine studies can never mimic human systems (Nguyen TL, Vieira-Silva S, 
Liston A, 2015). Another possibility would be the usage of a microfluidics-based co-culture 
device such as HuMiX (Shah et al., 2016), which allows growth of bacteria, intestinal 
epithelial cells and human immune cells in different chambers, separated by membranes, 
which allow molecular cross-talk. Thus, interactions between those layers can be 
examined in a controlled environment with specific user-defined properties. Distinct 
bacterial communities (mimicking either a healthy GIT microbiome or a community in a 
dysbiotic state including potential pathogens) can be introduced or a non confluent layer 
of epithelial cells and membranes with larger pores, mimicking a 'leaky gut'. Observational 
studies in the clinical setting are still important and are needed. Validation of specific 
observations in different clinical studies is difficult, as heterogeneous patient cohorts in 
different studies might not reflect the same results. Ideally, studies in different settings, 
using different methodologies, would complement each other and finally allow integration 
of the knowledge. 
In order to tackle the complexity of this highly interconnected network, in a future study, 
only a small number of patients, ideally with similar age, disease and treatment should be 
included and followed throughout their treatment with a high sampling frequency. In order 
to get from observation to causality, specific, interesting findings could then be further 
analyzed using a meta-omic approach and validated using different methods. For 
example, concerning the results from this study, lactobacilli present in high abundance in 
patients after allo-HSCT could be isolated and cultured together with human (epithelial 
and immune) cells, to see if they were able to elicit an immune response, using cytokine 
detection assays and transcriptomics. The amount of SCFA (especially butyrate) in fecal 
samples as well as in the serum could be determined in order to see if the observed 
decrease in SCFA-producing bacteria actually resulted in lower amounts of SCFA.  
Despite extensive research efforts in the field of GIT microbiome, also in the context of 
cancer development and treatment, we are still only at the beginning of understanding this 
complex ecosystem and its interconnection with human health and disease. Clearly, the 
GIT microbiome plays an important role in human health and disease and carries the 
potential to be used as therapeutic agent (in the form of probiotics or FMT), emphasizing 
the importance and value of future research in this field. The results from this project 
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indicate that integrated omics, including different layers of information are needed to 
understand the complex mechanisms and interconnection of the GIT microbiome and its 
host. Ultimately, exhaustive personalized analyses could possibly enable an accordingly 
tailored treatment in the future. !
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antibiotic resistance genes suggests that prophylactic antibiotic administration may 
adversely affect overall treatment outcome. We even present novel data suggesting that 
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effects during a stem cell transplantation. Our analyses may initiate follow up studies that 
might enable clinicians to adjust the therapy regimens according to individuals.
2. The main findings: while we observed a drastic decrease in bacterial diversity, the 
eukaryotic community seemed to be more resilient against the intensive treatment. 
Furthermore, no specific pattern in response to treatment was found in the archaeal 
populations. Additionally, detailed metagenomic and metatranscriptomic analyses of 
samples from one patient highlight the long-term effects that this intensive treatment has on 
the gastrointestinal microbiome. We further observed a clear enrichment in the copy 
numbers and expression of antibiotic resistance genes.
3. The novelty of the analysis approach and the dataset: According to our knowledge, 
the manuscript describes the first detailed analysis of the changes in the gastrointestinal 
microbiome of patients undergoing an allogeneic stem cell transplantation. The study 
includes information on all three domains of life in addition to metagenomic and 
metatranscriptomic data of samples from one specific patient who displayed an extensive 
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347 Abstract 
48 In patients undergoing allogeneic hematopoietic stem cell transplantation 
49 (allo-HSCT), treatment-induced changes to the gastrointestinal tract (GIT) 
50 microbiome have been linked to adverse treatment outcomes, most notably 
51 graft-versus-host disease (GvHD). However, it is not known whether this 
52 relationship is directly causal. Here, we performed an integrated meta-omic 
53 analysis to gain deeper insight into GIT microbiome changes during allo-
54 HSCT and accompanying treatments. We used 16S and 18S rRNA gene 
55 amplicon sequencing to resolve archaea, bacteria and eukaryotes in the GIT 
56 microbiomes of 16 patients undergoing allo-HSCT for treatment of 
57 hematologic malignancies. This study reveals a major shift in the GIT 
58 microbiome after allo-HSCT, including a marked reduction in bacterial 
59 diversity but limited changes among eukaryotes and archaea. An integrated 
60 analysis of metagenomic and metatranscriptomic data was performed on 
61 samples collected from one patient before and after treatment for acute 
62 myeloid leukemia. This patient developed severe GvHD, which led to death 
63 nine months after allo-HSCT. In addition to a drastically decreased bacterial 
64 diversity, the post-treatment sample showed a higher overall number and 
65 higher expression levels for antibiotic resistance genes (ARGs). An organism 
66 causing a paravertebral abscess was shown to be linked to the GIT dysbiosis, 
67 suggesting loss of intestinal barrier integrity. The apparent selection for 
68 bacteria expressing ARGs suggests that prophylactic antibiotic administration 
69 may adversely affect overall treatment outcome. Detailed analyses including 
70 information about the selection of pathogenic bacteria expressing ARGs may 
71 help to support clinicians in tailoring the procedural therapy protocols in a 
472 personalized fashion to improve overall outcome in the future.
73
74 Introduction
75 Humans live in a close relationship with microorganisms that are referred to 
76 as the “microbiome”, comprising bacteria, archaea and eukaryotes. The most 
77 densely populated human body habitat is the gastrointestinal tract (GIT), 
78 which is estimated to contain 500 – 1000 different microbial species.1 The GIT 
79 microbiome plays a myriad of important roles in human physiology, including 
80 for example in the digestion of food, the synthesis of vitamins, the production 
81 of short-chain fatty acids and the prevention of colonization by pathogens 
82 through exclusion.2 It is generally accepted that, within a healthy human GIT, 
83 a homeostatic state exists among the different microorganisms which is tightly 
84 regulated by the host's immune system.3–5 However, perturbations, such as 
85 the intake of antibiotics, infections or immunosuppression, can lead to a 
86 disruption of this balanced state, typically referred to as "dysbiosis".3,6 In a 
87 dysbiotic state, pathogens can overgrow the community.6 Furthermore, 
88 reduced intestinal barrier function can facilitate translocation of 
89 microorganisms and microbial products from the GIT lumen to mesenteric 
90 lymph nodes and/or the bloodstream,7 putting the host at risk for local 
91 infections and sepsis.6,8
92 Allogeneic hematopoietic stem cell transplantation (allo-HSCT) represents an 
93 effective treatment for several hematologic malignancies. It is preceded by an 
94 intense conditioning regimen, consisting of either total body immune ablative 
95 irradiation or high doses of chemotherapy, to facilitate engraftment of 
96 transplanted stem cells. Allo-HSCT is known to greatly impact stability and 
597 integrity of the GIT microbiome.9 A substantial loss in bacterial diversity and 
98 the dominance of single bacterial taxa have been observed in patients 
99 undergoing allo-HSCT.9 
100 Supportive care of patients receiving allo-HSCT includes prophylactic broad-
101 spectrum antibiotic treatment,10 an intervention that also influences the GIT 
102 microbiome by selection for potential pathogens carrying antibiotic resistance 
103 genes (ARGs)11 as well as driving transfer of ARGs among commensal 
104 bacteria, including many opportunistic pathogens.12 In addition, loss of the 
105 normal bacterial GIT community following antibiotic treatment can facilitate 
106 expansion of yeasts including invasive Candida albicans infections with 
107 potentially fatal consequences.13,14
108 The intensive conditioning treatment for allo-HSCT may lead to mucositis 
109 along the GIT, which culminates in the formation of painful ulcers, dysphagia 
110 and diarrhea.15 The most significant complication of allo-HSCT is acute graft-
111 versus-host disease (aGvHD) which affects 35 % - 50 % of patients and is a 
112 major cause of mortality.16 GvHD, a systemic, inflammatory disease, is 
113 provoked by a complex anti-allogeneic immune response, which primarily 
114 affects the skin, liver and GIT.17 Glucksberg et al.18 divided each organ 
115 involvement into four stages from mild to severe. These are integrated into an 
116 overall grade of GvHD, where I-II are considered as mild and III-IV are 
117 considered as severe. Usually, intestinal GvHD dominates the clinical picture 
118 in severe aGvHD, which typically occurs within 100 days after allo-HSCT and 
119 is initiated by alloreactive donor T cells that recognize antigens on host 
120 cells.19
6121 It has been suggested that the GIT microbiome might be implicated in the 
122 development or exaggeration of aGvHD, as the damaged GIT epithelial 
123 barrier in patients undergoing allo-HSCT allows translocation of 
124 microorganisms or pathogen-associated-molecular patterns (PAMPs).20 
125 These PAMPs can activate antigen-presenting cells and thereby lead to 
126 alloactivation and proliferation of donor T cells which trigger aGvHD.20 
127 Antibiotic treatment has been shown to have ambiguous effects on treatment 
128 outcome. On the one hand, a low bacterial diversity at engraftment, possibly 
129 caused by a preceding combination of chemotherapy, total body irradiation 
130 and broad spectrum antibiotics has been linked to a worse outcome.21 On the 
131 other hand, GIT decontamination using antimicrobials has been observed to 
132 lower the rate of aGvHD.22,23
133 Previous studies have investigated changes in the bacterial community 
134 structures of the GIT microbiome directly after allo-HSCT or conditioning 
135 treatment.21,24–26 However, it is not yet known how GIT microbial communities 
136 including archaea and eukaryotes evolve over longer periods of time and what 
137 effects the disruption of the microbiome, for example through the 
138 administration of antibiotic regimens, has on the human host with respect to 
139 aGvHD and overall treatment outcome. 
140 Recent advances in high-throughput next-generation sequencing allow for a 
141 detailed analysis of the GIT microbiome in the context of allo-HSCT and 
142 treatment outcome. Here, a meta-omic approach was used to provide an 
143 exhaustive view of the changes which occur in the GIT microbial community 
144 of patients with hematologic malignancies undergoing allo-HSCT treatment. 
145 We expand upon previous studies by analyzing changes not only in the 
7146 bacterial populations, but also among archaea and eukaryotes, thereby 
147 covering all three domains of life. Additionally, we present a detailed analysis 
148 of metagenomic (MG) and metatranscriptomic (MT) data from one patient with 
149 a fatal treatment outcome, including identification of ARGs, corresponding 
150 expression levels and genetic variation in dominant bacterial populations. This 
151 study serves as a proof of concept for future meta-omic studies of the GIT 
152 microbiome in the context of allo-HSCT treatment and other intensive medical 
153 treatments. 
154
155 Material and methods
156 Study participants and fecal sample collection
157 The study was approved by the Ethics review board of the Saarland 
158 amendment 1 and 2 (reference number 37/13), and by the Ethics Review 
159 Panel of the University of Luxembourg (reference number ERP-15-029). After 
160 provision of written informed consent, 16 patients undergoing allo-HSCT were 
161 enrolled in the study. 
162 For microbial diversity and richness analyses, patients were included only if 
163 fecal samples were obtained from at least two of the following time points: i) 
164 up to eight days before allo-HSCT (designated time point (TP) 1), ii) directly 
165 after allo-HSCT (up to four days after allo-HSCT, designated TP2) and/or iii) 
166 around the time of engraftment between day 20 and day 33 after allo-HSCT 
167 (designated TP3). One additional patient was selected for a detailed analysis 
168 of the effects of the treatment over an extended period of time. From this 
169 patient, samples were collected 13 days before allo-HSCT, as well as 75 and 
170 119 days after allo-HSCT. Fecal samples were immediately flash-frozen on-
8171 site and preserved at -80 °C to ensure integrity of the biomolecules of interest.
172
173 Extraction of biomolecules from fecal samples
174 DNA and RNA were extracted from unthawed subsamples of 150 mg, after 
175 pre-treatment of the weighed subsamples with 1.5 ml RNAlater-ICE 
176 (LifeTechnologies) overnight at -20 °C. The biomolecules were extracted from 
177 the mixture as described previously, using the AllPrep DNA/RNA/Protein kit 
178 (Qiagen).27,28 To increase the overall yield, DNA fractions were supplemented 
179 with DNA extracted from 200 mg subsamples using the PowerSoil DNA 
180 isolation kit (MO BIO). The quality and quantity of the DNA extracts were 
181 verified using 1 % agarose gel electrophoresis and NanoDrop 2000c 
182 spectrophotometer (Thermo Fisher Scientific), while RNA extracts were 
183 verified using Agilent 2100 Bioanalyzer (Agilent Technologies). Only fractions 
184 with RNA integrity number (RIN, Agilent Technologies) > 7 were sequenced. 
185 Extracted biomolecules were stored at -80 °C until sequencing.
186
187 16S and 18S rRNA gene amplicon sequencing and data analysis
188 Amplification and paired-end sequencing of extracted and purified DNA was 
189 performed on an Illumina MiSeq platform at the Groupe Interdisciplinaire de 
190 Génoprotéomique Appliquée (GIGA, Belgium). The V4 region of the 16S 
191 rRNA gene, which allows resolution of bacteria and archaea, was amplified 
192 and sequenced using the primers 515F_GTGBCAGCMGCCGCGGTAA and 
193 805R_GACTACHVGGGTATCTAATCC29,30 with paired-end reads of 300 nt 
194 each. The V4 region of the 18S rRNA gene was amplified and sequenced 
195 using the primers 574*f and 1132r (574*f_CGGTAAYTCCAGCTCYV 
9196 1132r_CCGTCAATTHCTTYAART31) to resolve the eukaryotic community 
197 structure.
198 16S rRNA gene sequencing reads were processed using the LotuS pipeline32 
199 (version 1.34) with default parameters. Processed reads were clustered into 
200 operational taxonomic units (OTUs), designating taxa with similar amplicon 
201 sequences at 97 % identity level. For taxonomic assignment of 16S rRNA 
202 gene amplicon sequencing data, the Ribosomal Database Project (RDP) 
203 classifier33 was used. OTUs with a confidence level below 0.8 at the domain 
204 level were filtered out, as well as OTUs that were not represented by more 
205 than 10 reads in any given sample. 
206 To process the 18S rRNA gene sequencing reads, a workflow specifically 
207 designed to process reads that are not overlapping was used.34 For 
208 classification of 18S rRNA gene amplicon sequencing data, the PR2 
209 database35–37 was employed. After processing, OTUs represented by less 
210 than 10 reads in all samples were removed as well as unclassified OTUs and 
211 OTUs belonging to the taxon Craniata, since they were most likely derived 
212 from human sequences. For following analyses, the 16S and 18S rRNA gene 
213 sequencing data were rarefied to the lowest number of respective reads for 
214 any sample (16S to 71,051 reads and 18S to 1,020 reads).
215 Statistical analyses and plots were generated in R (version 3.2.1).38 Microbial 
216 alpha-diversity and richness were determined at the OTU level, by calculating 
217 the Shannon diversity index and the Chao1 index after rarefaction, using the 
218 vegan package.39 Statistical comparison of diversity and richness was carried 
219 out using the Kruskal-Wallis test, the non-parametric Wilcoxon rank sum test, 
220 or, when applicable, Wilcoxon signed-rank test. When P values < 0.05 were 
10
221 observed, groups were considered as statistically significantly different. 
222 Differential analysis of taxa based on 16S rRNA gene sequencing data was 
223 performed using the DESeq2 package40 and significant differences on 
224 taxonomic levels were determined using the Wald test, after multiple-testing 
225 adjustment.
226
227 Metagenomic and metatranscriptomic sequencing, processing and 
228 assembly
229 MG and MT sequencing of the extracted DNA and RNA fractions was 
230 conducted by GATC Biotech AG, Konstanz, Germany. Ribosomal RNA 
231 (rRNA) was depleted from the RNA fractions using the Ribo-Zero Gold rRNA 
232 Removal kit (Epidemiology, Illumina) and a strand-specific cDNA library was 
233 prepared according to standard protocols, optimized by GATC. Libraries 
234 representing both nucleic acid fractions were sequenced using a 100 bp 
235 paired-end approach on an Illumina HiSeq 2500 using HiSeq V3 reagents. 
236 MG and MT datasets were processed using a newly in-house developed 
237 workflow, the Integrated Meta-omics Pipeline (IMP) version 1.1.41 
238 Within IMP, the average depth of coverage Dx of a gene or contig x was 
239 determined both for the metagenome and the metatranscriptome by 
240 calculating the average number of reads mapping to each nucleotide within a 
241 gene, respectively in a contig. 
242 𝐷𝑥 =  ∑𝑟𝑥𝑙𝑒𝑛𝑔𝑡ℎ𝑥
243 where rx is the number of reads mapping to a gene or contig x at each 
244 nucleotide. 
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245 Here, gene expression of a gene x was calculated as the ratio of average 
246 metatranscriptomic depth of coverage to the average metagenomic depth of 
247 coverage for individual genes x. 
248 𝐸𝑥 =  𝐷𝑥(𝑀𝑇)𝐷𝑥(𝑀𝐺)
249 Published human GIT microbiome MG and MT read data from four healthy 
250 individuals was obtained from the NCBI Sequence Read Archive [MG: 
251 SRX247379, SRX247391, SRX247401, SRX247405; MT: SRX247335, 
252 SRX247345, SRX247349, SRX247340].42 The sequencing reads were 
253 processed using IMP version 1.2.1.41 Data from the individuals "X310763260", 
254 "X316192082", "X317690558" and "X316701492" are in the following referred 
255 to as the "reference healthy microbiome", averaged as "RHMs" or individually 
256 referred to as "RHM1", "RHM2", "RHM3" and "RHM4".
257
258 Population-level binning of contigs from the co-assembly
259 To analyze and compare the population-level structure of the microbial 
260 communities based on the assembled genomic information, contiguous 
261 sequences (contigs) were binned into (partial) population-level genomes. 
262 Using VizBin,43,44 2D embeddings based on BH-SNE of the contigs of at least 
263 1,000 nt were produced, as part of IMP. In these embeddings, contigs with 
264 similar genomic signatures are closer together, hence, individual clusters of 
265 contigs represent individual microbial populations.45 Population-level clusters 
266 were selected following the method described in Heintz-Buschart et al.46 
267 Resulting bins are referred to as “population-level genomes” in the following. 
268 Within a community, the relative population size of a cluster (i) was 
269 determined by dividing the number of MG reads mapping to the contigs 
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270 forming this cluster (ci), by the total number of MG reads mapping to all the 
271 contigs used in the assembly (C) according to the following formula:
272 𝑁𝑖 =  𝑐𝑖 ∗  100𝐶
273
274 Taxonomic affiliation of reconstructed population-level genomes
275 Taxonomic affiliation of population-level genomes was determined using 
276 complementary methods. Contigs forming the population-level genomes were 
277 first aligned to the NCBI nucleotide collection (nr/nt) database using the 
278 BLAST webservice.47 Parameters were left at default (using program 
279 megablast), and the output was analyzed using the MEtaGenome ANalyzer 
280 (MEGAN version 5.10.5).48 Whenever the rpoB gene could be recovered 
281 within a population-level genome, the closest neighbour (in terms of sequence 
282 identity) was determined in the nucleotide collection (nr/nt) database using the 
283 MOLE-BLAST webservice.49 Additionally, AMPHORA250 was used to identify 
284 the taxonomic affiliation of up to 31 bacterial or 104 archaeal phylogenetic 
285 marker genes.
286
287 Reassembly
288 Population-level genomes were reassembled using all MG and MT reads 
289 mapping to the contigs of the population-level genomes with the same 
290 taxonomic assignment. Reassembly of all recruited reads was carried out 
291 using SPAdes51 (version 3.5.0) using standard parameters. MG and MT reads 
292 were subsequently mapped to the contigs forming this reassembly to 
293 determine expression levels and variant density. 
294
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295 Sequence comparison of population-level genomes
296 The average nucleotide identity (ANI) calculator52 was used with standard 
297 settings to compare the reassembly from population-level genomes to publicly 
298 available reference genomes. A gene-wise protein sequence comparison of 
299 different population-level genomes was performed using the RAST server53 
300 using standard parameters.
301
302 Detection of antibiotic resistance genes
303 Antibiotic resistance genes (ARGs) within a community or population were 
304 searched against Resfams version 1.254 using HMMer version 3.1b255. We 
305 used the core version of the Resfams database, which includes 119 protein 
306 families. In accordance with the HMMer user manual, only identified genes 
307 with a bitscore higher than the binary logarithm of the total number of genes 
308 (of the community or population) were retained.
309
310 Variant identification 
311 Variants were identified in population-level reassembled genomes using 
312 SAMtools mpileup56 with default settings, which include the calling of single 
313 nucleotide variants (SNVs) as well as the identification of small 
314 insertions/deletions (indels). The output of SAMtools mpileup was filtered 
315 using a conservative heuristic established in Eren et al.57 which takes into 
316 account the ratio of the frequencies of both bases and the depth of coverage 
317 at the corresponding nucleotide position, in order to reduce the effect of 
318 sequencing errors.
319
14
320 Extraction, sequencing and analysis of bacterial DNA from a blood 
321 culture
322 DNA was extracted from a blood culture of an organism identified as a 
323 multidrug-resistant E. coli and sequenced on an Illumina MiSeq, 300 bp 
324 paired-end at GIGA. The genome was assembled with SPAdes.51 Using 
325 PanPhlAn58 and the provided database including 118 E. coli reference strains, 
326 their relation was assessed based on their gene set. While the PanPhlAn 
327 database includes 31,734 genes, only genes present in 10 or more genomes 
328 were considered, resulting in 7,845 genes for comparison.
329
330 Availability of data and materials
331 Reassembled population-level genomes of Escherichia coli (ID 
332 6666666.166711) and Enterococcus faecium (ID 6666666.166708) are 
333 accessible via the RAST guest account (http://rast.nmpdr.org, login: guest; 
334 password: guest). For samples A07-1 and A07-3, preprocessed MG and MT 
335 reads (after adapter trimming, quality filtering, rRNA removal and removal of 
336 reads mapping to the human genome) were submitted to the NCBI Sequence 
337 Read Archive (SRA) repository under the BioProject ID PRJNA317435 
338 (http://www.ncbi.nlm.nih.gov/bioproject/317435). Supplementary tables are 
339 archived on Zenodo (https://doi.org/10.5281/zenodo.268914).
340
341 Results 
342 Patient characteristics and treatment
343 Anthropometric and clinical information of the ten female and six male 
344 patients included in the study are provided in Table 1. They were between 30 
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345 and 67 years old (median 55). Five patients with relapsed or refractory 
346 lymphoma received FluBuCy (fludarabine, busulfan, cyclophosphamide) as 
347 conditioning treatment, six acute myeloid leukemia (AML) patients received 
348 BuCy (busulfan, cyclophosphamide), one myeloma and one comorbid AML 
349 patient received Treo/Flu (treosulfan, fludarabine), one comorbid AML patient 
350 received FluBu (fludarabine, busulfan) and two refractory AML patients 
351 received FLAMSA-Bu (fludarabine, amsacrine, busulfan) conditioning 
352 treatment. Grafts from eight full match unrelated, three mismatch unrelated 
353 and five sibling donors were used. 1.5 years after allo-HSCT, ten patients 
354 were still alive, while six patients had deceased. Twelve patients developed 
355 aGvHD and were treated with steroids (0.5 – 2 mg/kg/day). Three of them 
356 progressed to at least grade III aGvHD. 
357 As a prophylactic treatment, patients received a fluoroquinolone antibiotic 
358 during leukopenia. At occurrence of fever, patients were treated with 
359 piperacillin-tazobactam, followed by meropenem and subsequently 
360 vancomycin, if necessary. In case of suspected fungal infection, patients also 
361 received antifungal treatment with liposomal amphotericin B or caspofungin 
362 (Table 1). 
363
364 Changes within the GIT microbiome of patients undergoing allo-HSCT
365 We assessed the diversity and richness in the microbial community separately 
366 for the prokaryotic (bacteria and archaea; 16S rRNA gene sequencing) and 
367 eukaryotic (18S rRNA gene sequencing) community structures. The 
368 prokaryotic communities showed a drastic and statistically significant 
369 decrease in diversity from TP1 to TP3 (Fig. 1A). Similar to the observed 
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370 changes in terms of diversity, prokaryotic richness (Fig. 1B) decreased over 
371 the course of the study, with a significant decrease between TP1 and TP3 
372 over all samples. Differences in average relative abundance on different 
373 taxonomic levels were tested. On the genus level, average decreases of 119-, 
374 47- and 44-fold in the relative abundances of the genera Roseburia, 
375 Bifidobacterium and Blautia (Fig. 1C) were observed from TP1 to TP3. On the 
376 order level, a decrease in Bacteroidales relative abundance was observed in 
377 parallel with an increase in Bacillales (Fig. 1D). Only one OTU belonging to 
378 the domain archaea could be identified, the methanogen Methanobrevibacter 
379 smithii.59 It was detected in 13 out of the total 35 samples (and 10 out of 15 
380 patients) with a total of 914 reads.60
381 The analysis of the eukaryotic community did not reveal statistically significant 
382 differences for Shannon diversity (Fig. 1E) or Chao1 richness (Fig. 1F) 
383 between the different TPs. Both indices stayed relatively constant from TP1 to 
384 TP2 and even increased slightly at TP3 with no apparent statistically 
385 significant difference being observed for the 8 patients who underwent 
386 antifungal treatments. Overall, per sample, around 99 % of classified 
387 eukaryotic OTUs belonged to the fungal domain with the majority representing 
388 the genera Saccharomyces, Candida and Kluyveromyces. Only few different 
389 and lowly abundant protists could be identified, including a Vorticella sp., 
390 Prorodon teres, and a Phytophthora sp.60 We observed a lower prokaryotic 
391 diversity at TP of engraftment in patients who deceased (within 1.5 years after 
392 allo-HSCT), than in those who survived (Fig. 1G).
393 In summary, we found a general decrease in bacterial diversity after allo-
394 HSCT while the eukaryotic community stayed relatively stable throughout the 
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395 treatment. To further explore the effects of treatment on the structure and 
396 function of the GIT microbiome, we applied a detailed meta-omic approach on 
397 one patient.
398
399 Patient A07 - description of treatment and status of the patient
400 We chose to focus on patient A07, a patient who displayed a marked 
401 reduction in bacterial diversity with high relative abundances of opportunistic 
402 pathogens (Fig. 2A and 2B) and a fatal treatment outcome. This 63 year old 
403 patient had acute myeloid leukemia with deletion 7q. The patient was 
404 refractory to conventional induction (3+7) and salvage chemotherapy with 
405 high-dose cytarabine and mitoxantrone and therefore needed further 
406 treatment. FLAMSA-Bu,61 a modified sequential conditioning regimen for 
407 refractory acute myeloid leukemia was used (fludarabine 30 mg/m² day -11 to 
408 -8, cytarabine 2000 mg/m² day -11 to -8, amsacrine 100 mg/m² day -11 to -8 
409 and busulfan 3,2 mg/kg day -7 to -4) for remission induction and 
410 transplantation. She received peripheral blood stem cells from a single HLA-C 
411 antigen mismatched unrelated donor. After engraftment on day 26, bone 
412 marrow was hypocellular, but free of leukemia. Planned immunosuppression 
413 consisted of antithymocyte globulin (ATG) on day -4 to -2, mycophenolate 
414 mofetil until day 28 and cyclosporine until day 100. 
415 A high level of C-reactive protein (CRP) before and around allo-HSCT was 
416 observed which decreased slightly but stayed considerably high throughout 
417 the entire observation period60 (Fig. 2C). After leukocyte depletion around 
418 allo-HSCT, the count increased to around 3600/μl 20 days after allo-HSCT 
419 and further increased to a normal value around 80 days after allo-HSCT. 
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420 However, high fluctuations and later a decrease in the leukocyte count were 
421 observed60 (Fig. 2C). 
422 As the patient had prolonged neutropenia due to refractory leukemia and 
423 intensive chemotherapy, various antibiotics and antifungals were used to treat 
424 infectious complications before and during transplantation. More specifically, 
425 beginning from day -17 she received piperacillin/tazobactam for neutropenic 
426 fever and this was changed to meropenem on day -14 for refractory fever. On 
427 day -11, vancomycin was added and on day -4, meropenem was exchanged 
428 for tigecycline. Additionally, the patient was treated with a fluoroquinolone 
429 (levofloxacin), ceftazidime and liposomal amphotericin B (Fig. 2D). 
430 74 days after allo-HSCT, the patient developed aGvHD overall grade III, skin 
431 stage 2 and GIT stage 3. As the patient did not respond to 2 mg/kg 
432 prednisolone and deteriorated rapidly, ATG (5 mg/kg body weight) was 
433 administered for four days as second line GvHD treatment. A partial remission 
434 of intestinal GvHD was noted with reduction of diarrhea from > 20 stools per 
435 day to 4-5 per day. She was bedridden with general fatigue and malaise. With 
436 continuous signs of infection and lower back pain an MRI scan of the spine 
437 showed a paravertebral abscess, which was removed surgically on day 126. 
438 A multidrug-resistant Escherichia coli was isolated both from the abscess and 
439 from a blood culture, and was analyzed further. After surgery, the patient's 
440 health status improved, she was able to walk again and could be discharged 
441 from hospital at day 209. She was readmitted on day 260 with suspected 
442 sepsis. The patient deceased at day 268 due to GvHD and systemic 
443 inflammatory response syndrome suspected to be bacterial sepsis. However, 
444 no pathogen could be recovered from blood cultures.
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445 In order to explore the treatment-induced effects on the GIT microbiome in 
446 more detail and relate them to the detrimental treatment outcome, we used a 
447 meta-omic approach including MG and MT analyses in addition to rRNA gene 
448 amplicon sequencing. For this patient, samples at later time points were 
449 available, i.e. four months after allo-HSCT, which allowed investigation of the 
450 GIT microbiome over an extended period of time. 
451
452 Patient A07 - changes in the microbial community structure during the 
453 treatment
454 Fecal samples were taken, as indicated in Fig. 2D, at days -13 (sample A07-
455 1), day 75 (sample A07-2) and day 119 (sample A07-3). The prokaryotic 
456 diversity decreased markedly after allo-HSCT (Fig. 2B). Similarly, in sample 
457 A07-1 177 different OTUs were detected, while A07-2 and A07-3 contained 
458 only 62 and 79 OTUs, respectively. 
459 Dominant OTUs of sample A07-1 reappeared in A07-3, more precisely 
460 several OTUs representing Bacteroides spp., Escherichia/Shigella sp. and 
461 Enterococcus sp. (Fig. 2A). However, many of the less abundant OTUs, 
462 belonging to 25 different genera disappeared entirely, including for example 
463 Anaerostipes and Clostridium cluster IV.60 OTUs with decreased abundance 
464 in sample A07-3 (compared to sample A07-1) represented 50 genera, for 
465 example Alistipes, Barnesiella, Blautia, Clostridium cluster XIVa and cluster 
466 XI, Prevotella, Roseburia and Ruminococcus. In addition, OTUs belonging to 
467 the genus Lactobacillus exhibited a 10-fold increase in relative abundance. 
468 Furthermore, different OTUs belonging to the genus Bacteroides increased in 
469 relative abundance resulting in a total relative abundance of Bacteroides spp. 
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470 in A07-3 of 63 % compared to a total relative abundance of 27 % in A07-1 
471 (Fig. 2A). This difference was mainly due to the increase in relative 
472 abundance of two Bacteroides OTUs, with an increase from 2.2 % to 23.5 % 
473 and from 0.9 % to 11.1 %, respectively. In total, 19 different OTUs belonging 
474 to the genus Bacteroides were detected in the first sample, 23 different OTUs 
475 in the last sample, and only 5 different Bacteroides OTUs were identified at 
476 TP2 which accounted for 0.07 % overall. One OTU belonging to the domain 
477 archaea could be identified, Methanobrevibacter smithii, which accounted for 
478 3.4 % total relative abundance in A07-1. Similar to the short-term 
479 developments observed in the whole cohort and described above, the 
480 eukaryotic microbial community did not exhibit pronounced changes over time 
481 (Fig. 2B). Taken together, a drastic decrease in prokaryotic diversity, with 
482 relative expansion of few bacteria, including potential pathogens, was 
483 observed. 
484
485 Metagenomic and metatranscriptomic data generation
486 Coupled MG and MT datasets of samples A07-1 (pre-treatment) and A07-3 
487 (post-treatment) were generated and analyzed in order to inspect the changes 
488 in the GIT microbiome and the effects of allo-HSCT and concurrent antibiotics 
489 use after an extended period of time. As a comparison, samples from four 
490 healthy individuals (referred to as "reference healthy microbiomes" or 
491 "RHMs") were analyzed in the same way.60 
492
493 Population-level structure of the pre- and post-treatment microbial 
494 communities 
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495 To gain a comprehensive overview of the populations present in either 
496 sample, a method for automated binning of the contigs based on the BH-SNE 
497 embedding was employed. This binning method allowed the identification of 
498 134 and 14 individual population-level genomic complements, representing 
499 individual populations, in the pre-treatment and post-treatment samples, 
500 respectively (Fig. 3A and 3B). The visual impressions of the two embeddings 
501 reflect the drastic change in the GIT microbiome, in particular the decrease in 
502 diversity with the representation of the post-treatment sample A07-3 being 
503 exceptionally sparse (Fig. 3B). The most abundant populations were identified 
504 as Escherichia coli, Enterococcus faecium, Lactobacillus reuteri, Lactobacillus 
505 rhamnosus and several species assigned to the genus Bacteroides, which is 
506 in agreement with the 16S rRNA gene sequencing-based results (Fig. 2A). 
507 Representation of both samples within a single plot allows visual 
508 discrimination of clusters that are specific to one sample, or present in both 
509 samples (Fig. 3C). In accordance with the results from 16S rRNA gene 
510 sequencing (Fig. 2A), the majority of the clusters were only found in the pre-
511 treatment sample, while other clusters comprised contigs from both samples 
512 and two clusters in the post-treatment sample were identified as Lactobacillus 
513 reuteri and Lactobacillus rhamnosus, which were either not present, or lowly 
514 abundant in sample A07-1 (Fig. 3C). 
515 Given the potential role of opportunistic pathogens in aGvHD,20 we were 
516 specifically interested in two opportunistic pathogens that were found in both 
517 samples and whose genomes could be recovered with high completeness. 
518 We identified populations of Escherichia coli and Enterococcus faecium, 
519 which were inspected further. The population-level genomes from both
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520 samples were reassembled to allow direct comparison of identified variants as 
521 well as of the complement of antibiotic resistance genes (ARGs) encoded by 
522 them and detected in each sample. 
523
524 Evidence for selective pressure at the strain-level 
525 To uncover evidence of possible selective sweeps in the populations of 
526 interest (the opportunistic pathogens Escherichia coli and Enterococcus 
527 faecium), caused by administration of antibiotics, we performed a gene-wise 
528 protein sequence comparison of the different population-level genomes. This 
529 analysis revealed that 97.4 % of the genes found in the different population-
530 level genomes of E. coli, reconstructed from samples A07-1 and A07-3, were 
531 100 % identical and only 1.1 % of the genes were less than 95 % identical. In 
532 E. faecium, only 76 % of the genes were completely identical and 13.2 % of 
533 the genes showed less than 95 % identity. 
534 The MG depth of coverage and number of variants in each sample are 
535 displayed in Fig. 4A and 4B for E. coli and in 4C and 4D for E. faecium. The 
536 average MG depths of coverage (Fig. 4E and 4F) indicated that the population 
537 size of E. coli was smaller after allo-HSCT (in sample A07-3), while the 
538 population size of E. faecium remained rather constant. In E. coli, a similarly 
539 high number of variants was identified in both the pre- and post-treatment 
540 samples, with an important overlap of variants identified in both populations 
541 (Fig. 4B), whereas only a few variants were present in E. faecium of both 
542 samples (Fig. 4D). A similar pattern of variant distributions (Fig. 4E and 4G) in 
543 both samples was observed for E. coli, while the variant pattern in E. faecium 
544 (Fig. 4F and 4H) changed between both samples. Observed nucleotide 
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545 variant frequencies and patterns of variant distributions indicated that the E. 
546 coli populations were composed of different strains in both samples, which 
547 persisted over the course of the treatment. In contrast, E. faecium was mainly 
548 represented by a single strain in each sample, and the strain of the first 
549 sample was replaced by a different strain in the second sample. 
550
551 Coupled metagenomic and metatranscriptomic analysis of antibiotic 
552 resistance genes in pre- and post-treatment samples from patient A07
553 The relative abundance of detected ARGs (percentage of ARGs relative to the 
554 total number of genes, Fig. 5A) in the post-treatment sample (0.39 %) was 
555 significantly higher than the relative abundance of ARGs in the pre-treatment 
556 sample (0.28 % ARGs, P value 6.9 *10-4, Fisher's exact test) while the relative 
557 abundances of ARGs of both the pre- and post-treatment sample were higher 
558 than the average relative abundance in the RHMs60 (0.20 % ± 0.01 %, P 
559 value 5.601 * 10-7 and 3.278 * 10-10). Moreover, the expression of ARGs was 
560 higher in both samples from patient A07 when compared to the RHMs (Fig. 
561 5B). 
562
563 Identification of antibiotic resistance genes in population-level genomes 
564 of opportunistic pathogens
565 Given the higher number and expression of ARGs in the post-treatment 
566 sample of patient A07, we were interested in whether this could also be 
567 detected in the specific populations E. coli and E. faecium. Within the 
568 population-level genome of E. coli, 31 ARGs were identified in both samples 
569 and 2 additional genes were detected in the post-treatment sample only. In E. 
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570 faecium, 25 ARGs were identified in both samples of which 21 genes were 
571 identical in both samples (summaries of the ARGs identified in each 
572 population-level genome are listed in Table 2 and Table 3).60 In E. coli, 20 of 
573 the 31 ARGs that were found in both samples, exhibited higher levels of 
574 expression in the post-treatment sample while in E. faecium, 18 out of 21 
575 ARGs showed higher expression post-HSCT.60 Although patient A07 was only 
576 treated with antibiotics until day 18 (Fig. 2D), expression of the ARGs was in 
577 general higher in the post-treatment sample, both in the whole sample (Fig. 
578 5B), as well as in the specific populations (Fig. 5C). 
579
580 Genomic characterization of a blood culture Escherichia coli isolate and 
581 comparison to GIT populations 
582 The genomes of a blood culture isolate and GIT population-level genomes of 
583 E. coli from patient A07 exhibited an average nucleotide identity of 100 %. A 
584 heatmap and corresponding dendrogram based on the E. coli pangenomes 
585 indicated that the genomes of the E. coli isolated from patient A07 and 
586 genomes from the GIT MG data were closer related to each other than to any 
587 other reference E. coli (Fig. S1). In the genome of the E. coli isolate, the same 
588 ARGs as in the pre- and post-treatment GIT E. coli could be identified, with 4 
589 additional ARGs compared to the post-treatment GIT E. coli. 
590
591 Discussion
592 Short-term structural changes in the gastrointestinal microbiome 
593 following an allogeneic stem cell transplantation
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594 We observed a strong impact of allo-HSCT and accompanying treatment 
595 including antibiotic use on the GIT microbiome, with a marked decrease in 
596 bacterial diversity. The observed diversity indices are in agreement with 
597 values found in an earlier study.9 The observed trend of a reduced bacterial 
598 diversity at engraftment in patients who did not survive (Fig. 1G), is in 
599 accordance with a study focussing on this link.21 A significant decrease in 
600 important short-chain-fatty-acid (SCFA) producers62–64 (the three bacterial 
601 genera Roseburia, Bifidobacterium and Blautia, Fig. 1C) was observed. 
602 SCFAs, especially the histone deacetylase inhibitor butyrate, are the main 
603 energy source for colonocytes,62 as well as anti-inflammatory agents which 
604 regulate NF-κB activation in colonic epithelial cells.62 Additionally, butyrate 
605 enhances the intestinal barrier function by regulating assembly of epithelial 
606 tight junctions65 and a recent study showed that local administration of 
607 exogenous butyrate mitigated GvHD in mice.66 Depletion of these important 
608 bacteria has been highlighted to pose an additional risk for developing GvHD 
609 or infections after allo-HSCT.26,67 Therefore, in addition to damage in epithelial 
610 cells due to chemotherapy, loss in SCFA-producing bacteria could further 
611 compromise intestinal barrier integrity and facilitate translocation of bacteria 
612 and PAMPs. 
613 We found that fungi were the most prominent eukaryotes and that the 
614 eukaryotic diversity was stable during the treatment and thus not affected by 
615 antibiotic treatment and ensuing changes in bacterial community structure. 
616 However, antibiotic treatment might indirectly increase the risk for invasive 
617 fungal infections, by opening niches to these organisms, which were 
618 previously occupied by commensal bacteria. Although we did not observe any 
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619 clear treatment-induced effects on the eukaryotic communities in the patient 
620 samples analyzed, it is nonetheless important to also account for the 
621 eukaryotes in future studies as overgrowth thereof has previously been linked 
622 to adverse treatment outcomes.14 
623
624 Long-term effect of allogeneic stem cell transplantation on the 
625 gastrointestinal microbiome
626 Employing detailed integrated meta-omic analyses of the samples from one 
627 patient, we demonstrate the effects of allo-HSCT and accompanying 
628 treatment on the GIT microbiome and consequently on the patient over an 
629 extended period of time. Only one study so far has followed the GIT 
630 microbiome trajectory up to three months after allo-HSCT.68 Contrary to this 
631 study, which observed that the richness and metabolic capacity of the 
632 microbial community recovered after two months,68 our study found that the 
633 GIT microbial community in patient A07 did not regain its initial composition 
634 even four months after allo-HSCT, which is likely linked to the detrimental 
635 treatment outcome. Diversity was still decreased and many bacterial taxa 
636 remained absent or at drastically decreased relative levels. Taxa with 
637 decreased relative abundance were mainly bacteria whose presence in the 
638 human GIT is associated with health-promoting properties (such as butyrate 
639 production) and whose absence has been linked to negative consequences 
640 (such as inflammation).69–71 The genus Blautia for instance, has been linked 
641 to reduced aGvHD-associated death and improved overall survival26 and 
642 Barnesiella with resistance to intestinal domination with vancomycin-resistant 
643 enterococci in allo-HSCT patients.72 On the other hand, potential pathogens 
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644 like Fusobacterium sp. and Proteus sp. appeared in the post-treatment 
645 sample, which were not detected in the first sample. Consecutive loss in 
646 intestinal barrier integrity could have allowed a GIT-borne E. coli to cause a 
647 paravertebral abscess.
648 Coinciding with the development of severe aGvHD (expressed by severe 
649 diarrhea) 75 days after allo-HSCT, 16S rRNA gene amplicon sequencing 
650 revealed a GIT microbiome in a notably dysbiotic state with a low diversity 
651 and dominance of two opportunistic pathogens, E. coli and E. faecium. The 
652 dominance of E. faecium has been observed to be quite common in allo-
653 HSCT recipients and has been linked to higher occurrence of bacteremia 
654 and/or GIT GvHD.9,24 A high relative abundance of E. faecium is also 
655 observed in sample A07-2. Broad-spectrum antibiotic therapy, which has 
656 been associated with higher GvHD-related mortality,73 can reduce mucosal 
657 innate immune defences through elimination of commensal microbes, thereby 
658 allowing the expansion of specific bacterial taxa, such as E. faecium, which 
659 carry multiple antibiotic resistance mechanisms.74–76 Our findings suggest that 
660 this specific population expanded in response to antibiotic treatment. 
661 Bacteroides spp. are normal commensals of the human GIT microbiome, they 
662 usually make up around 25 % of the community, as it is the case in sample 
663 A07-1 (Fig. 2A). However, they can also cause infections with associated 
664 mortality.77 Bacteroides spp. might be able to penetrate the colonic mucus 
665 and persevere within crypt channels. These reservoirs might persist even 
666 during antibiotic treatment.78 Different species of the genus Bacteroides 
667 produce bacteriocins,79–81 a trait that might have made it possible for these 
668 bacteria to repopulate the GIT and expand after the dysbiosis in A07-2, 
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669 occupying specific niches, resulting in a relative abundance of 63 % in A07-3 
670 (day 119). 
671 Facultative anaerobes such as members of the orders Lactobacillales and 
672 Enterobacteriales are often observed to increase in relative abundance after 
673 treatment while obligate anaerobes such as members of the order 
674 Clostridiales often decrease in abundance.82 Lactobacillus rhamnosus and 
675 Lactobacillus reuteri (which were detected in sample A07-3) are both often 
676 combined in probiotic formulations and are commonly considered safe and 
677 even beneficial through inhibition of potential pathogen (such as E. coli and E. 
678 faecium) expansion.83–85 Even in patients undergoing allo-HSCT, 
679 Lactobacillus plantarum administration has not been found to result in higher 
680 incidence of bacteremia or aGvHD.86 However, bacteria found in probiotic 
681 formulations, especially Lactobacillus species have occasionally also caused 
682 bloodstream infections.87 Our data suggest that probiotics should be 
683 administered with great caution and should be subject to further investigations 
684 to clearly ensure safety of their usage.
685
686 Identification of antibiotic resistance genes in population-level genomes 
687 of opportunistic pathogens and evidence for selective pressure at the 
688 strain-level
689 A higher ratio of ARGs within the microbial community was observed post-
690 treatment, even a few months after the antibiotic treatment was concluded 
691 (Fig. 5A). Importantly, the observed expression of ARGs was higher in the 
692 post-treatment sample (Fig. 5B) when compared to the pre-treatment sample. 
693 Strains that carry mutations which lead to higher expression of ARGs might 
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694 have been selected for by the antibiotic treatment.88 In E. coli, three different 
695 genes conferring resistance against β-lactams were identified, one of which 
696 was only detected in the post-treatment sample, which might have been 
697 acquired due to selective pressure given the administration of three different 
698 β-lactam antibiotics during the treatment. 
699 Observed nucleotide variant frequencies and patterns of variant distributions 
700 indicated that the treatment may have constituted a genetic bottleneck for E. 
701 faecium, culminating in the observed lower genetic diversity. This also 
702 suggests that two different mechanisms influenced the respective 
703 compositions of E. coli and E. faecium populations. While the E. coli 
704 population remained relatively unaffected, the E. faecium population 
705 underwent a selective sweep in response to the antibiotic treatment with 
706 selection of a specific genotype expressing ARGs. Overall, our observations 
707 indicate that antibiotic pressure and associated selection of bacteria encoding 
708 ARGs are likely essential factors in governing the observed expansion in 
709 opportunistic pathogens.
710 Interestingly, the multidrug-resistant E. coli that was isolated from a blood 
711 culture, was closely related to the GIT-borne E. coli population. The overlap of 
712 ARGs identified in each genome further indicates their association. These 
713 findings are a proof for the potential fatal effects of dysbiosis associated 
714 pathogen dominance in the GIT and subsequent systemic infections on 
715 patient survival.
716 Based on our observation, one strategy to avoid a treatment-induced 
717 intestinal domination by pathogens could consist in the tailored administration 
718 of several, not single probiotic strains, composed in dependence of the 
30
719 individual GIT microbiome changes during therapy. A different approach could 
720 consist in fecal microbiome transplantation, either as "autologous" 
721 (transplanting the pre-transplant microbiome) or "allogeneic" graft (from the 
722 donor of the stem cells). Preservation of a diverse microbiome, able to inhibit 
723 expansion of potential pathogens, might be a new approach to avoid 
724 treatment related side effects tolerance or improve the overall efficacy of the 
725 therapy.
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1016 Figure legends
1017 Figure 1 Changes of gastrointestinal microbial community structure in 
1018 patients receiving allo-HSCT. Boxplots depicting (A, E) diversity (Shannon 
1019 diversity index) and (B, F) richness (Chao1 richness estimator) per collection 
1020 time point (TP), for (A, B) prokaryotes (determined by 16S rRNA gene 
1021 amplicon sequencing) and (E, F) eukaryotes (determined by 18S rRNA gene 
1022 amplicon sequencing), respectively. The number of samples per collection TP 
1023 is indicated above each box. Diversity and richness were determined after 
1024 rarefaction of the dataset. Statistically significant decrease in prokaryotic 
1025 diversity between TP1 and TP3 (P value 0.014 in Kruskal-Wallis rank sum 
1026 test) and in prokaryotic richness between TP1 and TP3 (P value 0.026, 
1027 Wilcoxon rank sum test) was observed. (C) Changes in relative abundance of 
1028 three bacterial genera between TP1 and TP3. Genera with at least 1.5-fold 
1029 decrease, adjusted P value < 0.05 and a relative abundance of at least 5 % in 
1030 one sample are included (adjusted P value 0.0025, 0.026 and 3.68 * 10-5, 
1031 Wald test). (D) Changes in relative abundance of two bacterial orders 
1032 between TP1 and TP3 (adjusted P value 0.0054 and 0.009, Wald test). (G) 
1033 Prokaryotic diversity at TP1 and TP3 in relation to outcome 1.5 years after 
1034 allo-HSCT. Samples from five patients who survived (S) and three patients 
1035 who deceased (M) are represented. (C, D and G) Data from all eight patients 
1036 who had samples collected at TP1 and TP3 are displayed. Collection TP1 
1037 includes samples that were taken (up to eight days) before allo-HSCT. TP2 
1038 includes samples that were taken up to four days after the transplantation. 
1039 TP3 includes samples that were taken between day 20 and day 33 after the 
1040 transplantation. Significant differences between TPs are indicated by asterisks 
43
1041 (* P value < 0.05, ** P value < 0.01).
1042
1043 Figure 2 Variation of the microbial community structure over the course 
1044 of the allo-HSCT treatment in patient A07. (A) Relative proportions of the 
1045 10 most abundant operational taxonomic units (OTUs) based on 16S rRNA 
1046 gene sequencing. The remaining OTUs are summarized as "others". Similar 
1047 shades of the colors represent genera belonging to the same phylum. (B) 
1048 Prokaryotic (triangle) and eukaryotic (circle) diversity represented by Shannon 
1049 diversity index at sampling TPs throughout the treatment. (C) C-reactive 
1050 protein (CRP) blood levels (green line) and leukocyte blood count (blue line). 
1051 (D) Drugs (antibiotics, antifungals and antithymocyte globulin) administered 
1052 throughout the treatment. Along the x-axis, days relative to the day of 
1053 transplantation are indicated. Abbreviations: Vancom=vancomycin; 
1054 Tigecycl=tigecycline; Fluoroq=fluoroquinolone; Antif=antifungal; 
1055 ATG=antithymocyte-globulin.
1056
1057 Figure 3 BH-SNE-based visualization of genomic fragment signatures of 
1058 microbial communities present in samples of patient A07.
1059 Points represent contigs ≥ 1000 nt. Clusters are formed by contigs with similar 
1060 genomic signatures. (A) Visualization of pre-treatment sample contigs. (B) 
1061 Visualization of post-treatment sample contigs. (A and B) Points within 
1062 clusters are colored according to the reconstructed genomes' completeness, 
1063 based on the number of unique essential genes. Lines within the colored bar 
1064 indicate the number of clusters at each percentage of completeness. (C) 
1065 Combined visualization of contigs derived from pre-treatment sample (A07-1, 
44
1066 blue squares) and post-treatment (A07-3, red crosses) samples. The inset 
1067 displays a magnification of a section of the plot representing two populations 
1068 (Lactobacillus reuteri and Lactobacillus rhamnosus), which are only present in 
1069 the post-treatment sample. In each representation, clusters representing 
1070 Escherichia coli and Enterococcus faecium are indicated.
1071
1072 Figure 4 Number and distribution of variants in Escherichia coli and 
1073 Enterococcus faecium. (A and C) Violin plots representing distribution of 
1074 depth of coverage of the contigs contained in each population-level genome. 
1075 (B and D) Venn diagrams indicating the number of variant positions exclusive 
1076 to each sample respectively the number of variant positions found in both 
1077 samples. (E and F) Representation of exemplary sections of the reassembled 
1078 population-level genomes with aligned reads of both samples highlighting 
1079 occurrences of variants in each population, visualized with the Integrative 
1080 Genomics Viewer. Length of the represented section is indicated as well as 
1081 the average MG depth of coverage of each reconstructed population-level 
1082 genome. (G and H) Histogram of the variant frequencies of the minor 
1083 nucleotide at all variant positions. Panels on the left represent results for E. 
1084 coli, panels on the right represent results for E. faecium. Blue figure elements 
1085 refer to the pre-treatment sample (A07-1), red figure elements refer to the 
1086 post-treatment sample (A07-3).
1087
1088 Figure 5 Expression levels and relative abundances of antibiotic 
1089 resistance genes (ARGs). (A) Percentage of identified ARGs (in relation to 
1090 total number of genes) in the pre-treatment (A07-1) and post-treatment (A07-
45
1091 3) sample and in the GIT microbiome of four healthy untreated individuals 
1092 (RHMs; ** P value < 0.01, Fisher's exact test). (B) Histogram of the ratios of 
1093 metatranscriptomic (MT) to metagenomic (MG) depths of coverage of ARGs 
1094 in the pre-treatment and post-treatment sample and in the RHMs. (C) 
1095 Histograms of the ratios of MT to MG depths of coverage of ARGs in 
1096 population-level genomes of Escherichia coli and of Enterococcus faecium in 
1097 the pre- and post-treatment samples. Bars representing the number of ARGs 
1098 at a specific expression rate in the pre-treatment sample are blue, bars 
1099 representing the genes in the post-treatment sample are red and bars 
1100 representing the genes in the RHMs are green. For the RHMs, the average of 
1101 four datasets is represented with standard deviation as error bar. 
1102
1103 Appendix
1104 Figure S1. Gene set profiles of the 118 reference strains and 3 E. coli 
1105 isolated from patient A07 (highlighted in red and marked with a light blue box). 
1106 Each row represents a gene (blue: present, yellow: absent), each column 
1107 represents a strain. 
1108
Table 1: Anthropometric and clinical information of the study cohort
Patient Sex Age Underlying 
diseasea
Donor relationship 
and HLAb
Conditioning 
regimenc
Antimicrobialsd GvHDe, f Outcome 1.5 years after allo-
HSCT
A01 m 43 lymphoma MRD FluBuCy F, M, P-T, V Skin I° alive 
A03 m 56 lymphoma MRD FluBuCy AF, F, M, P-T, other - deceased day 66, relapse
A04 f 43 AML MUD BuCy AF, F, M, V Skin I° alive 
A05 m 49 lymphoma MMUD FluBuCy AF, F, M, P-T, V Skin II° deceased day 275, pneumonia
A06 m 52 AML MRD BuCy AF, F, M, P-T, V, other - alive 
A07 f 63 AML MMUD FLAMSA-Bu AF, F, M, P-T, V, other Skin II°, GIT III° deceased day 268, GvHD
A08 f 50 AML MUD BuCy AF, F, M, P-T, V Skin I° alive 
A09 m 30 lymphoma MUD FluBuCy F, M, P-T - deceased day 212, pneumonia
A10 m 54 AML MRD BuCy F, M, P-T Skin I°, GIT II° alive 
A12 m 57 lymphoma MUD FluBuCy F, M, P-T, V, other Skin III° alive 
A13 m 57 AML MRD BuCy AF, F, M, V Skin I°, lung II° alive 
A17 m 66 AML MUD BuCy F, M, V Skin II° alive 
A18 f 67 AML MUD FluBu F, M, P-T, V, other Skin III°, GIT III° deceased day 184, GvHD
A19 f 58 myeloma MUD Treo/Flu F, M, P-T - deceased day 39, relapse
A20 m 51 AML MMUD FLAMSA-Bu AF, F, M, P-T, V, other Skin II°, GIT II° alive 
A21 f 64 AML MUD Treo/Flu AF, M, P-T, V, other Skin II° alive 
a: AML: acute myeloid leukemia
b: MRD: matched related, MUD: matched unrelated, MMUD: mismatched unrelated
c: Bu: busulfan, Cy: cyclophosphamide, Flu: fludarabine, FLAMSA: fludarabine, amsacrine, Treo: treosulfan
d: AF: antifungal, F: fluoroquinolone, M: meropenem; P-T: piperacillin-tazobactam, V: vancomycin
e: Organ involvement, stages according to Glucksberg et al.18
f: Bold: aGvHD with summed stages ≥ 4 considered as severe aGvHD
Table 2: Antibiotic resistance genes identified in population-level genomes of 
GIT E. coli from patient A07
Resfams_ID
Number 
of Genes Resfam Family Name Mechanism
RF0005 1 AAC6-Ib
Aminoglycoside 
Modifying Enzyme
RF0007 3 ABCAntibioticEffluxPump ABC Transporter
RF0027 1 ANT3
Aminoglycoside 
Modifying Enzyme
RF0035 1 baeR
Gene Modulating 
Resistance
RF0053 1 ClassA Beta-Lactamase
RF0055 1 ClassC-AmpC Beta-Lactamase
RF0056 1 ClassD Beta-Lactamase
RF0065 1 emrB MFS Transporter
RF0088 1 macA ABC Transporter
RF0089 1 macB ABC Transporter
RF0091 1 marA
Gene Modulating 
Resistance
RF0098 1 MexE RND Antibiotic Efflux
RF0101 1 MexX RND Antibiotic Efflux
RF0112 1 phoQ
Gene Modulating 
Resistance
RF0115 6 RNDAntibioticEffluxPump RND Antibiotic Efflux
RF0121 1 soxR
Gene Modulating 
Resistance
RF0147 1 tolC ABC Transporter
RF0168 6 TE_Inactivator Antibiotic Inactivation
RF0172 1 APH3'' Phosphotransferase
RF0173 1 APH3' Phosphotransferase
RF0174 1 ArmA_Rmt rRNA 
Methyltransferase
Table 3: Antibiotic resistance genes identified in population-level genomes of 
GIT E. faecium from patient A07
Resfams_ID
Number 
of Genes Resfam Family Name Mechanism
RF0004 1 AAC6-I
Aminoglycoside 
Modifying Enzyme
RF0007 9 ABCAntibioticEffluxPump ABC Transporter
RF0033 1 APH3
Aminoglycoside 
Modifying Enzyme
RF0066 1 emrE Other Efflux
RF0067 1
Erm23SRibosomalRNAM
ethyltransferase
rRNA 
Methyltransferase
RF0104 1 MFSAntibioticEffluxPump MFS Transporter
RF0134 1
Tetracycline_Resistance_
MFS_Efflux_Pump
Tetracycline MFS 
Efflux
RF0154 1 vanR
Gylcopeptide 
Resistance
RF0155 2 vanS
Gylcopeptide 
Resistance
RF0168 1 TE_Inactivator Antibiotic Inactivation
RF0172 2 APH3''
Aminoglycoside 
Modifying Enzyme
RF0173 2 APH3'
Aminoglycoside 
Modifying Enzyme
RF0174 6 ArmA_Rmt
Aminoglycoside 
Resistance
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Abstract
Existing workflows for the analysis of multi-omic microbiome datasets are lab-specific and often result in sub-optimal
data usage. Here we present IMP, a reproducible and modular pipeline for the integrated and reference-independent
analysis of coupled metagenomic and metatranscriptomic data. IMP incorporates robust read preprocessing, iterative
co-assembly, analyses of microbial community structure and function, automated binning, as well as genomic
signature-based visualizations. The IMP-based data integration strategy enhances data usage, output volume,
and output quality as demonstrated using relevant use-cases. Finally, IMP is encapsulated within a user-friendly
implementation using Python and Docker. IMP is available at http://r3lab.uni.lu/web/imp/ (MIT license).
Keywords: Multi-omics data integration, Metagenomics, Metatranscriptomics, Microbial ecology, Microbiome,
Reproducibility
Background
Microbial communities are ubiquitous in nature and
govern important processes related to human health and
biotechnology [1, 2]. A significant fraction of naturally
occurring microorganisms elude detection and investiga-
tion using classic microbiological methods due to their
unculturability under standard laboratory conditions [3].
The issue of unculturability is largely circumvented
through the direct application of high-resolution and
high-throughput molecular measurements to samples
collected in situ [4–6]. In particular, the application of
high-throughput next-generation sequencing (NGS) of
DNA extracted from microbial consortia yields metage-
nomic (MG) data which allow the study of microbial
communities from the perspective of community struc-
ture and functional potential [4–6]. Beyond metage-
nomics, there is also a clear need to obtain functional
readouts in the form of other omics data. The sequen-
cing of reverse transcribed RNA (cDNA) yields
metatranscriptomic (MT) data, which provides informa-
tion about gene expression and therefore allows a more
faithful assessment of community function [4–6]. Al-
though both MG and MT data allow unprecedented in-
sights into microbial consortia, the integration of such
multi-omic data is necessary to more conclusively link
genetic potential to actual phenotype in situ [4, 6]. Given
the characteristics of microbial communities and the
resulting omic data types, specialized workflows are re-
quired. For example, the common practice of subsamp-
ling collected samples prior to dedicated biomolecular
extractions of DNA, RNA, etc. has been shown to inflate
variation, thereby hampering the subsequent integration
of the individual omic datasets [7, 8]. For this purpose,
specialized wet-lab methods which allow the extraction
of concomitant DNA, RNA, proteins, and metabolites
from single, unique samples were developed to ensure
that the generated data could be directly compared
across the individual omic levels [7, 8]. Although stan-
dardized and reproducible wet-lab methods have been
developed for integrated omics of microbial communi-
ties, corresponding bioinformatic analysis workflows
have yet to be formalized.
* Correspondence: paul.wilmes@uni.lu
†Equal contributors
1Luxembourg Centre for Systems Biomedicine, 7, avenue des
Hauts-Fourneaux, Esch-sur-Alzette L-4362, Luxembourg
Full list of author information is available at the end of the article
© The Author(s). 2016 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Narayanasamy et al. Genome Biology  (2016) 17:260 
DOI 10.1186/s13059-016-1116-8
Bioinformatic analysis methods for MG and MT NGS
data can be broadly classified into reference-dependent or
reference-independent (de novo) methods [5]. Reference-
dependent methods are based on the alignment/mapping
of sequencing reads onto isolate genomes, gene catalogs,
or existing MG data. A major drawback of such methods
is the large number of sequencing reads from uncultured
species and/or divergent strains which are discarded dur-
ing data analysis, thereby resulting in the loss of poten-
tially useful information. For example, based on analyses
of MG data from the human gut microbiome (arguably
the best characterized microbial community in terms of
culture-derived isolate genomes), approximately 43% of
the data are typically not mappable to the available isolate
genomes [9]. Conversely, reference-independent meth-
odologies, such as approaches based on de novo assem-
blies, enable the retrieval of the actual genomes and/or
potentially novel genes present in samples, thereby
allowing more of the data to be mapped and exploited
for analysis [4, 5, 10]. Furthermore, it has been demon-
strated that the assembly of sequencing reads into lon-
ger contiguous sequences (contigs) greatly improves the
taxonomic assignments and prediction of genes as
opposed to their direct identification from short se-
quencing reads [11, 12]. Finally, de novo MG assem-
blies may be further leveraged by binning the data to
resolve and retrieve population-level genomes, includ-
ing those from hitherto undescribed taxa [13–21].
Given the advantages of reference-independent
methods, a wide array of MG-specific assemblers such as
IDBA-UD [22] and MEGAHIT [23] have been developed.
Most MT data analyses involve reference-based [24–26]
or MG-dependent analysis workflows [27–29]. A com-
parative study by Celaj et al. [12] demonstrated that
reference-independent approaches for MT data analyses
are also applicable using either specialized MT assemblers
(e.g., IDBA-MT [12, 30]), MG assemblers (e.g., IDBA-UD
[22, 30, 31] and MetaVelvet [12, 32]) or single-species
transcriptome assemblers (e.g., Trinity [12, 33]). In all
cases, the available assemblers are able to handle the un-
even sequencing depths of MG and MT data. Although
dedicated assembly methods have been developed for MG
and MT data, formalized pipelines allowing the integrated
use of both data types are not available yet.
Automated bioinformatic pipelines have so far been
mainly developed for MG data. These include
MOCAT [34] and MetAMOS [10], which incorporate
the entire process of MG data analysis, ranging from
preprocessing of sequencing reads, de novo assembly,
and post-assembly analysis (read alignment, taxo-
nomic classification, gene annotation, etc.). MOCAT
has been used in large-scale studies such as those
within the MetaHIT Consortium [35, 36], while MetA-
MOS is a flexible pipeline which allows customizable
workflows [10]. Both pipelines use SOAPdenovo [37]
as the default de novo assembler, performing single-
length kmer-based assemblies which usually result in
fragmented (low contiguity) assemblies with low gene
coverage values [38].
Multi-omic analyses have already provided new insights
into microbial community structure and function in various
ecosystems. These include studies of the human gut micro-
biome [28, 39], aquatic microbial communities from the
Amazon river [27], soil microbial communities [40, 41],
production-scale biogas plants [29], hydrothermal vents
[42], and microbial communities from biological wastewa-
ter treatment plants [43, 44]. These studies employed differ-
ing ways for analyzing the data, including reference-based
approaches [27, 28, 42], MG assembly-based approaches
[29, 40], MT assembly-based approaches [42], and inte-
grated analyses of the meta-omic data [39, 42–44].
Although these studies clearly demonstrate the power
of multi-omic analyses by providing deep insights into
community structure and function, standardized and
reproducible computational workflows for integrating
and analyzing the multi-omic data have so far been un-
available. Importantly, such approaches are, however,
required to compare results between different studies
and systems of study.
Due to the absence of established tools/workflows to
handle multi-omic datasets, most of the aforementioned
studies utilized non-standardized, ad hoc analyses,
mostly consisting of custom workflows, thereby creating
a challenge in reproducing the analyses [10, 45–47].
Given that the lack of reproducible bioinformatic work-
flows is not limited to those used for the multi-omic
analysis of microbial consortia [10, 45–47], several ap-
proaches have recently been developed with the explicit
aim of enhancing software reproducibility. These include
a wide range of tools for constructing bioinformatic
workflows [48–50] as well as containerizing bioinfor-
matic tools/pipelines using Docker [29, 46–48].
Here, we present IMP, the Integrated Meta-omic
Pipeline, the first open source de novo assembly-based
pipeline which performs standardized, automated, flex-
ible, and reproducible large-scale integrated analysis of
combined multi-omic (MG and MT) datasets. IMP in-
corporates robust read preprocessing, iterative co-
assembly of metagenomic and metatranscriptomic data,
analyses of microbial community structure and function,
automated binning, as well as genomic signature-based vi-
sualizations. We demonstrate the functionalities of IMP
by presenting the results obtained on an exemplary data
set. IMP was evaluated using datasets from ten different
microbial communities derived from three distinct
environments as well as a simulated mock microbial com-
munity dataset. We compare the assembly and data inte-
gration measures of IMP against standard MG analysis
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strategies (reference-based and reference-independent) to
demonstrate that IMP vastly improves overall data usage.
Additionally, we benchmark our assembly procedure
against available MG analysis pipelines to show that IMP
consistently produces high-quality assemblies across all
the processed datasets. Finally, we describe a number of
particular use cases which highlight biological applications
of the IMP workflow.
Results
Overview of the IMP implementation and workflow
IMP leverages Docker for reproducibility and deploy-
ment. The interfacing with Docker is facilitated through
a user-friendly Python wrapper script (see the “Details of
the IMP implementation and workflow” section). As
such, Python and Docker are the only prerequisites for
the pipeline, enabling an easy installation and execution
process. Workflow implementation and automation is
achieved using Snakemake [49, 51]. The IMP workflow
can be broadly divided into five major parts: i) prepro-
cessing, ii) assembly, iii) automated binning, iv) analysis,
and v) reporting (Fig. 1).
The preprocessing and filtering of sequencing reads is
essential for the removal of low quality bases/reads, and
potentially unwanted sequences, prior to assembly and
analysis. The input to IMP consists of MG and MT (the
latter preferably depleted of ribosomal RNA prior to se-
quencing) paired-end reads in FASTQ format (section
“Input data”). MG and MT reads are preprocessed inde-
pendently of each other. This involves an initial quality
control step (Fig. 1 and section “Trimming and quality
filtering”) [52] followed by an optional screening for
host/contaminant sequences, whereby the default
screening is performed against the human genome while
other host genome/contaminant sequences may also be
used (Fig. 1 and section “Screening host or contaminant
sequences”). In silico rRNA sequence depletion is exclu-
sively applied to MT data (Fig. 1 and section “Ribosomal
RNA filtering”).
The customized assembly procedure of IMP starts with
an initial assembly of preprocessed MT reads to generate
an initial set of MT contigs (Additional file 1: Figure S1).
MT reads unmappable to the initial set of MT contigs
undergo a second round of assembly. The process of as-
sembling unused reads, i.e., MG or MT reads unmappable
to the previously assembled contigs, is henceforth referred
to as “iterative assembly”. The assembly of MT reads is
performed, first as transcribed regions are covered much
more deeply and evenly in MT data. The resulting MT-
based contigs represent high-quality scaffolds for the
subsequent co-assembly with MG data, overall leading to
enhanced assemblies [43]. Therefore, the combined set of
MT contigs from the initial and iterative MT assemblies
are used to enhance the subsequent assembly with the
MG data. MT data are assembled using the MEGAHIT de
novo assembler using the appropriate option to prevent
the merging of bubbles within the de Bruijn assembly
graph [23, 36]. Subsequently, all preprocessed MT and
MG reads, together with the generated MT contigs, are
used as input to perform a first co-assembly, producing a
first set of co-assembled contigs. The MG and MT reads
unmappable to this first set of co-assembled contigs then
undergo an additional iterative co-assembly step. IMP
implements two assembler options for the de novo co-
assembly step, namely IDBA-UD or MEGAHIT. The con-
tigs resulting from the co-assembly procedure undergo a
subsequent assembly refinement step by a contig-level as-
sembly using the cap3 [53] de novo assembler. This aligns
highly similar contigs against each other, thus reducing
overall redundancy by collapsing shorter contigs into
longer contigs and/or improving contiguity by extending
contigs via overlapping contig ends (Additional file 1:
Figure S1). This step produces the final set of contigs. Pre-
processed MG and MT reads are then mapped back
against the final contig set and the resulting alignment in-
formation is used in the various downstream analysis pro-
cedures (Fig. 1). In summary, IMP employs four measures
for the de novo assembly of preprocessed MG and MT
reads, including: i) iterative assemblies of unmappable
reads, ii) use of MT contigs to scaffold the downstream
assembly of MG data, iii) co-assembly of MG and MT
data, and iv) assembly refinement by contig-level as-
sembly. The entire de novo assembly procedure of IMP
is henceforth referred to as the “IMP-based iterative
co-assembly” (Additional file 1: Figure S1).
Contigs from the IMP-based iterative co-assembly
undergo quality assessment as well as taxonomic annota-
tion [54] followed by gene prediction and functional anno-
tation [55] (Fig. 1 and section “Annotation and assembly
quality assessment”). MaxBin 2.0 [20], an automated bin-
ning procedure (Fig. 1 and section “Automated binning”)
which performs automated binning on assemblies pro-
duced from single datasets, was chosen as the de facto
binning procedure in IMP. Experimental designs involving
single coupled MG and MT datasets are currently the
norm. However, IMP’s flexibility does not forego the im-
plementation of multi-sample binning algorithms such as
CONCOCT [16], MetaBAT [18], and canopy clustering
[15] as experimental designs evolve in the future.
Non-linear dimensionality reduction of the contigs’
genomic signatures (Fig. 1 and section “Non-linear di-
mensionality reduction of genomic signatures”) is per-
formed using the Barnes-Hut Stochastic Neighborhood
Embedding (BH-SNE) algorithm allowing visualization
of the data as two-dimensional scatter plots (henceforth
referred to as VizBin maps [13, 56]). Further analysis
steps include, but are not limited to, calculations of the
contig- and gene-level depths of coverage (section
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“Depth of coverage”) as well as the calling of genomic
variants (variant calling is performed using two distinct
variant callers; section “Variant calling”). The informa-
tion from these analyses are condensed and integrated
into the generated VizBin maps to produce augmented
visualizations (sections “Visualization and reporting”).
These visualizations and various summaries of the out-
put are compiled into a HTML report (examples of the
HTML reports available via Zenodo [57]).
Exemplary output of IMP (using the default IDBA-UD
assembler) based on a human fecal microbiome dataset
is summarized in Fig. 2. The IMP output includes taxo-
nomic (Fig. 2a) and functional (Fig. 2b, c) overviews.
The representation of gene abundances at the MG and
MT levels enables comparison of potential (Fig. 2b) and
actual expression (Fig 2c) for specific functional gene
categories (see Krona charts within HTML S1 [57]). IMP
provides augmented VizBin maps [13, 56], including, for
Fig. 1 Schematic overview of the IMP pipeline. Cylinders represent input and output while rectangles represent processes. Arrows indicate the flow
between input, processes, and output. MG— Metagenomic data, MT— Metatranscriptomic data, rRNA— ribosomal RNA, NLDR-GS— genomic
signature non-linear dimensionality reduction. Processes, input, and output specific to MG and MT data are labeled in blue and red, respectively.
Processes and output that involve usage of both MG and MT data are represented in purple. A detailed illustration of the “iterative
co-assembly” is available in Additional file 1: Figure S1
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Fig. 2 (See legend on next page.)
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example, variant densities (Fig. 2d) as well as MT to MG
depth of coverage ratios (Fig. 2e). These visualizations
may aid users in highlighting subsets of contigs based on
certain characteristics of interest, i.e., population hetero-
geneity/homogeneity, low/high transcriptional activity,
etc. Although an automated binning method [20] is in-
corporated within IMP (Fig. 2f ), the output is also com-
patible with and may be exported to other manual/
interactive binning tools such as VizBin [56] and Anvi’o
[17] for additional manual curation. Please refer to the
HTML reports for additional examples [57].
The modular design (section “Automation and modu-
larity”) and open source nature of IMP allow for
customization of the pipeline to suit specific user-
defined analysis requirements (section “Customization
and further development”). As an additional feature,
IMP also allows single-omic MG or MT analyses (sec-
tion “Details of the IMP implementation and work-
flow”). Detailed parameters for the processes implemented
in IMP are described in the section “Details of the IMP
implementation and workflow” and examples of detailed
workflow schematics are provided within the HTML
reports [57].
Assessment and benchmarking
IMP was applied to ten published coupled MG and MT
datasets, derived from three types of microbial systems,
including five human fecal microbiome samples (HF1,
HF2, HF3, HF4, HF5) [28], four wastewater sludge micro-
bial communities (WW1, WW2, WW3, WW4) [43, 44],
and one microbial community from a production-scale
biogas (BG) plant [29]. In addition, a simulated mock
(SM) community dataset based on 73 bacterial genomes
[12], comprising both MG and MT data was generated to
serve as a means for ground truth-based assessment of
IMP (details in section “Coupled metagenomic and meta-
transcriptomic datasets”). The SM dataset was devised
given the absence of a standardized benchmarking dataset
for coupled MG and MT data (this does solely exist for
MG data as part of the CAMI initiative (http://www.cami-
challenge.org)).
Analysis with IMP was carried out with the two avail-
able de novo assembler options for the co-assembly step
(Fig. 1; Additional file 1: Figure S1), namely the default
IDBA-UD assembler [22] (hereafter referred to as IMP)
and the optional MEGAHIT assembler [23] (henceforth
referred to as IMP-megahit). IMP was quantitatively
assessed based on resource requirement and analytical
capabilities. The analytical capabilities of IMP were eval-
uated based on data usage, output volume, and output
quality. Accordingly, we assessed the advantages of the
iterative assembly procedure as well as the overall data
integration strategy.
Resource requirement and runtimes
IMP is an extensive pipeline that utilizes both MG and
MT data within a reference-independent (assembly-
based) analysis framework which renders it resource-
and time-intensive. Therefore, we aimed to assess the
required computational resource and runtimes of IMP.
All IMP-based runs on all datasets were performed on
eight compute cores with 32 GB RAM per core and
1024 GB of total memory (section “Computational plat-
forms”). IMP runtimes ranged from approximately 23 h
(HF1) to 234 h (BG) and the IMP-megahit runtimes
ranged from approximately 21 h (HF1) up to 281 h (BG).
IMP was also executed on the Amazon cloud computing
(AWS) infrastructure, using the HF1 dataset on a machine
with 16 cores (section “Computational platforms”)
whereby the run lasted approximately 13 h (refer to
Additional file 1: Note S1 for more details). The analysis
of IMP resulted in an increase in additional data of around
1.2–3.6 times the original input (Additional file 2: Table
S1). Therefore, users should account for the disc space for
both the final output and intermediate (temporary) files
generated during an IMP run. Detailed runtimes and data
generated for all the processed data sets are reported in
Additional file 2: Table S1.
We further evaluated the effect of increasing resources
using a small scale test dataset (section “Test dataset for
runtime assessment”). The tests demonstrated that re-
duced runtimes are possible by allocating more threads
to IMP-megahit (Additional file 2: Table S2). However,
no apparent speed-up is achieved beyond allocation of
eight threads, suggesting that this would be the optimal
number of threads for this particular test dataset. Con-
trastingly, no speed-up was observed with additional
memory allocation (Additional file 2: Table S3). Apart
from the resources, runtime may also be affected by the
input size, the underlying complexity of the dataset and/
or behavior of individual tools within IMP.
(See figure on previous page.)
Fig. 2 Example output from the IMP analysis of a human microbiome dataset (HF1). a Taxonomic overview based on the alignment of contigs
to the most closely related genomes present in the NCBI genome database (see also HTML report S1 [57]). a, b Abundances of predicted genes
(based on average depths of coverage) of various KEGG Ontology categories represented both at the MG (b) and MT (c) levels (see also Krona
charts within HTML report S1). d–f Augmented VizBin maps of contigs ≥1 kb, representing contig-level MG variant densities (d), contig-level ratios
of MT to MG average depth of coverage (e), and bins generated by the automated binning procedure (f). Please refer to the HTML reports [57]
for additional examples
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Data usage: iterative assembly
De novo assemblies of MG data alone usually result in a
large fraction of reads that are unmappable to the assem-
bled contigs and therefore remain unused, thereby leading
to suboptimal data usage [43, 58–60]. Previous studies
have assembled sets of unmappable reads iteratively to
successfully obtain additional contigs, leading to an overall
increase in the number of predicted genes, which in turn
results in improved data usage [43, 58–60]. Therefore,
IMP uses an iterative assembly strategy to maximize NGS
read usage. In order to evaluate the best iterative assembly
approach for application within the IMP-based iterative
co-assembly strategy, we attempted to determine the
opportune number of assembly iterations in relation to
assembly quality metrics and computational resources/
runtimes.
The evaluation of the iterative assembly strategy was
applied to MG and MT datasets. For both omic data
types, it involved an “initial assembly” which is defined
as the de novo assembly of all preprocessed reads.
Additional iterations of assembly were then conducted
using the reads that remained unmappable to the gener-
ated set of contigs (see section “Iterative single-omic as-
semblies” for details and parameters). The evaluation of
the iterative assembly procedure was carried out based
on the gain of additional contigs, cumulative contig
length (bp), numbers of genes, and numbers of reads
mappable to contigs. Table 1 shows the evaluation results
of four representative data sets and Additional file 2:
Table S4 shows the detailed results of the application of
the approach to 11 datasets. In all the datasets evaluated,
all iterations (1 to 3) after the initial assembly lead to an
increase in total length of the assembly and numbers of
mappable reads (Table 1; Additional file 2: Table S4).
However, there was a notable decline in the number of
additional contigs and predicted genes beyond the first it-
eration. Specifically, the first iteration of the MG assembly
yielded up to 1.6% additional predicted genes while the
equivalent on the MT data yielded up to 9% additional
predicted genes (Additional file 2: Table S4). Considering
the small increase (<1%) in the number of additional con-
tigs and predicted genes beyond the first assembly iter-
ation on one hand and the extended runtimes required to
perform additional assembly iterations on the other
hand, a generalized single iteration assembly approach
was retained and implemented within the IMP-based it-
erative co-assembly (Fig. 1; Additional file 1: Figure S1).
This approach aims to maximize data usage without dras-
tically extending runtimes.
Despite being developed specifically for the analysis of
coupled MG and MT datasets, the iterative assembly
can also be used for single omic datasets. To assess
IMP’s performance on MG datasets, it was applied to
the simulated MG datasets from the CAMI challenge
(http://www.cami-challenge.org) and the results are
shown in Additional file 1: Figure S2. IMP-based MG as-
sembly using the MEGAHIT assembler on the CAMI
dataset outperforms well-established MG pipelines such
Table 1 Statistics of iterative assemblies performed on MG and MT datasets
MG iterative assembly MT iterative assembly
Dataset Iteration Number of
contigs
(≥1 kb)
Cumulative length
of assembled
contigs (bp)
Number of
predicted
genes
Number of
mapped reads
Number of
contigs (all)
Cumulative length
of assembled
contigs (bp)
Number of
predicted
genes
Number of
mapped
reads
SM Initial assembly 29063 182673343 186939 18977716 13436 8994518 13946 822718
1 16 483336 329 9515 1286 502535 1272 16038
2 6 213094 126 3425 48 18460 49 656
3 1 86711 47 1536 0 0 0 0
HF1 Initial assembly 27028 145938650 154760 20715368 40989 45300233 66249 17525586
1 15 966872 274 39839 2471 969614 2238 329400
2 −1 26822 5 1276 26 10315 24 45642
3 0 4855 0 172 3 1640 6 54788
WW1 Initial assembly 14815 77059275 81060 6513708 45118 22525759 49859 8423603
1 28 3146390 1136 73511 2115 723904 1589 529441
2 2 175634 114 4031 250 82048 201 13335
3 1 30032 16 572 31 10280 18 65866
BG Initial assembly 105282 545494441 593688 109949931 47628 27493690 60566 3754432
1 417 10998269 3902 456821 3956 1397409 3061 130131
2 5 335313 219 21647 717 250223 754 12766
3 7 79022 20 2511 24 9060 22 5827
Results for all datasets available in Additional file 2: Table S2
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as MOCAT in all measures. In addition, IMP-based it-
erative assemblies also exhibit comparable performance
to the gold standard assembly with regards to contigs
≥1 kb and number of predicted genes (http://www.cami-
challenge.org). Detailed results of the CAMI assemblies
are available in Additional file 2: Table S5. However, as
no MT and/or coupled MG and MT datasets so far exist
for the CAMI challenge, the full capabilities of IMP
could not be assessed in relation to this initiative.
Data usage: multi-omic iterative co-assembly
In order to assess the advantages of integrated multi-omic
co-assemblies of MG and MT data, IMP-based iterative co-
assemblies (IMP and IMP-megahit) were compared against
MG-only-based assemblies which include single-omic itera-
tive MG assemblies generated using IMP (referred to as
IMP_MG) and standard MG assemblies by MOCAT (here-
after referred to as MOCAT_MG) and MetAMOS (here-
after referred to as MetAMOS_MG). Furthermore, the
available reads from the human fecal microbiome dataset
(preprocessed with IMP) were mapped to the MetaHIT
Integrated Gene Catalog (IGC) reference database [35] to
compare the data usage of the different assembly proce-
dures against a reference-dependent approach.
IMP-based iterative co-assemblies consistently re-
cruited larger fractions of properly paired MG (Fig. 3a)
and/or MT (Fig. 3b) reads compared to single-omic
a
c
b
d
Fig. 3 Assessment of data usage and output generated from co-assemblies compared to single-omic assemblies. Heat maps show (a) fractions of
properly mapped MG read pairs, (b) fractions of properly mapped MT read pairs, (c) numbers of contigs ≥1 kb, and (d) numbers of unique predicted
genes. IMP and IMP-megahit represent integrated multi-omic MG and MT iterative co-assemblies while IMP_MG, MOCAT_MG, and MetAMOS_MG
represent single-omic MG assemblies. All numbers were row Z-score normalized for visualization. Detailed results available in Additional file 2: Table S5
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assemblies. The resulting assemblies also produced
larger numbers of contigs ≥1 kb (Fig. 3c), predicted non-
redundant unique genes (Fig. 3d), and, even more im-
portant, complete genes as predicted with start and stop
codon by Prodigal [61] (Additional file 2: Table S5).
Using the reference genomes from the SM data as
ground truth, IMP-based iterative co-assemblies resulted
in up to 25.7% additional recovery of the reference ge-
nomes compared to the single-omic MG assemblies
(Additional file 2: Table S5).
IMP-based iterative co-assemblies of the human fecal
microbiome datasets (HF1–5) allowed recruitment of
comparable fractions of properly paired MG reads and an
overall larger fraction of properly paired MT reads com-
pared to those mapping to the IGC reference database
(Table 2). The total fraction (union) of MG or MT reads
mapping to either IMP-based iterative co-assemblies and/
or the IGC reference database was higher than 90%, thus
demonstrating that the IMP-based iterative co-assemblies
allow at least 10% of additional data to be mapped when
using these assemblies in addition to the IGC reference
database. In summary, the complementary use of de novo
co-assembly of MG and MT datasets in combination with
iterative assemblies enhances overall MG and MT data
usage and thereby significantly increases the yield of
useable information, especially when combined with com-
prehensive reference catalogs such as the IGC reference
database.
Assembly quality: multi-omic iterative co-assembly
In order to compare the quality of the IMP-based itera-
tive co-assembly procedure to simple co-assemblies, we
compared the IMP-based iterative co-assemblies against
co-assemblies generated using MetAMOS [10] (hence-
forth referred to as MetAMOS_MGMT) and MOCAT
[34] (henceforth referred to as MOCAT_MGMT).
Although MetAMOS and MOCAT were developed for
MG data analysis, we extended their use for obtaining
MG and MT co-assemblies by including both MG and
MT read libraries as input (section “Execution of pipe-
lines”). The assemblies were assessed based on con-
tiguity (N50 length), data usage (MG and MT reads
mapped), and output volume (number of contigs above
1 kb and number of genes; Additional file 2: Table S5).
Only the SM dataset allowed for ground truth-based
assessment by means of aligning the generated de novo
assembly contigs to the original 73 bacterial genomes
used to simulate the data set (section “Simulated
coupled metagenomic and metatranscriptomic dataset”)
[12, 54]. This allowed the comparison of two additional
quality metrics, i.e., the recovered genome fraction and
the composite performance metric (CPM) proposed by
Deng et al. [62].
Assessments based on real datasets demonstrate
comparable performance between IMP and IMP-
megahit while both outperform MetAMOS_MGMT
and MOCAT_MGMT in all measures (Fig. 4a–c). The
ground truth assessment using the SM dataset shows
that IMP-based iterative co-assemblies are effective in
recovering the largest fraction of the original reference ge-
nomes while achieving a higher CPM score compared to
co-assemblies from the other pipelines. Misassembled
(chimeric) contigs are a legitimate concern within exten-
sive de novo assembly procedures such as the IMP-based
iterative co-assembly. It has been previously demonstrated
that highly contiguous assemblies (represented by high
N50 lengths) tend to contain higher absolute numbers of
misassembled contigs compared to highly fragmented as-
semblies, thereby misrepresenting the actual quality of
assemblies [38, 62, 63]. Therefore, the CPM score was de-
vised as it represents a normalized measure reflecting both
contiguity and accuracy for a given assembly [62]. Based
on the CPM score, both IMP and IMP-megahit yield as-
semblies that balance high contiguity with accuracy and
thereby outperform the other methods (Fig. 4c, d). In
summary, cumulative measures of numbers of contigs
≥1 kb, N50 lengths, numbers of unique genes, recovered
genome fractions (%), and CPM scores (the latter two
were only calculated for the SM dataset), as well as the
mean fractions (%) of mappable MG and MT reads, show
that the IMP-based iterative co-assemblies (IMP and
IMP-megahit) clearly outperform all other available
methods (Fig. 4e; Additional file 2: Table S5).
Use-cases of integrated metagenomic and
metatranscriptomic analyses in IMP
The integration of MG and MT data provides unique
opportunities for uncovering community- or population-
specific traits, which cannot be resolved from MG or
MT data alone. Here we provide two examples of
Table 2 Mapping statistics for human microbiome samples
Reference Average MG pairs
mapping (%)
Average MT pairs
mapping (%)
IGC 70.91 53.57
IMP 70.25 86.21
IMP-megahit 70.62 83.33
IMP_MG 68.08 58.54
MetAMOS_MG 57.31 37.34
MOCAT_MG 36.73 36.68
IMP + IGC 92.66 95.77
IMP-megahit + IGC 92.80 93.24
Average fractions (%) of properly paired reads from the human microbiome
datasets (HF1–5) mapping to various references, including IMP-based iterative
co-assemblies (IMP and IMP-megahit) and single-omic co-assemblies (IMP_MG,
MetAMOS_MG, and MOCAT_MG) as well as the IGC reference database. IMP +
IGC and IMP-megahit + IGC reports the total number of properly paired reads
mapping to IMP-based iterative co-assemblies and/or the IGC reference
database. Refer to Additional file 2: Table S3 for detailed information
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insights gained through the direct inspection of results
provided by IMP.
Tailored preprocessing and filtering of MG and MT data
The preprocessing of the datasets HF1–5 included filter-
ing of human-derived sequences, while the same step
was not necessary for the non-human-derived datasets,
WW1–4 and BG. MT data analyzed within this article
included RNA extracts which were not subjected to wet-
lab rRNA depletion, i.e., BG [29], and samples which
were treated with wet-lab rRNA removal kits (namely
HF1–5 [28] and WW1–4 [43]). Overall, the removal of
rRNA pairs from the MT data showed a large variation,
ranging from as low as 0.51% (HF5) to 60.91% (BG),
demonstrating that wet-lab methods vary in terms of
effectiveness and highlighting the need for such MT-
specific filtering procedures (Additional file 1: Note S2;
Additional file 2: Table S6).
Identification of RNA viruses
To identify differences in the information content of
MG and MT complements, the contigs generated using
IMP were inspected with respect to coverage by MG
and MT reads (Additional file 2: Table S7). In two exem-
plary datasets HF1 and WW1, a small fraction of the
contigs resulted exclusively from MT data (Additional
file 2: Table S7). Longer contigs (≥1 kb) composed exclu-
sively of MT reads and annotated with known viral/bac-
teriophage genes were retained for further inspection
(Table 3; complete list contigs in Additional file 2: Table S8
a d
eb
c
Fig. 4 Assessment of the IMP-based iterative co-assemblies in comparison to MOCAT- and MetAMOS-based co-assemblies. Radar charts summarizing
the characteristics of the co-assemblies generated using IMP, MetAMOS, and MOCAT pipelines on: a human fecal microbiome, b wastewater sludge
community, c biogas reactor, d simulated mock community. IMP co-assemblies were performed with two de novo assembler options, IDBA_UD and
MEGAHIT, whereas MetAMOS and MOCAT were executed using default settings. Assessment metrics within the radar charts include number of contigs
≥1 kb, N50 length (contiguity, cutoff 500 bp), number of predicted genes (unique), and fraction of properly mapped MG and MT read pairs. N50
statistics are reported using a 500-bp cutoff. Additional ground truth assessments for simulated mock dataset included recovered genome
fractions (%) and the composite performance metric (CPM) score with a cutoff of 500 bp [62]. e Summary radar chart reflecting the cumulative
measures and mean fraction of properly mapped MG and MT read pairs from all analyzed 11 datasets while incorporating ground truth-based
measures from the simulated mock dataset. Higher values within the radar charts (furthest from center) represent better performance. Detailed
information on the assembly assessments is available in Additional file 2: Table S5
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and S9). A subsequent sequence similarity search against
the NCBI NR nucleotide database [64] of these candidate
contigs revealed that the longer contigs represent almost
complete genomes of RNA viruses (Additional file 2: Table
S10 and S11). This demonstrates that the incorporation of
MT data and their contrasting to the MG data allow the
identification and recovery of nearly complete RNA viral
genomes, thereby allowing their detailed future study in a
range of microbial ecosystems.
Identification of populations with apparent high
transcriptional activity
To further demonstrate the unique analytical capabilities
of IMP, we aimed to identify microbial populations with
a high transcriptional activity in the HF1 human fecal
microbiome sample. Average depth of coverage at the
contig- and gene-level is a common measure used to
evaluate the abundance of microbial populations within
communities [14, 16, 43]. The IMP-based integrative
analysis of MG and MT data further extends this meas-
ure by calculation of average MT to MG depth of cover-
age ratios, which provide information on transcriptional
activity and which can be visualized using augmented
VizBin maps [56].
In our example, one particular cluster of contigs within
the augmented VizBin maps exhibited high MT to MG
depth of coverage ratios (Additional file 1: Figure S3). The
subset of contigs within this cluster aligned to the genome
of the Escherichia coli P12B strain (henceforth referred to
as E. coli). For comparison, we also identified a subset,
which was highly abundant at the MG level (lower MT
to MG ratio), which aligned to the genome of Collin-
sella intestinalis DSM 13280 strain (henceforth referred
to as C. intestinalis). Based on these observations, we
highlighted the subsets of these contigs in an aug-
mented VizBin map (Fig. 5a). The C. intestinalis and E.
coli subsets are mainly represented by clear peripheral
clusters which exhibit consistent intra-cluster MT to
MG depth of coverage ratios (Fig. 5a). The subsets were
manually inspected in terms of their distribution of
average MG and MT depths of coverage and were com-
pared against the corresponding distributions for all
contigs. The MG-based average depths of coverage of
the contigs from the entire community exhibited a bell-
shape like distribution, with a clear peak (Fig. 5b). In
contrast, MT depths of coverage exhibited more spread,
with a relatively low mean (compared to MG distribution)
and no clear peak (Fig. 5b). The C. intestinalis subset dis-
plays similar distributions to that of the entire community,
whereas the E. coli subset clearly exhibits unusually high
MT-based and low MG-based depths of coverage (Fig. 5b).
Further inspection of the individual omic datasets revealed
that the E. coli subset was not covered by the MG contigs,
while approximately 80% of the E. coli genome was
recoverable from a single-omic MT assembly (Fig. 5c). In
contrast, the C. intestinalis subset demonstrated genomic
recovery in all co-assemblies (IMP, IMP-megahit,
MOCAT_MGMT, MetAMOS_MGMT) and the single-
omic MG assemblies (IMP_MG, MOCAT_MG, MetA-
MOS_MG; Fig. 5c).
As noted by the authors of the original study by
Franzosa et al. [28], the cDNA conversion protocol used
to produce the MT data is known to introduce approxi-
mately 1–2% of E. coli genomic DNA into the cDNA as
contamination which is then reflected in the MT data.
According to our analyses, 0.12% of MG reads and
Table 3 Contigs with a likely viral/bacteriophage origin/function reconstructed from the metatranscriptomic data
Sample Contig ID* Contig length Average contig depth
of coverage
Gene product Average gene depth
of coverage
HF1 Contig_34 6468 20927 Virus coat protein (TMV like) 30668
Viral movement protein (MP) 26043
RNA-dependent RNA polymerase 22578
Viral methyltransferase 18817
Contig_13948 2074 46 RNA-dependent RNA polymerase 41
Viral movement protein (MP) 56
WW2 Contig_6405 4062 46 Tombusvirus p33 43
Viral RNA-dependent RNA polymerase 42
Viral coat protein (S domain) 36
Contig_7409 3217 21 Viral RNA-dependent RNA polymerase 18
Viral coat protein (S domain) 21
Contig_7872 2955 77 Hypothetical protein 112
Phage maturation protein 103
*Contigs of ≥1 kb and average depth of coverage ≥20 were selected
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1.95% of MT reads derived from this sample could be
mapped onto the E. coli contigs, which is consistent with
the numbers quoted by Franzosa et al. [28].
Consistent recovery of the E. coli genome was also ob-
served across all other assemblies of the human fecal
microbiome datasets (HF2–5) which included their
respective MT data (Additional file 1: Figure S4;
Additional file 2: Table S12). The integrative analyses of
MG and MT data within IMP enables users to efficiently
highlight notable cases such as this and to further inves-
tigate inconsistencies and/or interesting characteristics
within these multi-omic datasets.
Discussion
The microbiome analysis workflow of IMP is unique in
that it allows the integrated analysis of MG and MT
data. To the best of our knowledge, IMP represents the
only pipeline that spans the preprocessing of NGS reads
a
b
c
Fig. 5 Metagenomic and metatranscriptomic data integration of a human fecal microbiome. a Augmented VizBin map highlighting contig
subsets with sequences that are most similar to Escherichia coli P12b and Collinsella intestinalis DSM 13280 genomes. b Beanplots representing
the densities of metagenomic (MG) and metatranscriptomic (MT) average contig-level depth of coverage for the entire microbial community and
two subsets (population-level genomes) of interest. The dotted lines represent the mean. c Recovered portion of genomes of the aforementioned
taxa based on different single-omic assemblies and multi-omic co-assemblies (Additional file 2: Table S5)
Narayanasamy et al. Genome Biology  (2016) 17:260 Page 12 of 21
to the binning of the assembled contigs, in addition to
being the first automated pipeline for reproducible
reference-independent metagenomic and metatranscrip-
tomic data analysis. Although existing pipelines such as
MetAMOS or MOCAT may be applied to perform co-
assemblies of MG and MT data [44], these tools do not
include specific steps for the two data types in their pre-
and post-assembly procedures, which is important given
the disparate nature of these datasets. The use of Docker
promotes reproducibility and sharing, thereby allowing re-
searchers to precisely replicate the IMP workflow with
relative ease and with minimal impact on overall perform-
ance of the employed bioinformatic tools [29, 46–48]. Fur-
thermore, static websites will be created and associated
with every new version of IMP (Docker image), such that
users will be able to download and launch specific ver-
sions of the pipeline to reproduce the work of others.
Thereby, IMP enables standardized comparative studies
between datasets from different labs, studies, and environ-
ments. The open source nature of IMP encourages a
community-driven effort to contribute to and further im-
prove the pipeline. Snakemake allows the seamless inte-
gration of Python code and shell (bash) commands and
the use of make scripting style, which are arguably some
of the most widely used bioinformatic scripting languages.
Snakemake also supports parallel processing and the abil-
ity to interoperate with various tools and/or web services
[49, 51]. Thus, users will be able to customize and en-
hance the features of the IMP according to their analysis
requirements with minimal training/learning.
Quality control of NGS data prior to de novo assem-
blies has been shown to increase the quality of down-
stream assembly and analyses (predicted genes) [63]. In
addition to standard preprocessing procedures (i.e., re-
moval of low quality reads, trimming of adapter se-
quences and removal), IMP incorporates additional
tailored and customizable filtering procedures which ac-
count for the different sample and/or omic data types.
For instance, the removal of host-derived sequences in
the context of human microbiomes is required for pro-
tecting the privacy of study subjects. The MT-specific in
silico rRNA removal procedure yielded varying fractions
of rRNA reads between the different MT datasets des-
pite the previous depletion of rRNA (section “Tailored
preprocessing and filtering of MG and MT data”), indi-
cating that improvements in wet-lab protocols are ne-
cessary. Given that rRNA sequences are known to be
highly similar, they are removed in IMP in order to miti-
gate any possible misassemblies resulting from such
reads and/or regions [65, 66]. In summary, IMP is de-
signed to perform stringent and standardized prepro-
cessing of MG and MT data in a data-specific way,
thereby enabling efficient data usage and resulting in
high-quality output.
It is common practice that MG and MT reads are
mapped against a reference (e.g., genes, genomes, and/or
MG assemblies) [28, 29, 40] prior to subsequent data in-
terpretation. However, these standard practices lead to
suboptimal usage of the original data. IMP enhances
overall data usage through its specifically tailored itera-
tive co-assembly procedure, which involves four mea-
sures to achieve better data usage and yield overall
larger volumes of output (i.e., a larger number of contigs
≥1 kb and predicted unique and complete genes).
First, the iterative assembly procedure leads to in-
creases in data usage and output volume in each add-
itional iterative assembly step (section “Data usage:
iterative assembly”). The exclusion of mappable reads
in each iteration of the assembly serves as a means of
partitioning the data, thereby reducing the complexity
of the data and overall, resulting in a higher cumula-
tive volume of output [60, 63, 67].
Second, the initial assembly of MT-based contigs en-
hances the overall assembly, as transcribed regions are
covered much more deeply and evenly in MT data,
resulting in better assemblies for these regions [43]. The
MT-based contigs represent high-quality scaffolds for
the subsequent co-assembly with MG data.
Third, the co-assembly of MG and MT data allows the
integration of these two data types while resulting in a
larger number of contigs and predicted complete genes
against which, in turn, a substantially higher fraction of
reads can be mapped (section “Data usage: multi-omic
iterative co-assembly”). Furthermore, the analyses of the
human fecal microbiome datasets (HF1–5) demonstrate
that the numbers of MG reads mapping to the IMP-
based iterative co-assemblies for each sample are
comparable to the numbers of reads mapping to the
comprehensive IGC reference database (Table 2). Previ-
ously, only fractions of 74–81% of metagenomic reads
mapping to the IGC have been reported [35]. However,
such numbers have yet to be reported for MT data, in
which case we observe lower mapping rates to the IGC
reference database (35.5–70.5%) compared to IMP-based
assemblies (Additional file 2: Table S3). This may be at-
tributed to the fact that the IGC reference database was
generated from MG-based assemblies only, thus creating
a bias [35]. Moreover, an excess of 90% of MG and MT
reads from the human fecal datasets (HF1–5) are
mappable to either the IGC reference database and/or
IMP-based iterative co-assemblies, emphasizing that a
combined reference-based and IMP-based integrated-
omics approach vastly improves data usage (Table 2).
Although large fractions of MG and/or MT reads can be
mapped to the IGC, a significant advantage of using a de
novo reference-independent approach lies within the fact
that reads can be linked to genes within their respective
genomic context and microbial populations of origin.
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Exploiting the maximal amount of information is espe-
cially relevant for microbial communities with small
sample sizes and which lack comprehensive references
such as the IGC reference database.
Fourth, the assembly refinement step via a contig-level
assembly with cap3 improves the quality of the assemblies
by reducing redundancy and increasing contiguity by col-
lapsing and merging contigs (section “Assembly quality:
multi-omic iterative co-assembly”). Consequently, our re-
sults support the described notion that the sequential use
of multi-kmer-based de Bruijn graph assemblers, such as
IDBA-UD and MEGAHIT, with overlap-layout-consensus
assemblers, such as cap3, result in improved MG assem-
blies [38, 62] but importantly also extend this to MG and
MTco-assemblies.
When compared to commonly used assembly strat-
egies, the IMP-based iterative co-assemblies consisted of
a larger output volume while maintaining a relatively
high quality of the generated contigs. High-quality as-
semblies yield higher quality taxonomic information and
gene annotations while longer contigs (≥1 kb) are a pre-
requisite for unsupervised population-level genome re-
construction [14, 19, 56] and subsequent multi-omics
data integration [39, 43, 44]. Throughout all the different
comparative analyses which we performed, IMP per-
formed more consistently across all the different datasets
when compared to existing methods, thereby emphasiz-
ing the overall stability and broad range of applicability
of the method (section “Assembly quality: multi-omic it-
erative co-assembly”).
Integrated analyses of MG and MT data with IMP pro-
vide the opportunity for analyses that are not possible
based on MG data alone, such as the detection of RNA vi-
ruses (section “Identification of RNA viruses”) and the
identification of transcriptionally active populations (sec-
tion “Identification of populations with apparent high
transcriptional activity”). The predicted/annotated genes
may be used for further analyses and integration of add-
itional omic datasets, most notably metaproteomic data
[39, 43, 44]. Furthermore, the higher number of complete
genes improves the downstream functional analysis, be-
cause the read counts per gene will be much more accur-
ate when having full length transcript sequences and will
increase the probability to identify peptides. More specific-
ally, the large number of predicted genes may enhance the
usage of generated metaproteomic data, allowing more
peptides, and thus proteins, to be identified.
Conclusions
IMP represents the first self-contained and standardized
pipeline developed to leverage the advantages associated
with integrating MG and MT data for large-scale ana-
lyses of microbial community structure and function in
situ [4, 6]. IMP performs all the necessary large-scale
bioinformatic analyses, including preprocessing, assembly,
binning (automated), and analyses within an automated,
reproducible, and user-friendly pipeline. In addition, we
demonstrate that IMP vastly enhances data usage to pro-
duce high-volume and high-quality output. Finally, the
combination of open development and reproducibility
should promote the general paradigm of reproducible re-
search within the microbiome research community.
Methods
The details of the IMP workflow, implementation, and
customizability are described in further detail. We also
describe the additional analyses carried out for assess-
ment and benchmarking of IMP.
Details of the IMP implementation and workflow
A Python (v3) wrapper script was implemented for user-
friendly execution of IMP via the command line. The
full list of dependencies, parameters (see below), and
documentation is available on the IMP website (http://
r3lab.uni.lu/web/imp/doc.html). Although IMP was de-
signed specifically for integrated analysis of MG and MT
data, it can also be used for single MG or MT analyses
as an additional functionality.
Reproducibility
IMP is implemented around a Docker container that
runs the Ubuntu 14.04 operating system, with all rele-
vant dependencies. Five mounting points are defined for
the Docker container with the -v option: i) input direc-
tory, ii) output directory, iii) database directory, iv) code
directory, and v) configuration file directory. Environ-
ment variables are defined using the -e parameter, in-
cluding: i) paired MG data, ii) paired MT data, and iii)
configuration file. The latest IMP Docker image will be
downloaded and installed automatically upon launching
the command, but users may also launch specific ver-
sions based on tags or use modified/customized versions
of their local code base (documentation at http://r3lab.
uni.lu/web/imp/doc.html).
Automation and modularity
Automation of the workflow is achieved using Snake-
make 3.4.2 [49, 51], a Python-based make language
implemented specifically for building reproducible bio-
informatic workflows and pipelines. Snakemake is inher-
ently modular and thus allows various features to be
implemented within IMP, including the options of i) exe-
cuting specific/selected steps within the pipeline, ii)
check-pointing, i.e., resuming analysis from a point of
possible interruption/termination, iii) analysis of single-
omic datasets (MG or MT). For more details regarding
the functionalities of IMP, please refer to the documen-
tation of IMP (http://r3lab.uni.lu/web/imp/doc.html).
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Input data
The input to IMP includes MG and/or MT FASTQ paired
files, i.e., pairs-1 and pairs-2 are in individual files. The
required arguments for the IMP wrapper script are metage-
nomic paired-end reads (“-m” options) and/or metatran-
scriptomic paired-end reads (“-t” option) with the specified
output folder (“-o” option). Users may customize the com-
mand with the options and flags described in the documen-
tation (http://r3lab.uni.lu/web/imp/doc.html) and in the
“Customization and further development” section.
Trimming and quality filtering
Trimmomatic 0.32 [52] is used to perform trimming and
quality filtering of MG and MT Illumina paired-end
reads, using the following parameters: ILLUMINACLIP:
TruSeq3-PE.fa:2:30:10; LEADING:20; TRAILING:20;
SLIDINGWINDOW:1:3; MAXINFO:40:0.5; MINLEN:40.
The parameters may be tuned via the command line or
within the IMP config file. The output from this step in-
cludes retained paired-end and single-end reads (mate
discarded), which are all used for downstream processes.
These parameters are configurable in the IMP config file
(section “Customization and further development”)
Ribosomal RNA filtering
SortMeRNA 2.0 [68] is used for filtering rRNA from the
MT data. The process is applied on FASTQ files for both
paired- and single-end reads generated from the trimming
and quality filtering step. Paired-end FASTQ files are in-
terleaved prior to running SortMeRNA. If one of the
mates within the paired-end read is classified as an rRNA
sequence, then the entire pair is filtered out. After running
SortMeRNA, the interleaved paired-end output is split
into two separate paired-end FASTQ files. The filtered se-
quences (without rRNA reads) are used for the down-
stream processes. All available databases provided within
SortMeRNA are used for filtering and the maximum
memory usage parameter is set to 4 GB (option: “-m
4000”), which can be adjusted in the IMP config file (sec-
tion “Customization and further development”).
Read mapping
The read mapping procedure is performed using the
bwa mem aligner [69] with settings: “ -v 1” (verbose output
level), “-M” (Picard compatibility) introducing an auto-
mated samtools header using the “-R” option [69]. Paired-
and single-end reads are mapped separately and the
resulting alignments are merged (using samtools merge
[70]). The output is written as a binary aligment map
(BAM) file. Read mapping is performed at various steps in
the workflow, including: i) screening for host or contamin-
ant sequences (section “Screening host or contaminant
sequences”), ii) recruitment of unmapped reads within the
IMP-based iterative co-assembly (section “Extracting
unmapped reads”), and iii) mapping of preprocessed
MG and MT reads to the final contigs. The memory
usage is configurable in the IMP config file (section
“Customization and further development”).
Extracting unmapped reads
The extraction of unmapped reads (paired- and single-
end) begins by mapping reads to a given reference
sequence (section “Read mapping”). The resulting BAM
file is used as input for the extraction of unmapped
reads. A set of paired-end reads are considered unmap-
pable if both or either one of the mates do not map to
the given reference. The unmapped reads are converted
from BAM to FASTQ format using samtools [70] and
BEDtools 2.17.0—bamToFastq utility [71]. Similarly, un-
mapped single-end reads are also extracted from the
alignment information.
Screening host or contaminant sequences
By default, the host/contaminant sequence screening is
performed by mapping both paired- and single-end reads
(section “Read mapping”) onto the human genome ver-
sion 38 (http://www.ncbi.nlm.nih.gov/projects/genome/
assembly/grc/), followed by extraction of unmapped reads
(section “Extracting unmapped reads”). Within the IMP
command line, users are provided with the option of i) ex-
cluding this procedure with the “--no-filtering” flag, ii)
using other sequence(s) for screening by providing the
FASTA file (or URL) using “--screen” option, or iii) speci-
fying it in the configuration file (section “Customization
and further development”).
Parameters of the IMP-based iterative co-assembly
The IMP-based iterative co-assembly implements MEGA-
HIT 1.0.3 [23] as the MT assembler while IDBA-UD 1.1.1
[22] is used as the default co-assembler (MG and MT),
with MEGAHIT [23] as an alternative option for the co-
assembler (specified by the “-a” option of the IMP com-
mand line). All de novo assemblies are performed on
kmers ranging from 25-mers to 99-mers, with an incre-
mental step of four. Accordingly, the command line
parameters for IDBA-UD are “--mink 25 --maxk 99 --step
4 - -similar 0.98 - -pre-correction” [22]. Similarly, the
command line parameters for MEGAHIT are “--k-min 25
- -k-max 99 - -k-step 4”, except for the MT assemblies
which are performed with an additional “--no-bubble” op-
tion to prevent merging of bubbles within the assembly
graph [23]. Furthermore, contigs generated from the MT
assembly are used as “long read” input within the “-l” flag
of IDBA-UD or “-r” flag of MEGAHIT [22, 23]. Kmer
ranges for the IDBA-UD and MEGAHIT can be adjusted/
specified in the configuration file (section “Customization
and further development”). Cap3 is used to reduce the re-
dundancy and improve contiguity of the assemblies using
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a minimum alignment identity of 98% (“-p 0.98”) with a
minimum overlap of 100 bases (“-o 100”), which are ad-
justable in the configuration file (section “Customization
and further development”). Finally, the extraction of reads
that are unmappable to the initial MT assembly and initial
co-assembly is described in the “Extracting unmapped
reads” section.
Annotation and assembly quality assessment
Prokka 1.11 [55] with the “- -metagenome” setting is used
to perform functional annotation. The default BLAST and
HMM databases of Prokka are used for the functional an-
notation. Custom databases may be provided by the user
(refer to the “Databases” and “Customization and further
development” sections for details).
MetaQUAST 3.1 [54] is used to perform taxonomic an-
notation of contigs with the maximum number of down-
loadable reference genomes set to 20 (“--max-ref-number
20”). In addition, MetaQUAST provides various assembly
statistics. The maximum number of downloadable refer-
ence genomes can be changed in the IMP config file (see
“Customization and further development” for details).
Depth of coverage
Contig- and gene-wise depth of coverage values are calcu-
lated (per base) using BEDtools 2.17.0 [71] and aggregated
(by average) using awk, adapted from the CONCOCT
code [16] (script: map-bowtie2-markduplicates.sh; https://
github.com/BinPro/CONCOCT) and is non-configurable.
Variant calling
The variant calling procedure is performed using Sam-
tools 0.1.19 [70] (mpileup tool) and Platypus 0.8.1 [72],
each using their respective default settings and which
are non-configurable. The input is the merged paired-
and single-end read alignment (BAM) against the final
assembly FASTA file (section “Read mapping”). The out-
put files from both the methods are indexed using tabix
and compressed using gzip. No filtering is applied to the
variant calls, so that users may access all the information
and filter it according to their requirements. The output
from samtools mpileup is used for the augmented
VizBin visualization.
Non-linear dimensionality reduction of genomic signatures
VizBin [56] performs non-linear dimensionality reduction
of genomic signatures onto contigs ≥1 kb, using default
settings, to obtain two-dimensional embeddings. Parame-
ters can be modified in the IMP config file (section
“Customization and further development”).
Automated binning
Automated binning of the assembled contigs is per-
formed using MaxBin 2.0. Default setting are applied
and paired-end reads are provided as input for abun-
dance estimation [20]. The sequence length cutoff is set
to be same as VizBin (section “Non-linear dimensionality
reduction of genomic signatures”) and is customizable
using the config file (section “Customization and further
development”).
Visualization and reporting
IMP compiles the multiple summaries and visualizations
into a HTML report [57]. FASTQC [73] is used to
visualize the quality and quantity of reads before and after
preprocessing. MetaQUAST [54] is used to report assem-
bly quality and taxonomic associations of contigs. A
custom script is used to generate KEGG-based [74] func-
tional Krona plots by running KronaTools [75] (script:
genes.to.kronaTable.py, GitHub URL: https://github.com/
EnvGen/metagenomics-workshop). Additionally, VizBin
output (two-dimensional embeddings) is integrated with
the information derived from the IMP analyses, using a
custom R script for analysis and visualization of the
augmented maps. The R workspace image is saved such
that users are able to access it for further analyses. All
the steps executed within an IMP run, including pa-
rameters and runtimes, are summarized in the form of
a workflow diagram and a log-file. The visualization
script is not configurable.
Output
The output generated by IMP includes a multitude of
large files. Paired- and single-end FASTQ files of prepro-
cessed MG and MT reads are provided such that the
user may employ them for additional downstream ana-
lyses. The output of the IMP-based iterative co-assembly
consists of a FASTA file, while the alignments/mapping
of MG and MT preprocessed reads to the final co-
assembly are also provided as BAM files, such that users
may use these for further processing. Predicted genes
and their respective annotations are provided in the vari-
ous formats produced by Prokka [55]. Assembly quality
statistics and taxonomic annotations of contigs are pro-
vided as per the output of MetaQUAST [54]. Two-
dimensional embeddings from the NLDR-GS are pro-
vided such that they can be exported to and further cu-
rated using VizBin [56]. Additionally, abundance and
expression information is represented by contig- and
gene-level average depth of coverage values. MG and
MT genomic variant information (VCF format), includ-
ing both SNPs and INDELs (insertions and deletions), is
also provided. The results of the automated binning
using MaxBin 2.0 [20] are provided in a folder which
contains the default output from the program (i.e., fasta
files of bins and summary files).
The HTML reports [57], e.g., HTML S1 and S2, com-
pile various summaries and visualizations, including, i)
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augmented VizBin maps, ii) MG- and MT-level func-
tional Krona charts [75], iii) detailed schematics of the
steps carried out within the IMP run, iv) list of parame-
ters and commands, and v) additional reports (FASTQC
report [73], MetaQUAST report [54]). Please refer to the
documentation of IMP for a detailed list and description
of the output (http://r3lab.uni.lu/web/imp/doc.html).
Databases
The IMP database folder (db) contains required data-
bases required for IMP analysis. The folder contains the
following subfolders and files with their specific content:
i. adapters folder — sequencing adapter sequences.
Default version contains all sequences provided
by Trimmomatic version 0.32 [52]
ii. cm, genus, hmm, and kingdom folders — contains
databases provided by Prokka 1.11 [55]. Additional
databases may be added into the corresponding
folders as per the instructions in the Prokka
documentation (https://github.com/tseemann/
prokka#databases)
iii. sortmerna folder — contains all the databases
provided in SortMeRNA 2.0 [68]. Additional
databases may be added into the corresponding
folders as per the instructions in the SortMeRNA
documentation (http://bioinfo.lifl.fr/RNA/sortmerna/
code/SortMeRNA-user-manual-v2.0.pdf)
iv. ec2pathways.txt — enzyme commission (EC) number
mapping of amino acid sequences to pathways
v. pathways2hierarchy.txt — pathway hierarchies used
to generated for KEGG-based functional Krona
plot (section “Visualization and reporting”)
Customization and further development
Additional advanced parameters can be specified via the
IMP command line, including specifying a custom config-
uration file (“-c” option) and/or specifying a custom data-
base folders (“-d” option). Threads (“- -threads”) and
memory allocation (“--memcore” and “- -memtotal”) can be
adjusted via the command line and the configuration file.
The IMP launcher script provides a flag (“- -enter”) to
launch the Docker container interactively and the option to
specify the path to the customized source code folder (“-s”
option). These commands are provided for development
and testing purposes (described on the IMP website and
documentation: http://r3lab.uni.lu/web/imp/doc.html). Fur-
ther customization is possible using a custom configuration
file (JSON format). The customizable options within the
JSON file are specified in individual subsections within the
“Details of the IMP implementation and workflow” section.
Finally, the open source implementation of IMP allows
users to customize the Docker image and source code of
IMP according to their requirements.
Iterative single-omic assemblies
In order to determine the opportune number of itera-
tions within the IMP-based iterative co-assembly strat-
egy an initial assembly was performed using IMP
preprocessed MG reads with IDBA-UD [22]. Cap3 [53]
was used to further collapse the contigs and reduce the
redundancy of the assembly. This initial assembly was
followed by a total of three assembly iterations, whereby
each iteration was made up of four separate steps: i) ex-
traction of reads unmappable to the previous assembly
(using the procedure described in the “Extracting un-
mapped reads” section), ii) assembly of unmapped reads
using IDBA-UD [22], iii) merging/collapsing the contigs
from the previous assembly using cap3 [53], and iv) evalu-
ation of the merged assembly using MetaQUAST [54].
The assembly was evaluated in terms of the per-iteration
increase in mappable reads, assembly length, numbers of
contigs ≥1 kb, and numbers of unique genes.
Similar iterative assemblies were also performed for
MT data using MEGAHIT [23], except CD-HIT-EST
[76] was used to collapse the contigs at ≥95% identity
(“-c 0.95”) while MetaGeneMark [77] was used to pre-
dict genes. The parameters and settings of the other pro-
grams were the same as those defined in the “Details of
the IMP implementation and workflow” section.
The aforementioned procedures were applied to all the
datasets analyzed within this article. The merged contig
sets (non-redundant) from the first iteration of both the
MG and MT iterative assemblies were selected to repre-
sent the IMP single-omics assemblies (IMP_MG and
IMP_MT) and were compared against co-assemblies.
Execution of pipelines
MetAMOS v1.5rc3 was executed using default settings.
MG data were provided as input for single-omic assem-
blies (MetAMOS_MG) while MG and MT data were
provided as input for multi-omic co-assemblies (MetA-
MOS_MGMT). All computations using MetAMOS were
set to use eight computing cores (“-p 8”).
MOCAT v1.3 (MOCAT.pl) was executed using de-
fault settings. Paired-end MG data were provided as in-
put for single-omic assemblies (MOCAT_MG) while
paired-end MG and MT data were provided as input
for multi-omic co-assemblies (MOCAT_MGMT). All
computations using MOCAT were set to use eight
computing cores (“-cpus 8”). Paired-end reads were first
preprocessed using the read_trim_filter step of MOCAT
(“-rtf”). For the human fecal microbiome datasets (HF1–5),
the preprocessed paired- and single-end reads were add-
itionally screened for human genome-derived sequences
(“-s hg19”). The resulting reads were afterwards assembled
with default parameters (“-gp assembly -r hg19”) using
SOAPdenovo.
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IMP v1.4 was executed for each dataset using different
assemblers for the co-assembly step: i) default setting
using IDBA-UD, and ii) MEGAHIT (“-a megahit”). Add-
itionally, the analysis of human fecal microbiome data-
sets (HF1–5) included the preprocessing step of filtering
human genome sequences, which was omitted for the
wastewater sludge datasets (WW1–4) and the biogas
(BG) reactor dataset. Illumina TruSeq2 adapter trimming
was used for wastewater dataset preprocessing since the
information was available. Computation was performed
using eight computing cores (“- -threads 8”), 32 GB
memory per core (“--memcore 32”) and total memory of
256 GB (“- -memtotal 256 GB”). The customized param-
eters were specified in the IMP configuration file (exact
configurations listed in the HTML reports [57]). The
analysis of the CAMI datasets were carried using the
MEGAHIT assembler option (“-a megahit”), while the
other options remained as default settings.
In addition, IMP was also used on a small scale dataset
to evaluate performance of increasing the number of
threads from 1 to 32 and recording the runtime (“time”
command). IMP was launched on the AWS cloud com-
puting platform running the MEGAHIT as the assembler
(“-a megahit”) with 16 threads (“- -threads 16”) and
122 GB of memory (“--memtotal 122”).
Data usage assessment
Preprocessed paired-end and single-end MG and MT
reads from IMP were mapped (section Read mapping)
onto the IMP-based iterative co-assemblies and IMP_MG
assembly. Similarly, preprocessed paired-end and single-
end MG and MT reads from MOCAT were mapped onto
the MOCAT co-assembly (MOCAT_MGMT) and the
MOCAT single-omic MG assembly (MOCAT_MG).
MetAMOS does not retain single-end reads; therefore,
preprocessed MG and MT paired-end reads from MetA-
MOS were mapped onto the MetAMOS co-assembly
(MetAMOS_MGMT) and MetAMOS single-omic MG
assembly (MetAMOS_MG).
Preprocessed MG and MT reads from the human fecal
datasets (HF1–5) were mapped using the same parameters
described in the “Read mapping” section to the IGC refer-
ence database [35] for evaluation of a reference-based ap-
proach. Alignment files of MG and MT reads mapping to
the IMP-based iterative co-assemblies and the aforemen-
tioned alignments to the IGC reference database were
used to report the fractions of properly paired reads
mapping in either IMP-based iterative co-assembly, IGC
reference database, or both. These fractions were then
averaged across all the human fecal datasets (HF1–5).
Assembly assessment and comparison
Assemblies were assessed and compared using Meta-
QUAST by providing contigs (FASTA format) from all
different (single- and multi-omic) assemblies of the same
dataset as input [54]. The gene calling function (“-f”) was
utilized to obtain the number of genes which were
predicted from the various assemblies. An additional par-
ameter within MetaQUAST was used for ground truth
assessment of the simulated mock (SM) community assem-
blies by providing the list of 73 FASTA format reference ge-
nomes (“-R”). The CPM measure was computed based on
the information derived from the results of MetaQUAST
[54]. In order to be consistent with the reported values (i.e.,
N50 length), the CPM measures reported within this article
are based on alignments of 500 bp and above, unlike the
1-kb cutoff used in the original work [62]. Prodigal was
also used for gene prediction to obtain the number of
complete and incomplete genes [61].
Analysis of contigs assembled from MT data
A list of contigs with no MG depth of coverage together
with additional information on these contigs (contig
length, annotation, MT depth of coverage) was retrieved
using the R workspace image, which is provided as part
IMP output (sections “Visualization and reporting” and
“Output”). The sequences of these contigs were ex-
tracted and subjected to a BLAST search on NCBI to de-
termine their potential origin. Furthermore, contigs with
length ≥1 kb, average depth of coverage ≥20 bases, and
containing genes encoding known virus/bacteriophage
functions were extracted.
Analysis of subsets of contigs
Subsets of contigs within the HF1 dataset were identified
by visual inspection of augmented VizBin maps gener-
ated by IMP. Specifically, detailed inspection of contig-
level MT to MG depth of coverage ratios was carried
out using the R workspace provided as part of IMP out-
put (sections “Visualization and reporting” and “Out-
put”). The alignment information of contigs to isolate
genomes provided by MetaQUAST [54] was used to
highlight subsets of contigs aligning to genomes of the
Escherichia coli P12B strain (E. coli) and Collinsella
intestinalis DSM 13280 (C. intestinalis).
An additional reference-based analysis of MetaQUAST
[54] was carried out for all the human fecal microbiome
assemblies (HF1–5) by providing the genomes of E. coli
P12B and C. intestinalis DSM 13280 as reference (flag:
“-R”) to assess the recovery fraction of the aforemen-
tioned genomes within the different assemblies.
Computational platforms
IMP and MetAMOS were executed on a Dell R820 ma-
chine with 32 Intel(R) Xeon(R) CPU E5-4640 @ 2.40GHz
physical computing cores (64 virtual), 1024 TB of DDR3
RAM (32 GB per core) with Debian 7 Wheezy as the op-
erating system. MOCAT, IMP single-omic assemblies, and
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additional analyses were performed on the Gaia cluster of
the University of Luxembourg HPC platform [78].
IMP was executed on the Amazon Web Services
(AWS) cloud computing platform using EC2 R3 type
(memory optimized) model r3.4xlarge instance with 16
compute cores, 122 GB memory, and 320 GB of storage
space running a virtual Amazon Machine Image (AMI)
Ubuntu v16.04 operating system.
Additional files
Additional file 1: Supplementary figures and notes. Figures S1–S3 and
Notes S1–S2. Detailed figure legends available within file. (PDF 1047 kb)
Additional file 2: Supplementary tables. Tables S1–S12. Detailed table
legends available within file. (XLSX 4350 kb)
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Coupled metagenomic and metatranscriptomic datasets
The published human fecal microbiome datasets (MG and MT) were
obtained from NCBI Bioproject PRJNA188481 (https://www.ncbi.nlm.nih.gov/
bioproject/PRJNA188481). They include samples from individuals
X310763260, X311245214, X316192082, X316701492, and X317690558 [28],
designated within this article as HF1–5, respectively. Only samples labeled as
“Whole” (samples preserved by flash-freezing) were selected for analysis [28].
The published wastewater sludge microbial community datasets (MG and
MT) were obtained from NCBI Bioproject with the accession code
PRJNA230567 (https://www.ncbi.nlm.nih.gov/bioproject/PRJNA230567). These
include samples A02, D32, D36, and D49, designated within this article as
WW1–4, respectively [43].
The published biogas reactor microbial community data set (MG and MT) was
obtained from the European Nucleotide Archive (ENA) project PRJEB8813
(http://www.ebi.ac.uk/ena/data/view/PRJEB8813) and is designated within this
article as BG [29].
Simulated coupled metagenomic and metatranscriptomic dataset
The simulated MT data were obtained upon request from the original authors
[12]. A complementary metagenome was simulated using the same set of 73
bacterial genomes used for the aforementioned simulated MT [12]. Simulated
reads were obtained using the NeSSM MG simulator (default settings) [79]. The
simulated mock community is designated as SM within this article [79]. The
simulated data along with the corresponding reference genomes used to
generate the MG data are made available via LCSB WebDav (https://webdav-
r3lab.uni.lu/public/R3lab/IMP/datasets/) and is archived on Zenodo [80].
CAMI simulated community metagenomic datasets
The medium complexity CAMI simulated MG data and the corresponding
gold standard assembly were obtained from the CAMI website (http://
www.cami-challenge.org).
Test dataset for runtime assessment
A subset of ~5% of reads from both the WW1 MG and MT datasets (section
“Coupled metagenomic and metatranscriptomic datasets”) was selected and
used as the data to perform runtime assessments. This dataset could be
used to test IMP on regular platforms such as laptops and desktops. It is
made available via the LCSB R3 WebDav (https://webdav-r3lab.uni.lu/public/
R3lab/IMP/datasets/) and is archived on Zenodo [81].
Software and source code
IMP is available under the MIT license on the LCSB R3 website (http://
r3lab.uni.lu/web/imp/), which contains necessary information related to IMP.
These include links to the Docker images on the LCSB R3 WebDav (https://
webdav-r3lab.uni.lu/public/R3lab/IMP/dist/) and is archived on Zenodo [82].
Source code is available on LCSB R3 GitLab (https://git-r3lab.uni.lu/IMP/IMP),
GitHub (https://github.com/shaman-narayanasamy/IMP), and is archived on
Zenodo [83]. Scripts and commands for additional analyses performed
specifically within this manuscript are available on LCSB R3 GitLab
(https://git-r3lab.uni.lu/IMP/IMP_manuscript_analysis) and on GitHub
(https://github.com/shaman-narayanasamy/IMP_manuscript_analysis).
Frozen pages containing all necessary material related to this article are
available at http://r3lab.uni.lu/frozen/imp/.
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